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A B S T R A C T
Designer nucleases are developed to modify the genome in various
organisms, and are promising molecular tools for the advancement of
gene therapy. They should introduce only one specific double-strand
or single-strand break in a complex genome in order to trigger the
DNA repair mechanisms of the cell such that the DNA damage is re-
paired by homologous directed repair (HDR) or non-homologous end
joining (NHEJ), an error-prone repair mechanism that can be applied
to knock out genes. With the addition of an external DNA fragment,
HDR can be exploited to correct or add a gene.
Transcription activator-like effector (TALE) nucleases belong to a
platform of designer nucleases and are known to be highly specific,
efficient and easy to customize for any given target. Nevertheless,
there is still a need to improve the accuracy of TALE nucleases for
their reliable application in vivo. To this end, off-target activity should
be avoided without compromising cleavage efficiency. This can be
achieved by optimization of the catalytic domain as well as by im-
proving the binding domain.
The subjects of this comparative study are the homing endonucle-
ase I-SceI, the widely used TALE-FokI fusion protein, the new RNA
guided Cas9 nuclease and our recently developed TALE-PvuII vari-
ants as well as the TALE-MutH fusion protein, whose nuclease do-
main is a sequence- and strand-specific nickase. In the study we have
analyzed the toxicity and cleavage efficiency of these specific nucle-
ases in a yeast based single-strand annealing assay as well as in vitro.
The present study also focus on the characterization of the in vitro
binding mechanism of TALE. Binding characteristics of AvrBs3(1
N152-C28) were analyzed via anisotropy measurements, specific single-
and double-labeled TALE variants were designed and DNA::Protein
complexes were analyzed employing FRET measurements. We gained
labeled variants remaining their binding characteristics and enables
the investigation of the in vitro binding mechanism of TALE proteins.
Our results demonstrate convincingly that the monomeric TALE-
MutH nickase displays less toxicity in Saccharomyces cerevisiae com-
pared to the widely used dimeric TALE-FokI nuclease and is able to
introduce the repair of the DNA damage via single-strand anneal-
ing as efficient as I-SceI, the gold standard for cleaving genomic
DNA. To improve the design of TALE-MutH nickases, we analyzed
the cleavage behavior on various specific loci in vitro and in vivo.
The results presented show that the TALE-MutH fusion protein is
a promising programmable nickase for in vivo applications and these
results were confirmed by a TALE-MutH addressing a relevant thera-
peutic gene.
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Z U S A M M E N FA S S U N G
Konstruierte Nukleasen wurden entwickelt um das Genom in ver-
schiedenen Organismen zu modifizieren und sind viel versprechen-
de Werkzeuge zur Weiterentwicklung von effizienten Gentherapien.
Spezifische Nukleasen sollten einen spezifischen Doppel- oder Ein-
zelstrangbruch in dem komplexem Genom induzieren und hierdurch
den DNA Reparaturmechanismus der Zelle auslösen. Die DNA wird
hierbei durch homologous directed repair (HDR) oder non-homologous
end joining (NHEJ) repariert. NHEJ ist ein zu Fehlern neigender Repa-
raturmechanismus und kann zur Ausschaltung eines Gens angewen-
det werden. Mit Hilfe eines externen DNA Fragments kann HDR zur
Korrektur oder zum Hinzufügen eines Gens genutzt werden. Tran-
scription activator-like effector (TALE) Nukleasen bilden eine Gruppe
der konstruierten spezifischen Nukleasen und sind aufgrund ihrer
hohen Spezialität, Effizienz und einfachen Anfertigung für beliebige
adressierte Sequenzen bekannt. Dennoch werden weitere Verbesse-
rungen benötigt um die Genauigkeit von TALENs für die zuverläs-
sige in vivo Anwendung zu gewährleisten. Hierbei müssen off-target
Ereignisse vermieden werden ohne dabei die Spaltaktivität zu kom-
promittieren. Dies kann durch die Optimierung der katalytischen Do-
mäne, sowie durch die Verbesserung der Bindungsdomäne erreicht
werden.
Die Themen dieser vergleichenden Arbeit sind die Homing Endo-
nuklese I-SceI, das weit verwendeten TALE-FokI Fusionsprotein, die
neuartige RNA gesteuerte Cas9 Nuklease und die erst kürzlich eta-
blierten TALE-PvuII Varianten, sowie das TALE-MutH Fusionspro-
tein. Letzteres besitzt eine Nuklease Domäne, welche eine Sequenz-
und Strand-spezifische Nickase darstellt. In der Arbeit haben wir die
Toxizität und Spaltaktivität dieser spezifischen Nukleasen in Hefe
durch einen single-strand annealing assay und in vitro analysiert. Die
aktuelle Studie konzentriert sich auch auf die in vitro Charakterisie-
rung des Bindungsmechanismus von TALE. Die Bindungscharakte-
ristika von AvrBs3(1 N152-C28) wurden durch Anisotropiemessun-
gen bestimmt, spezifisch einzel- oder doppelt-markierte TALE Varian-
ten wurden hergestellt und DNA::Protein Komplexe wurden durch
FRET-Messungen untersucht. Wir konstruierten fluoreszenzmarkier-
te Varianten die ihre Bindungscharakteristiken behielten und somit
die Untersuchung der in vitro Bindungsmechanismen ermöglichen.
Die Ergebnisse zeigen dass die monomere TALE-MutH Nickase ei-
ne geringere Toxizität in Saccharomyces cerevisiae im Vergleich zu der
dimer TALE-FokI Nuklease aufweist. Des weiteren ist TALE-MutH
zur Reparatur des DNA Schaden durch single-strand annealing fähig
und hierbei genauso effizient wie der Goldene Standard I-SceI. Zur
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Verbesserung des TALE-MutH Designs wurde das Spaltverhalten auf
verschiedene Loci in vitro und in vivo getestet. Die präsentierten Er-
gebnisse zeigen dass das TALE-MutH Fusionsprotein eine vielver-
sprechende Nickase für in vivo Anwendungen darstellt mit welchem
auch therapeutisch relevante Gene adressiert werden können.
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Part I
I N T R O D U C T I O N

1
I N T R O D U C T I O N
In 1990, the Human Genome Project (HGP) was initiated to deci-
pher the human genome. It took until 2003 to complete sequenc-
ing of the entire human genome, which improved our understanding
of genetic disease mechanisms and resulted in the development of
new therapeutic strategies. One therapeutic approach was to silence
dysfunctional genes with small interfering RNAs (siRNAs), resulting
in the transient down-regulation of the expression specific targeted
genes. However, its use is limited by the relatively low efficiency
and its unfavorably safety profile [4, 114, 50]. Another approach is a
therapy, which inserts the relevant gene by packing the encoding se-
quences into a viral-vector. A successful application of a viral-vector
based therapeutic is Glybera, it treats lipoprotein lipase deficiency
(LPLD) and is marketed in Europa since 2014. Glybera is injected
into the skeletal muscle and introduces a healthy lipoprotein lipase
gene [84, 232]. However, editing therapies carrying the risk of an im-
mune response to the viral-vector and the non-specific insertion of
the correct gene [121]. This has been shown where gene therapy was
successfully employed to cure severe combined immunodeficiency-
X1 (SCID X-1) via introducing a retroviral vector containing the en-
coding sequence of the relevant protein. However, some patients de-
veloped leukemia-like symptoms as a result of an unspecific insertion
[121, 92]. Furthermore, a lethal immunological response was reported
in a therapeutic trial using adenovirus vectors for the insertion of the
relevant gene [216].
Homologous recombination (HR) of an exogenous DNA template
with chromosomal DNA can be used to add sequences to the genome
by gene correction or gene addition. However, recombination in
mammalians is a rare event and therefore very inefficient. Chromo-
somal HR can be increased over 1000 fold by introducing double
strand breaks (DSBs) in the target, thus facilitating gene targeting
[61, 130, 182, 207, 181]. Various specific nucleases have been devel-
oped to introduce specific DSBs into the genome, such as meganucle-
ases [87, 9, 201], zinc finger nucleases (ZFNs) [220, 176, 31], transcrip-
tion activator-like effector nucleases (TALENs) [155, 41, 148] and the
RNA-guided Cas9 nuclease [108, 140, 39, 47, 102] (Figure 1).
Site-specific DSBs trigger the cell to repair the lesion by the error
prone repair mechanism non-homology end joining (NHEJ) [131] or
by homology directed repair (HDR) [30, 95, 159, 60, 187]. NHEJ intro-
duces small insertions or deletions (INDELs), leading to a disruption
of the gene [131]. Thus, it can be applied to silence a pathologic gene
[189, 211].
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Figure 1: Gene targeting with meganucleases, fusion-proteins or RNA-
guided endonucleases
Specific nucleases induce a DSB into the genome and trigger the error
prone NHEJ mechanism or HDR. NHEJ results in INDELs and can dis-
rupt the gene. HDR is based on a DNA template containing duplication
fragments. HDR can bee used for gene correction, gene replacement, or
gene addition.
NHEJ is the more efficient repair mechanism compared to the pre-
cise homologous direct repair and is active throughout the whole cell
cycle [186, 197]. The ends of the disrupted DNA are literally sticked
together via NHEJ [131]. However, if a precise gene correction or gene
addition is needed, a DNA template has to be introduced, which will
be assembled to the DNA via HDR [61, 130, 182, 207]. However, HDR
does primarily occur during the S/G2 phase of the cell cycle [43, 35]
and is therefore less active and restricted to dividing cells [50].
To increase the possibility of HDR, several modifications were made
[50]. For instance, suppressing the key players of NHEJ [42], but
also single-strand breaks (SSBs) were introduced instead of DSBs to
the DNA locus [145, 52, 222], single-stranded oligonucleotides were
used instead of double- stranded substrates [36, 146], and the simi-
larity was increased between the DNA template and the DSB site to
promote formation of intermediates during the template integration
[19, 154, 158].
The improvement of gene targeting is an ongoing process. Thus,
the specific nucleases have to be optimized to reduce safety risks,
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such as off-target activity [228, 93, 77] and a deeper understanding of
the binding mechanism could improve their specificity [142, 205, 193,
194]. Furthermore, the precise characterization of the repair mech-
anisms could optimize HDR efficiency [113]. Finally, improving the
delivery systems to the target site could be an important step towards
the effective manipulation of the human genome [121].
1.1 tools for genome editing
The tools for genome editing are the specific nucleases, which require
a number of features to be effective and safe. They have to be highly
specific and highly efficient, but also easy to handle and to design.
The most important specific nucleases are reviewed below.
1.1.1 Meganucleases/Homing endonucleases
Homing endonucleases (HEs) are one of the first engineered nucle-
ases [61, 130, 182, 207, 181]. HEs, also known as meganucleases, target
an extremely rare large recognition site (12-40 bp) and are grouped
into five families based on sequence and structural motifs [206]. HEs
are located and encoded within protein encoding genes. HEs are self-
splicing introns (RNA) or self-splicing inteins (protein splicing). They
are considered as “selfish” nucleases as they support their own pro-
liferation. The HE induces a DSB infto the foreign DNA lacking the
HE gene, triggering HDR. In turn, HDR uses the intron containing
allel as the repair matrix and the HE gene becomes duplicated [141].
I-SceI belongs to the best analyzed laglidadg family, characterized
by the αββαββα motif. Two laglidadg motifs form a bipartite cat-
alytic center. Each center α-helix contains the laglidadg motif and
enclose one of the two acidic residues, which coordinate the divalent
metal ion cofactor Mg2+ for cleavage of the phosphodiester bonds.
The four β-sheets recognize the target by forming a saddle like struc-
ture around the DNA. HEs exist as homodimer with two copies of
the laglidadg motif in each monomer (e.g. I-CreI) or as monomeric
enzyme containing two laglidadg motifs fused by a linker (I-SceI)
[201, 141, 171]. I-SceI recognizes a non-palidromic 18 bp sequence
and is the established Golden Standard due to its high specificity
combined with its high nuclease activity. Meganucleases are charac-
terized by a non-modular structure, thus engineering of their binding
domains proofed to be challenging, but can be realized by rational de-
sign and/or directed evolution [218, 106].
1.1.2 Fusion-proteins
In contrast to meganucleases, the repetitive nature of the DNA bind-
ing region of the fusion proteins ZFNs [220, 176, 31] and TALENs
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[155, 41, 148] enable them to address a high number of sequences.
The programmable binding domains of ZFs and TALEs are typically
fused to the non-specific cleavage domain of the Typ IIs endonuclease
FokI, which functions as a dimer [117]. Improved designs have been
established and are reviewed in section 1.1.4.
Another option to engineer programmable fusion proteins is to
use triple-helix forming oligonucleotides (TOFs) as binding modules.
TOFs build stable triple helices with the DNA through hoogsteen
base pairs [63, 171]. Due to the challenging cell delivery of TOF nu-
cleases and the slow rate of triple-helix formation, this platform of
specific nucleases has no current relevance in genome editing [171].
1.1.2.1 Zinc finger nucleases
A set of zinc-fingers consist of three individual zinc-fingers and each
Cys2-His2 finger is composed of 30 amino acids formed to a ββα-motif.
Two cysteine and two histidine residues coordinate one divalent zinc
ion. Three defined amino acid residues located in the α-helix recog-
nize 3 bp in the major groove of the DNA [66]. A zinc-finger binding
domain comprise three to four zinc-finger sets to target 9-12 bp. Sev-
eral methods have been developed to construct zinc-finger proteins
[3]. For example, modular assembly, which is based on a preselected
library of zinc finger modules [196] or by using the oligomerized pool
engineering (OPEN) method, which selects multi-finger arrays from
a library and members with binding affinity are isolated with a bac-
terial two-hybrid (B2H) selection method [137, 136]. Unfortunately,
crosstalk between adjacent zinc fingers affects the binding specificity
[103] and interfere with zinc finger assembling [178]. Additionally,
ZFN revealed a high off-target activity, when compared to TALEN
[156].
1.1.2.2 Transcription activator-like effector (TALE)
Deciphering the code of a TAL (transcription activator-like) effector
of the plant pathogenic Xanthomonas was a crucial step to improve
binding domains for highly programmable specific nucleases. TAL
effectors are virulence factors, which simulate eukaryotic transcrip-
tion factors [25]. Gram-negative plant-phathogenic bacteria of the
genus Xanthomonas inject a cocktail of effector proteins by a type III
secretion system into plant cells, thus causing diseases in crop plants
[115]. TAL effectors are composed of a N-terminal trans-location sig-
nal, a central repeat domain (CRD) and a C-terminal region carrying
a nuclear localization signal (NLS) and a transcription activator do-
main [24, 26] (Figure 2 (A)). TALEs enter the nucleus and bind to
a UPT (upregulated by TALE) box to activate host-susceptibility (S)
genes, promoting bacterial proliferation. AvrBs3 is a well studied
TALE protein from the pepper (Capsicum spec.) and tomato (Solanum
lycopersicum) pathogenic strain Xanthomonas campestris pv. vesicato-
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ria (Xcv). AvrBs3 interacts with the S gene UPA (upregulated by
AvrBs3) inducing cellular hypertrophy of mesophyll cells [152]. Due
to plant-pathogen co-evolution, disease resistance (R) genes exist in
some plants. For instance, the pepper plant contains a Bs3 R gene.
Here, AvrBs3 induces programmed cell death, called hypersensitive
response [185].
NLS
(B)
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 α-h
eli
ce
s (
1-1
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Figure 2: 3D structure of TALE (pdb: 2YPF) [205].
(A) TALE consist of the N-terminal region (NTR) carrying the type
3 secretion signal (T3SS), the central repeat domain (e.g. 17.5 RVDs),
and the C-terminus containing the nuclear localization signal (NLS) and
a transcription activator domain (AD). Δ152 indicates the truncated N-
terminus, while the complete C-terminus carry 278 aa after its last half
repeat. (B) Crystal structure of TALE bound to DNA. TALE forms a right-
handed superhelix wrapped around the major groove of the DNA. The
pseudo repeats at the N-terminal region (NTR) are colored in magenta,
the CRD is shown in green.(B) Magnification of one repeat. The repeat
variable diresidue (RVD) at position 12 and 13 is illustrated as sticks in
orange and the residues G14, K16 and Q17 are also illustrated as sticks.
8 introduction
Another Xcv TAL effector is AvrBs4, which is 97% identical to
AvrBs3 [28]. Its corresponding R gene Bs4 is also found in some
tomato plants, but can not be induced by AvrBs3 [152, 192]. Similar
to the TALE protein from the plant pathogenic Xanthomonas, a TAL
effector (RipTAL) from Ralstonia solanacearum with high sequence sim-
ilarity to the TAL effector of Xanthomonas was identified [54], as well
as a modular DNA binding protein, BurrH, from Burkholderia rhizox-
inica [110, 204].
1.1.2.3 Structure and binding mechanism
The crystal structure of the binding domain of a TAL effector PthXo1
was accomplished from the rice pathogen Xanthomonas oryzae [139].
Later, AvrBs3 bound to DNA was crystallized by Stella et al. [205]
(Figure 2 (B)). The central binding module is composed of highly con-
served repeats, ranging from 1.5-33.5 repeats. The last repeat does
always contain half of the repeat residues [24, 25]. There exist con-
flicting evidences regarding the necessity of the last half repeat; both
a significant impact [226, 27] as well as a minor relevance [142, 248]
for the binding character of TALEs have been reported. The mini-
mum number of repeats to induce gene expression is 6.5 repeats [25]
and each repeat contains ˜34 conserved residues. At position 12 and
13 the so called repeat variable diresidue (RVD) is located and is re-
sponsible for the “one repeat to one base” [193] specific recognition
code [25, 153]. Every repeat forms two α-helices connected by a three-
residue loop carrying the RVD (Figure 2 (C)). The TAL effector bound
to double stranded DNA forms a right-handed superhelix wrapped
around the DNA major groove [139, 205] (Figure 2 (B)). A total of
20 unique RVD sequences have been described [48], but only a few
promote specific binding. RVD “HD” prefer binding to cytosine (C),
RVD “NG” binds mainly to thymine (T) and RVD “NI” binds usually
to adenine (A). RVD “NN” can bind to adenine (A) and to guanine
(G), whereas RVD “NS” binds to adenine (A) and to cysteine (C) [25].
RVDs “NK”, “HN” or “NA” can be used to target guanine (G) [153].
The RVD “N*” missing the glycine residue at position 13, has been
described to overcome the sensibility of TALEs to methylated bases
[221].
The single repeats can be assembled to an artificial functional TALE
by the golden gate cloning strategy [33]. This cloning strategy en-
able rapid assembling of TALEs and the use of TALEs for any given
target [33].
The residue at position 13 directly contacts the DNA and the residue
at position 12 is responsible to stabilize the interaction between DNA
and TALE [139, 57]. The residues G14, K16 and Q17 interact by non-
specific polar and charge interactions with the DNA backbone [230].
Furthermore, the N-terminal region (NTR) contributes to DNA bind-
ing and consists of four continuous repeats (N-3, N-2, N-1, N0) forming
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a right handed superhelical structure similar to the CRD, but differing
in its sequence [81]. Truncated versions of TALEs have been designed
to reduce the overall size of the protein. It has been shown that the N-
terminus missing 152 aa and the C-terminus carrying 28 aa retains its
binding ability [148]. A binding sequence beginning with a thymine
(T0) facilitates TALE binding, but other bases can also be recognized
by TALE [148, 209]. Tryptophan at position 232 in repeat N-1 is re-
sponsible for its T0 preference. By structure-guided library design,
a N-terminal domain preferring guanine (G0) has been constructed
[124]. It has been reported that Ralstonia solanacearum TALE requires
G0 and carrying an arginine at position 232 in repeat N-1 , similar to
the TALE designed by structure-guided library [124, 54].
The naturally occurring TALEs from Xanthomonas bind to a DNA
sequence containing a 5‘ T0 [25, 153]. Interestingly, there is no nat-
urally occurring TALE protein which matches perfectly to its target
promoter. For instance, AvrBs3 has two HD-A mismatches and one
NG-C mismatch at its Bs3 box [142]. It has been reported that TALEs
from Xanthomonas possess single repeats with aberrant length. These
repeats can be truncated or extended, when compared to the canon-
ical repeat carrying 34 aa. The aberrant repeats allow an additional
binding conformation in which the repeat loops out and therefore
introduce a local flexibility to TALE-DNA binding [183].
A detailed analyses of the RVDs revealed that the overall compo-
sition of RVDs contribute to the TALE-DNA binding affinity. The
order of contribution of single RVDs has been shown to be HD ≥
NG ≥ NN >>> NI > NK. Furthermore, the TALE-DNA recognition
is influenced by a polarity-effect, thus the N-terminal repeats have an
higher impact on the specificity and affinity of TALE compared to the
C-terminal repeats [142].
Each repeat carries a conserved cysteine (C) residue at position 30,
which is located in the second α-helices in a solvent-exposed outer
loop [57, 139]. The cysteine residues are required to dimerize via
disulfide bridges to homodimers, which occur prior to the import into
the nucleus [91, 194]. However, complex formation inhibits binding
to the DNA and it has therefore been suggested that the homodimers
dissociate in the nucleus. Monomeric binding of TALE to its target
has been shown by EMSA (electrophoretic mobility shift assays) data
[194] and by the structural data [205, 139, 57] of TALE. While substi-
tution off all cysteine residues to serine or alanine in AvrBs3 revealed
that the cysteine is required for gene activation in planta, the lack of
cysteine residues slightly reduces the binding ability of TALEs un-
der in vitro conditions. These results suggest that the substitution
slightly affects the plasticity of AvrBs3 [194]. X-ray crystallography
revealed that TALE undergoes a conformational change upon bind-
ing to the DNA. The superhelical pitch gets reduced from 60 A° to
35 A° [57, 230]. Furthermore, conformation elasticity of TALE was
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predicted by computational studies [226, 70]. Just recently, single-
molecule experiments were performed with Cy3 labeled AvrBs3. The
protein was labeled by hydrazine-functionalized Cy3 organic dyes at
the N-terminus carrying an unnatural aldehyde and a two-state mech-
anism enclosing a dynamic conformation change between search and
recognition state was reported [51]. The NTR binds to non-specific
DNA and facilitates 1D sliding [138, 81, 51]. An extended superheli-
cal pitch exists, which minimizes the strong interaction between CRD
and the DNA backbone. This enables sliding and hopping of the
TALE protein along the DNA. The single molecule results revealed
an arrested state in 1D diffusion, which indicates a transition from
the search state to the recognition state. The recognition state has a
more compact conformation, when compared to the search state. Fur-
thermore, they suggested that large TALEs suffer from a “slowdown”
in 1D diffusion. This results in a higher frequency of transition from
search to recognition state and thus results in higher off-target rates
[51].
1.1.3 Clustered regularly interspaced short palindromic repeats (CRISPR)-
associated endonuclease Cas9
The clustered regularly interspaced short palindromic repeats (CRISPR)/
CRISPR-associated (Cas)-system is an adaptive immune system in
bacteria and archaea to defend the organism against invading viruses
or plasmids (Figure 3) [231].
The type II CRISPR-Cas system integrates foreign sequences (pro-
tospacer) to the CRISPR cluster and transcribes these to pre-CRISPR
RNAs (pre-crRNAs), which are processed to short crRNA and hy-
bridized with transactivating CRISPR RNA (tracrRNA) and the Cas9
protein. The complex Cas9::crRNA::tracrRNA binds to its target by
RNA-mediated Watson-Crick interaction and induces a DSB. To sim-
plify the system for genome editing, a single crRNA-tracrRNA chimera
was established by fusing crRNA to a truncated tracrRNA which re-
sulted in a guide RNA (gRNA) [108]. RNA-guided Cas9 nuclease rec-
ognizes a 20 bp target which requires the protospacer adjacent motif
(PAM) sequence downstream of the target for binding and cleaving
activity. The commonly used Streptococcus pyogenes Cas9 (spCas9) pro-
tein primarily recognizes 5‘ NGG PAM sequence [108, 107]. The Cas9
protein contains two nuclease motifs, RuvC and HNH. RuvC induces
a SSB to the complementary strand and HNH induces a SSB into the
non-complementary strand, resulting in a blunt end 3 bp upstream
to the 5‘ PAM motif [83]. The required PAM motif represents a limi-
tation for the application of the gRNA endonuclease Cas9. However,
there have been attempts to overcome the issue of the PAM motif
[107, 119, 7, 72]. Partial binding of gRNA::Cas9 was demonstrated
to the PAM sequence 5‘ NAG [107]. The design of an engineered
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Figure 3: CRISPR-Cas system
(I) integration of a short foreign sequences (protospacer) into the CRISPR
array. The protospacers are illustrated in orange, green, and red. The re-
peat arrays are displayed in balck. (II) Encoding tracrRNA, Cas9 protein
and pre-crRNA. (III) The tracr RNA hybridizes to the repeat arrays of
the pre-crRNA and (IV) are processed to short cr-RNAs. (V) Complex
formation of Cas9::crRNA::tracrRNA. The complex scans the dsDNA for
its target. (VI) Specific binding of the Cas9::crRNA::tracrRNA complex
to the complementary protospacer sequence by Watson-Crick interaction.
The PAM sequence is required to induce a DSB to the foreign DNA.
spCas9 protein with novel PAM recognition has been shown to be
challenging [7], but has been recently achieved by a bacterial selec-
tion system [119]. Another attempt to improve the diversity of PAMs
was the characterization of orthologues Cas9 proteins from other bac-
teria [119, 72]. Especially, the Staphylococcus aureus Cas9 (saCas9) re-
vealed to be promising [119, 179]. It recognizes three novel PAM sites
(NNGGGT, NNGAAT, NNGAGT) [119] and the protein saCas9 has
the benefit to be ~1kb shorter compared to spCas9 [179]. The small
size improves the packing features of the Cas9 protein into adeno-
associated virus (AAV) vectors, a commonly applied delivery method.
AAV vectors allow to pack 4.5 kb, which limits packing of the widely
used spCas9 (~4.2 kb) and its gRNA into one AAV vector [179]. Ad-
ditional a further CRISPR-Cas system was characterized containing a
Cpf1 protein. In contrary to the Cas9 protein the Cpf1 protein does
not require a transactivating CRISPR RNA, addresses a target site
with a 5‘ T-rich PAM sequence and induces a DSB with a 4 nt or 5 nt
5‘ overhang[243].
A significant advantage of the gRNA endonuclease is the ability of
re-targeting a new sequence by simply changing the sequence of the
gRNA. Furthermore, the possibility to introduce multiple DSBs (mul-
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tiplexing) allows new applications for the Cas9 system [47]. Nonethe-
less, the Cas9 nuclease does tolerate mismatches especially in the 5‘
upstream region [163, 101, 76]. This limits the application of Cas9 for
genome editing, especially when a high level of precision is required.
To improve the specificity of RNA-guided Cas9, a nickase has been es-
tablished, by introducing a point mutation in either the RuvC (D10A)
or HNH (H840A) domain [108, 47]. This led to the possibility to use
RNA-guided Cas9 endonuclease for inducing SSBs, but also as an
inactive binding domain [174, 247].
1.1.4 Catalytic domains
1.1.4.1 Cleavage domains
Different types of nucleases have been used in fusion constructs as
cleavage domains [238, 78, 22, 27]. Nucleases are phosphordiesterases
hydrolyzing the phosphordiester bond, thus creating most commonly
5‘-phosphates and 3‘-OH groups. These proteins are essential for de-
fending the host against invading nucleic acids [21, 175], DNA repli-
cation [111] and RNA processing [2]. Phosphordiester bond cleavage
occurs due to a bimolecular nucleophile substitution (SN2), which
inverts the configuration of the phosphorous. A neighboring water
molecule is deprotonated to a strong nucleophile, which attacks the
partially positive phosphor. Simultaneously, 3‘-O- is released. The
reaction step can be catalyzed by diverse mechanisms depending
on none-, one-, two-, or three-metal-ions [169, 237]. The cleavage
domains analyzed in the present work belong to the two-metal-ion
mechanism (FokI, PvuII and MutH) (Figure 4).
One divalent metal-ion facilitates deprotonation of the water molecule
and both metal-ions stabilize the pentavalent transition intermediate.
The two divalent metal-ions are coordinated by a conserved asparate,
a hallmark of the two-metal-ion mechanism [236, 169]. Homing en-
donucleases were also used as cleavage domains in fusion constructs.
The laglidadg homing endonucleases I-CreI [22] and I-AniI [27] be-
long to the two-metal-ion-dependent nucleases and were fused to the
binding domain TALE. Furthermore, one-metal-ion dependent nucle-
ases, like the giy-yig homing endonuclease I-TevI [20] and the non-
specific endonucleases ColE7, NucA and EndA [22] have been shown
to function as cleavage domains. The cleavage domains of the ana-
lyzed specific nucleases are reviewed in detail.
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Figure 4: Cleavage domain of FokI, restriction enzyme PvuII and MutH
The essential residues of the cleavage domains are illustrated as purple
sticks. One subunit is colored in blue and the second subunit in light
blue. (A) Dimeric FokI (PDB: 2FOK) cleavage domains [224]. The active
center is build by the residues D450, D467 and K468. (B) PvuII (PDB:1PvI)
with its catalytic residues D58, E68 and K70 in each subunit [99]. Natu-
rally, the PvuII restriction enzyme function as homodimer. To design a
heterodimeric PvuII, the substitution D30K or K38D was introduced to
one subunit, respectively. D30 and K38 are displayed as orange sticks.
In red the linker (Gly-Ser-Gly-Gly) used to fuse the identical subunits of
PvuII and to create a scPvuII variant is shown. (C) Monomeric nickase
MutH interacting with its target DNA. (PDB: 2AOQ) Catalytic residues
are D70, E77 and K79 [125]. Double stranded DNA is demonstrated in
gray.
1.1.4.2 FokI
The endonuclease FokI, isolated from Flavobacterium okeanokoites, be-
longs to the type IIS restriction endonucleases.
The enzyme recognizes a 5 bp asymmetric nucleotide sequence,
cleaving 9 (top-strand) and 13 (bottom-strand) nt downstream of the
site (5‘-GGATG(N)93NNNN113) [208].
Two domains shape the FokI restriction endonuclease, a N-terminal
binding domain (41 kDa) and a C-terminal cleavage domain (25 kDa)
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[128]. The two domains are fused by a flexible linker and the cleavage
domain is kept in an compact conformation until binding to the sub-
strate [167]. Binding to the DNA target induces a conformational
change, which recruits the catalytic cleavage domain 13 nt down-
stream of the site to the bottom-strand. Next, a second monomeric
FokI enzyme dimerizes by protein-protein interaction and is respon-
sible to cut the the top-strand 9 nt away from the recognition site
[167, 188, 23].
The second monomeric FokI endonuclease can be bound to a prox-
imate second recognition site or is available from the free solution
[93]. However, the dimerization between bound and free FokI pro-
teins is unstable, resulting in a low cleavage rate for one-target site
DNA [23]. Unless free FokI enzyme concentration is >>100 nM, since
the equilibrium dissociation constant of the second FokI monomer
is ≈100 nM [32]. Consequently, the catalytic domain of FokI is an
unspecific cleavage domain, which requires dimerization to induce
DSBs [224, 23] (Figure 4 (A)).
The catalytic domain of FokI was fused to the C-terminus of a zinc-
finger domain by the Chandrasegaran group, creating the first re-
ported ZFN [117]. Thereafter, improved ZF-FokI designs were cre-
ated. One approach to increase the specificity was to design het-
erodimeric catalytic domains by introducing defined mutations [147,
212, 90]. Furthermore, sharkey, a FokI catalytic domain with increased
activity was designed and is reported to be compatible with the het-
erodimeric mutations [90]. Another approach to optimize the con-
struct was the design of the single-chain (sc) ZN-FokI specific nucle-
ase. Two copies of the FokI catalytic domain were fused with a flex-
ible (Gly-Gly-Gly-Gly-Ser)n polypetid linker to each other [149, 213].
When TALE, as a new binding domain was discovered, the cleavage
domain FokI was applied to the new design [33, 129, 148]. Likewise
to the scZN-FokI design, a scTALE-FokI [210] construct with a 95 aa
polypeptide linker was constructed. Recently, the unspecific catalytic
domain of FokI was fused to the amino-terminus of a catalytic inac-
tive Cas9 protein to improve the off-target character of the CRISPR/-
Cas9 -system [89, 219].
To enable FokI dimerization, two adjacent sites are placed 15-39
bp apart from each other with PAM sites facing outside. This new
dimeric RNA-guided FokI-dCas9 nuclease (RNF) has been shown to
improve the sensitivity to mismatches [8, 235].
1.1.4.3 PvuII
The restriction enzyme PvuII (Figure 4 (B)), isolated from Proteus vul-
garis, belongs to the type IIP restriction enzymes. PvuII addresses
a palidromic 6 bp sequence and induces a DSB through dimeriza-
tion, resulting in blunt ends (5‘-CAG3CTG-3‘). Each PvuII subunit
contains a PD...D/ExK motiv, characterized by the crucial aa of the
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active center (D58, E68 and K70) [37, 170, 169]. The advantage of
PvuII over the unspecific catalytic domain FokI is its additional site-
specific sequence specificity [239]. Similar to the catalytic domain
FokI, the PvuII enzyme was optimized for the use as cleavage domain.
Thus, a scPvuII version has been designed by fusion of two identical
PvuII subunits with a short aa linker (Gly-Ser-Gyl-Gly) [202, 144].
The first alternative architecture of programmable nucleases with the
PvuII cleavage domain was the triple-helix-formation oligonuleotide
(TFO)-scPvuII fusion construct [65]. However, this design has to
be pre-incubated in the absence of Mg2+ metal-ions and activated
with Mg2+ metal-ions to cleave the target site specifically. This re-
quired activation process complicates the application of TFO-scPvuII
in vivo [239]. Furthermore, PvuII was fused to inactivated homing en-
donuclease I-SceI* [71], to a zinc-finger array [190] and to the TALE
binding domain [239, 238]. The new site-specific architecture of pro-
grammable nucleases with PvuII proofed to be superior with the fu-
sion constructs with FokI compared to zinc- finger-PvuII and zinc-
finger-FokI [190]. PvuII connected to the truncated binding domain
TALE (ΔN152-C28) was analyzed as homodimer, as monomeric single-
chain construct and as heterodimer. Here, PvuII contained the T46G
mutation, which is known to reduce “star-activity” and has been
termed as high fidelity (hf) PvuII [250]. “Star-sites” are similar, but
not identical to the recognition site. To reduce the toxicity of TALE-
PvuII the cleavage domain PvuII was further optimized. Ten new
PvuII variants, each with a novel single mutation, were generated by
directed evolution. Five of these new variants retained the cleavage
activity of the fusion construct. Among these five variants, the TALE-
PvuII(T46G/G135W) variant revealed the best balance between activ-
ity and toxicity. Toxicity was analyzed in different Escherichia coli (E.
coli) strains (JM109 and XL10Gold), as well as in an eucaryotic cell line
(HEK293) [239, 238]. In addition, heterodimer PvuII subunits were
designed to increase the specificity. Therefore, PvuII subunits were
created containing a D30K mutation or a K38D mutation. These aa in-
teract with each other during the dimerization of the PvuII subunits.
The mutations are located centrally, but are not placed in the active
center. Due to the different charges of PvuII(D30K) and PvuII(K38D),
exclusively heterodimeric PvuII subunits can dimerize and induce a
DSB [238].
1.1.4.4 Programmable nickases
To further reduce off-target activity, nucleases were modified by the
utilization of nickases to induce SSBs rather than DSBs, thus favoring
the occurrence of HDR over the error prone repair mechanism NHEJ
[145, 52, 222].
Programmable nickases have been created by (i) inactivation of one
of the binary catalytic cleavage centers (e.g. N450A FokI [116, 188,
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177, 227], K223I I-SceI [157, 113] and D10A CAS9 Mali et al. [140], Ran
et al. [180], Cho et al. [40]), or (ii) by fusion of a naturally occurring
nickase to its binding domain, e.g. TALE-MutH [78]. Nickases have
been designed to induce SSBs in the sense or anti-sense strand. This
feature can be exploited to increase HDR efficiency, as it is crucial
when the transcribed or the non-transcribed strand are nicked [53].
Furthermore, specific nickases have been used for double nicking
(DN), thus inducing SSBs on both DNA strands, which resulted in
an enhanced genome editing specificity [191, 199, 180, 40]. It has
been shown by Ran et al. [180] that the efficiency of double nicking
depends on the offset between the two target sites and on the cre-
ated overhang. HDR efficiency triggered by paired Cas9 nickases has
been reported to be comparable with the HDR efficiency induced by
wt Cas9 endonuclease creating DSBs. Generating a 5‘overhang does
improve NHEJ and HDR efficiency [40, 180, 140]. While the offset can
be up to 100 bp, it is optimal upto 20 bp. Finally, at least one nick
should occur in the homologous part to optimize the efficiency and
no improvement of HDR efficiency could be detected by generating
a 3‘overhang [180, 140].
1.1.4.5 MutH
MutH (Figure 4 (C)) is a 28 kDa monomeric site and strand specific
latent endonuclease which requires activation by MutS and MutL as-
sociated with a mismatched base pair [125, 12]. It induces a SSB in
un- and hemi-methylated strands 5‘ to its recognition site3GATC.
The structure of MutH is surprisingly similar to the PvuII endonu-
clease. Furthermore, the active center of MutH contains the core aa
Asp70, Glu77 and Lys79 (the DEK triad), which is also found in the
PD...D/ExK motif of PvuII [12]. The monomeric endonuclease be-
longs to the mismatch repair system in system in E. coli and some
other bacteria. MutS recognizes the mismatch and recruits MutL [94].
This ternary complex activates MutH, which induces a SSB at the 5´-
side of a hemimethylated GATC site. The mismatch can be >1000
bp upstream or downstream of the GATC site [122]. Next, single-
stranded DNA is generated and digested by an exonuclease across
the original mismatch [151]. Without recruitment, the nickase MutH
is barely active or inactive under physiological conditions [229, 64].
This feature was exploited by Gabsalilow et al. [78], as they fused
the monomeric site and strand specific endonuclease to the binding
domain TALE.
TALE-MutH is a strand- and site-specific programmable nickase,
which has been characterized in vitro [78]. Dependent on the spacer
length between the TALE binding site and the GATC site, the SSB
is induced in the top- or bottom-strand. Targets containing a spacer
of 3 bp are nicked on the bottom-strand, whereas the optimal spacer
length for the top-strand cleavage is 6 bp [78]. This feature allows to
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specifically target either the transcribed or the non-transcribed strand
by TALE-MutH, which has been shown to be crucial in respect of
HDR efficiency and therefore successful genome editing [53].
1.1.4.6 Diversity of the catalytic domains
Beyond the function as specific nuclease the described “tools for genome
editing” were also modified for other applications. For instance, TALE
proteins were fused to activator (e.g. vp16) [245, 152, 148] or re-
pressor domains (e.g. KRAB) [82] to activate gene expression or
to down-regulate or even arrest gene expression. Other designed
fusion constructs were realized with DNA-methyltransferases [18],
with demethylases [134], or with histon-modifying enzymes [143, 38].
To catalyze DNA integration, excision, and inversion recombinases
[80, 85], or transposases [240] were fused to the binding domain
TALE [79]. Additionally, TALEs were fused to fluorescent proteins
to visualize target sequences [150]. Optical control of transcription
was achieved by an optogenetic two-hyprid system, employing the
light-inducible heterodimerizing proteins CRY2 and CIB1. This was
realized by fusing CIB1 to the transactivation domain VP64 and CRY2
to TALE [120] or to the inactive Cas9 protein [172]. In the presence of
blue light, a conformation change of CRY2 occurs and CIB1 forms a
heterodimer with CRY2. Furthermore, inactive Cas9 protein was ap-
plied to repress transcription by blocking the RNA polymerase [174].
These examples underline the high relevance of the discussed pro-
teins and their diverse applications.
1.2 therapeutic applications
A major limitation of the application of specific nucleases for genome
editing is their specificity. Studies compared the specificity of the
tools and revealed that the binding proteins tolerate mismatches de-
pending on location and composition [142, 40]. For instance, TALE
proteins are more sensitive to mismatches at the 5‘-end of the tar-
get [142], while Cas9::gRNA tolerates mismatches at the 5’-end better
than at the 3‘-end [108, 47, 107]. TALENs have been shown to be the
best choice when high accuracy is required (e.g. for gene correction)
[155, 156, 228]. However, by choosing unique target sites [40], the
possibility of double nicking with Cas9 proteins [40] and the fusion
construct Cas9::FokI [219] increased the specificity and the field of
application for Cas9 proteins. However, other factors affect the safe
and efficient application of specific nucleases.
1.2.1 Delivery systems
The gene editing technologies have to be delivered into the target cell
for their successful application. This can be realized by ex vivo or in
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vivo editing, using viral or non-viral vector-mediated delivery or by
employing physical delivery methods. The viral or non-viral vectors
carry the expression cassette for the specific nucleases and in some
case also the DNA template. The proteins can also be introduced to
the cell as purified proteins. For ex vivo editing therapy, the target
cell population is removed from the organ, modified and then re-
engrafted into the body. This enables the usage of a wide range of de-
livery methods and a control of the dosage of the delivered molecules.
However, ex vivo editing is limited to certain tissues, as the cell pop-
ulation needs to survive the manipulation outside the body and has
to be able to return back to the tissue after transplantation. In in vivo
therapies, the gene editing technologies are introduced directly into
the diseased cells. This allows to target tissues not amenable for ex
vivo editing therapy and the treatment of diseases affecting multiple
organ systems [50]. However, major drawbacks of in vivo editing ther-
apies are the possibility of an immune response to the viral-vector
and the non-specific insertion of the corrected gene [121].
1.2.1.1 viral vectors:
Integration-deficient lentiviral vectors (IDLVs) and adeno-associated
virus (AAV) are tools to deliver nucleases ex vivo and in vivo. They
are charcaterized with high transduction efficacy and long-term gene
expression. IDLVs provide the ability to pack the specific nuclease
and the donor DNA for HDR, but showed to integrate randomly into
the host genome. AAV vectors are non-pathogenic and facilitate de-
livery into dividing and non-dividing cells. Though, AAV vectors are
limited by their carrying capacity (~4.5 kb). ZFNs are relative small (
~1kb) and thus suitable for AAV vectors. However, TALENs can only
be packed as monomers with a small promoter sequence into the
AAV vectors. In the case of the spCas9 protein, a small orthogonal
saCas9 was developed, which can be packed with gRNA to the AAV
vector. Additionally, the repetitive nature of TALE-encoding genes
are an interferrence, as rearrangements and truncations occur using
both viral vectors [132, 121].
1.2.1.2 non-viral vectors:
Non-viral vectors possess a high carrying capacity, less toxicity and
are easily produced. But they revealed to be less efficient and also
toxic at high concentrations. Cationic liposomes and cationic poly-
mers such as polyethylenimine (PEI) are commonly used non-viral-
vectors [3]. The positive charge interact with the anionic nature of
the cell membrane and triggers cellular uptake [121]. Furthermore,
direct delivery of purified proteins was realized. Due to the positive
charge of the zinc fingers, they are cell-penetrating proteins. Mod-
ified TALENs with cell-penetrating peptides do also enable cellular
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uptake. A similar approach was used to promote cellular uptake of
the Cas9 protein and its gRNA [132].
1.2.1.3 Physical methods:
The most commonly used physical methods for delivery of specific
nucleases are electroporation and microinjection. Electroporation gen-
erates microscopic pores due to electrical pulses. By microinjection
the editing technology can be introduced directly to the cell, using a
needle (0.5 μm -20 μm in diameter) in combination with a specialized
microscope [3].
1.2.2 Impact of epigenetics on enzyme activation
The accessibility of the target sequence in the chromatin structure is
another aspect to consider. Relaxing the chromatin structure by the in-
hibition of epigenetic modulatory activity of the histone deacetylases
improved the targeting frequency of specific nucleases [29]. Silencing
a protein encoding gene which is required for chromatin remodel-
ing has been shown to improve the efficiency of specific nucleases
[56]. Additionally, blocking DNA-methyltransferase resulted in an
increased TALENs activity [29]. Consequently, an optimized TALE
RVD was designed to overcome the sensitivity to cysteine methyla-
tion [221]. Due to the epigenetic mechanisms of the cell cycle, the
chromatin structure is looser in the S phase, when DNA replication
occurs [13]. Thus, optimized cleavage takes place in the S phase of
the cell cycle [164].
1.2.3 Therapeutic potential
ZFNs are the most commonly used therapeutic tool, as they are the
first developed specific nucleases [117]. ZNFs addressing the CCR5
gene to treat Human immunodeficiency virus (HIV-1) resistance have
already completed an early phase of human clinical trails. The CCR5
gene is disrupted by NHEJ, which prevents expression of the CCR5
receptor. This receptor is needed for viral uptake to the CD4+ T cell,
which serves the virus as host cell [97, 166, 214]. TALENs and Cas9
proteins were employed to treat HIV-1 in different cell lines [241, 68].
Another clinical relevant example is hemophilia B, a genetic disorder
causing a deficiency of the coagulation factor IX (F9). Introducing
a donor DNA with the expression sequence of factor IX by HDR in-
creased the concentration of F9 and improved clotting time in trans-
genic hemophilic mice [126]. Treatment of the X-linked hereditary dis-
ease, Duchenne muscular dystrophy (DMD) was realized with ZFNs
[161], TALENs [161] and the CRISPR/Cas9 system [133]. The mono-
genetic disease is caused by a mutation in the dystrophin gene, which
is required for muscular function. Treatment was realized with ZFNs,
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an ex vivo protocol, and manipulated undifferentiated cells were trans-
planted back to the limb of mice [161]. Furthermore, the newly estab-
lished CRISPR/Cas9 system was used to treat DMD in mice [133].
Recently, a 11 month girl with B cell leukemia was successfully
treated with universal chimeric antigen receptor (UCAR)19 T-cells.
The UCAR19 T-cells were engineered by the TALEN-based editing
technology of Cellectis to suppress the alloreactivity of the T-cells and
acquire resistance to the monoclonal antibody Alemtuzumab, which is
a drug to treat B cell leukemia [173]. These examples demonstrate
the therapeutic potential of specific nucleases and the diversity of
their genetic targets [121].
1.2.3.1 Gene therapy without specific nucleases
1.2.3.2 Ocular gene therapy
Treatment of photoreceptor (PR) degeneration in the eye by gene
addition has been lately achieved [105, 11, 44]. The eye represent
an excellent target for gene therapy [14]. Three independent clin-
ical trails revealed the efficiency of gene therapy in patients with
RPE65-associated leber congenital amaurosis (LCA) ((NCT00481546,
NCT00516477, NCT00643747, clinicaltrials.gov). RPE65-associated LCA
is caused by RPE65 deficiency, an isomerase in the retinal pigment
epithelium (RPE) [44, 234]. RPE is a part of the blood-retinal barrier
and in metabolic relationship with the adjacent PR layer of the neural
retina.
The neural retina consists of the outer segment (OS) and the inner
segment (IS), which are linked by the connection cilium (CC). The
OS is light sensible and contains rods and cones, which are packed
with the G-protein-couple receptor opsin [233, 100]. The IS is respon-
sible for the protein production and the CC transports the proteins
from the IS to the OS by intraflagellar transport (IFT) [100]. The
light-sensitive chromophore 11-cis retinal is covalently bound to the
G-protein-couple receptor resulting rhodopsin (RHO) (Figure 5).
Activation of rhodopsin occur by light due to isomerization of 11-
cis retinal inducing a signal cascade [233]. Patients with RPE65 de-
ficiency have degeneration of RPE65 and PR, due to the missing iso-
merase which results in the accumulation of all-trans retinal [233]. By
introducing a recombinant AAV carrying the complete RPE65 gene,
the retinal sensibility could be improved [45, 44, 11, 105].
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1.2.3.3 X-linked form of retinitis pigmentosa (XLRP)
The successful application of gene therapy in RPE65-associated leber
congenital amaurosis resulted in attempts to treat other PR degenera-
tive diseases with gene therapy, such as the X-linked form of retinitis
pigmentosa (XLRP). XLRP represents 22% of all forms of retinitis pig-
mentosa and 80% of all XLRP cases are caused by a mutation in the re-
tinitis pigmentosa GTPase regulator (RPGR)-gene [100, 223, 198, 165].
The RPGR is concentrated in the CC, as well as in the OS of vertebrate
PRs and plays an essential role for CC trafficking. In fact, RPGR can
be found in many cells of the body in distinct splicing variants of the
gene. The RPGRORF15 splicing variant contains a terminal exon with
a repetitive glutamic acids rich domain, called open reading frame 15
(ORF15) and is found in large quantities in the PRs [100]. The ORF15
consists of an imperfect repeat motif, which carries 80% of sequence
alteration, causing a dysfunctional RPGR [223, 100]. Opsin miss-
location is often a hallmark for RPGR dysfunction [217, 234, 223].
Lately, AAV2/5 vectors carrying a full-length human RPGRORF15
cDNA were subretinally injected to four dogs which carried two dis-
tinct RPGR mutations [15]. Furthermore, the full-length RPGRORF15
packed into AAV 8 or 9 capsin were subretinally injected into Rpgr-
KO mice and could rescue the retinal structure and function [234].
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11-cis retinal
11-cis retinol
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Figure 5: The outer segment of the photoreceptore cells.
The outer segments (OS) are adjacent to the retinal pigment epithelium
(RPE). The light-sensitive chromophore 11-cis retinal is covalent bound
to opsin in the OS. Rhodopsin is activated by light, which trigger isomer-
ization of 11-cis retinal inducing a signal cascade. The resulting all-trans
retinal gets released from the rhodopsin and then it is transported to the
RPE. In the RPE it is modified to all-trans retinol, while it result in 11-cis
retinal by two following enzymatic catalyzed steps requiring RPE65 and
a dehydrogenase.
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1.3 aim
The aim of the present study was to characterize specific nucleases
with a focus on the site- and strand-specific nucleases TALE-MutH as
well as the binding domain AvrBs3.
We claim to analyze the mechanism of nicking and double nick-
ing by TALE-MutH in vitro as well as its enzymatic activity under
in vivo conditions using a Single-Strand-Annealing (SSA) assay in
Saccharomyces cerevisiae. In a comprehensive study the characteris-
tics of the monomeric nickase TALE-MutH, I-SceI and the widely
used TALE-FokI will be analyzed. Additionally, the characteristics
of TALE-PvuII variants and the gRNA nuclease under in vivo condi-
tion employing the SSA assay in S. cerevisiae should be defined and
compared to I-SceI. The most efficient specific nucleases will be chal-
lenged by targeting a relevant therapeutic gene, such as the RPGR
gene.
Furthermore, the thesis focused on the binding domain AvrBs3 and
aims to define the binding mechanism of TALE. There are several
studies characterizing the binding mechanism of TALE, while the ex-
act binding mechanism still remains to be elucidated. A hindrance to
investigate the binding mechanism are the lacking or restricted meth-
ods. Here, we claim to design an AvrBs3 which enable fluorescent
labeling at specific positions, while retaining the binding characteris-
tics. In 2015 AvrBs3 was labeled with Cy3 via an unnatural aldehyde
and for the first time the in vitro binding character of AvrBs3 was de-
scribed with single molecule studies [51]. In the present study, we
want to confirm the findings of Cuculis et al. [51] with a focus on
the conformation change between a non-specific TALE::DNA com-
plex and a specific TALE::DNA complex. This should be achieved
by Förster resonance energy transfer (FRET) experiments, which de-
pend on the distances between donor fluorophore and acceptor flu-
orophore. Two single labeled AvrBs3 variants should be designed,
which allows labeling of AvrBs3 specific and close to the N-terminus
region or close to the C-terminus region. We were aspired to design
an AvrBs3 labeled at two specific positions enabling to follow confor-
mational changes within the protein.
Part II
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2.1 materials
2.1.1 Chemical
Chemicals were applied from Merk, Roth, Sigma-Aldrich, Appli-
Chem or Qiagen and were diluted in molecular biology grade water.
2.1.2 Commercial DNA purification kits
Kits used for DNA purification are listed in table 1.
Table 1: Commercial purification kits for DNA
Commercial purification kit Provider
Wizard R SV Gel and PCR Clean – up System
PromegaPureYieldTM Plasmid Miniprep System
PureYieldTM Plasmid Midiprep System
2.1.3 Columns/matrices
By the principle of affinity chromatography the recombinant pro-
teins were purified above Strep-, His- beads and/or Heparin columns.
Labeled recombinant proteins were purified by the principle of size –
exclusion chromatography with Zeba Desalting spin columns. Table
2 gives the employed column and matrices.
Table 2: Columns and matrices
Column / matrix Provider
Ni-NTA agarose Macherey - Nagel
Strep-Tactin R Sepharose R IBA
HiTrap Heparin HP GE Healthcare Life Science
Zeba Desalting spin columns (40K) Pierce
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2.1.4 Dialyse tube
For dialyse the dialysis tube Visking type 8/32 (Roth) was used. The
semi-permeable membrane has an exclusion size of 14 kDa. The tubes
were boiled in ultra–pure water and stored in 20% ethanol at 4°C.
Before use the tubes were washed with ultra-pure water and dialyse
buffer.
2.1.5 Buffers and media
In this section, all employed buffers and media are listed. Buffers
and media were prepared with ultra-pure water from Mili-Q A10
ultra-pure water system (Milipore).
Buffer used for activity assays, for labeling reaction, as well as for
anisotropy and FRET experiments are given in table 3.
Table 3: Buffers for assays
Buffer compounds
low salt activity buffer 20 mM tris - acetate
50 mM potassium acetate pH 7.9
50 mM potassium acetate
10 mM magnesium acetate
1 mM DTT
labeling buffer 10 mM HEPES-KOH
1 mM EDTA
200 mM potassium chloride
10% Glycerin
physiological activity buffer 20 mM tris - acetate
e pH 7.5
120 mM potassium acetate
1 mM magnesium acetate
0.1 M DTT
1x NEB 3.1 buffer 50 mM Tris-HCl
pH 7.9
100 mM NaCl
10 mM MgCl2
100 ug/ml BSA
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To identify, quantify, and purify nucleic acid fragments, DNA elec-
trophoresis was used. The employed buffers are recorded in table
4.
Table 4: Buffers for DNA electrophoresis
Buffer Components
10 x Tris-phosphate-EDTA (TPE) buffer 0.9 M Tris,
pH 8.2
phosphoric acid
20 mM EDTA
10 x Tris-borate-EDTA (TBE) buffer 1 M Tris
pH 8.3
1 M boric acid
25 mM EDTA
50 x Tris-acetic acid-EDTA (TAE) buffer 2 M Tris
pH 8.0
1 M sodium acetate
50 mM EDTA
10 x Laemmli-SDS-electrophoresis-buffer 250 mM Tris
pH 8.3
1.9 M glycine
SDS 1% (w/v)
5 x AAP agarose loading buffer 250 mM EDTA
pH 8.0
sucrose 25% (w/v)
SDS 1.2% (w/v)
bromphenol blue 0.1% (w/v)
6 x SDS loading buffer 420 mM Tris-HCl
pH 6.8
0.1% SDS
2-mercaptoethanol 7.2 (v/v)
glycerol 36% (v/v)
bromphenol blue 0.06% (w/v)
Coomassie staining solution coomassie brilliant blue G250 0.1% (w/v)
phosphoric acid 2% (v/v)
aluminum sulfate 5% (w/v)
ethanol 10% (v/v)
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Table 5 provides buffers used for working with Saccharomyces
cerevisiae.
Table 5: Buffers for Saccharomyces cerevisiae
buffer components
transformation mix 0.1 M lithium acetate
10 mM tris-HCl
1 mM EDTA
polyethylene glycol (PEG 3350) 40% (v/v)
LTE buffer 0.1 M lithium acetate
10 mM tris-HCL
1 mM EDTA
10 x BU salt 250 mM NaH2PO4
pH 7
195 mM Na2HPO4 7 H2O
10 x dropout solution 200 mg/L L-Adenine hemisulfate salt
missing appropriate amino acid 200 mg/L L-Arginine HCl
200 mg/L L-Histidine HCl monohydrate
300 mg/L L-Isoleucine
1000 mg/L L-Leucine
300 mg/L L-Lysine HCl
200 mg/L L-Methionine
500 mg/L L-Phenylalanine
2000 mg/L L-Threonine
200 mg/L L-Tryptophan
300 mg/L L-Tyrosine
200 mg/L L-Uracil
1500 mg/LL-Valine
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Media used for E. coli and S. cerevisiae are given in table 6.
Table 6: Media for E. coli and Saccharomyces cerevisiae
media compounds
Lysogeny broth (LB) media trypton 1% (w/v)
yeat extract 0.5% (w/v)
NaCl 0.5% (w/v)
pH 7.5
SOC media bacto tryptone 2% (w/v)
yeast extract 0.5% (w/v)
10 mM NaCl
0.5 mM potassium chloride
10 mM MgCl2
10 mM MgSO4
20 mM glucose
pH 6.5
YPAD media yeast extract 1% (w/v)
bacto pentone 2% (w/v)
dextrose 2% (w/v)
bacto agar 2% (w/v)
adenine hemisulfate salt 7.5 x 10-3% (w/v)
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To grow E. coli colonies LB-plates containing antibiotics were used.
For S. cerevisiae drop out plates were employed(Table 7).
Table 7: LB-plates and drop out plates
plate compounds
LB-plate LB-media
agar 0.015 (w/v)
drop out plate yeast nitrogen base without aa 0.67% (w/v)
(-HIS/-TRP) agar 0.0 % (w/v)
1 x dropout solution (-HIS/-TRP)
dextrose 2% (w/v)
0,08 g/ml X-GAL
1 x BU salt buffer
drop out plate yeast nitrogen base without aa 0.67% (w/v)
(-His) agar 0.03% (w/v)
1 x dropout solution (-HIS)
dextrose 2% (w/v)
1 x BU salt buffer
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2.1.6 Fluorophores
Several fluorophores were used to either label target DNA or different
variants of AvrBs3 proteins and are listed in table 8.
Table 8: Physical properties of fluorophores used for labeling DNA and pro-
teins. Maleimide-fluorophores were utilized for protein labeling and re-
acted with the cysteine residues of the AvrBs3 variants. AF,max. and E
F, max.: Absorbance and fluorescence emission maxima in nm; * correction
factor of fluorophores at 280 nm and 260 nm.
Physical
properties
Cy3 Cy5 HEX Alexa594 Alexa488 Alexa647
AF,max.[nm] 550 649 535 590 495 650
E F, max.
[nm]
570 670 560 617 519 665
εmax[cm-1M-1] 150,000 250,000 96,000 73,000 71,000 239,000
cf280* - 0.05 - 0.56 0.11 0.030
cf260* 0.08 - 0.33 0.43 0.30 0.00
In figure 6 the chemical structure of the cyanine fluorophores Cy3
(I) and Cy5 (I) are given, as well as the chemical structure of the 6-
carboxy-2 ,4,4 ,5 ,7,7 -hexachlorofluorescein succinimidyl ester HEX
(II) fluorophore. Cy3 and HEX fluorophores were labeled to the DNA
and Cy5 maleimide was used to label the single cysteine AvrBs3 vari-
ants.
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Figure 6: Chemical structures of fluorophores
Chemical structure of the fluorophores Cy3 (I), Cy5 (II) and HEX (III).
32 material and methods
The chemical structures of the fluorophores used for labeling the
single cysteine variants, as well as the double cysteine AvrBs3 vari-
ants are given in figure 7. All fluorophores used to label the protein
contained a maleimide functional group.
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Figure 7: Chemical structures of fluorophores
Chemical structure of Alexa 488 (I), Alexa 594(II), and Alexa 647(III).
2.1.7 Plasmids
Plasmids were used to construct the binding domains TALE or as
expression and substrate vector.
2.1.7.1 Binding domains TALE
Binding domains TALE were cloned by the Golden Gate TALEN and
TAL effector kit 2.0. This plasmid Kit was a gift from Daniel Voytas
and Adam Bogdanove (Addgene kit # 1000000024) [33]. It contains
all required plasmid to construct a TALE binding domain.
2.1.7.2 Expression vectors
pqe – 30 vector The pQE-30 vectors can be used for protein
expression in all ampicillin – sensitive E. coli strains containing pREP4
repressor or lacZ gene on the F-factor episome. The vector harbours
a T5 – promoter, which is under control of the lac-repressor. The N-
terminal His-tag was sub cloned to the C-terminus coding sequence
and a Strep-tag was added to the N-terminal coding sequence.
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pqe-30_strep -avrbs3(n152-c28) contains the truncated version
of AvrBs3 (∆N152-C28).
pqe-30_strep -avrbs4 (28)-muth-his was a gift from Gabsalilow
et al. [78]. It expresses the fusion construct Strep-AvrBs4-MutH-His.
AvrBs4 is truncated at the N-terminus and the C-terminus (∆N152-
C28). The linker between the repeat array of AvrBs4 and MutH con-
sist of 28 amino acids behind the last half repeat of AvrBs4.
pzhy500 vector The shuttle vector pZHY500 was constructed by
Daniel Voytas (Addgene plasmid # 36186) as compatible yeast expres-
sion vector for TALENs [246]. It harbours a truncated TALEN archi-
tecture [246] and is a Golden gate compatible expression vector [33].
The N-terminus and C-terminus are truncated (∆N152-C68) and the
repeat array is replaced by a lacZ-gene. The homodimeric FokI nuc-
lease is fused direct to the C-terminus. pZHY500 contains a HIS3
selectable marker, as well as ampicilline resistance. For expression in
yeast a TEV-promoter is used.
cas9 system :
p414-tef1p-cas9-cyc1t For using the CRISPR-Cas system in Sac-
charomyces cerevisiae the Cas9 protein was expressed from the plas-
mid p414-TEF1p-Cas9-CYC1t, a gift of George Church [58] (Addgene
plasmid # 43802). It contains the selective marker TRP1.
prpr1_grna_handle_rpr1t The guided RNA was constructed
starting with the plasmid pRPR1_gRNA_handle_RPR1t from Lu T.
[69] (Addgene plasmid # 49014).
pvax This vector can be used for the expression of recombinant
proteins in eukaryotic cells. It harbours a kanamycin resistance gene
and expression is under control of a CMV promoter.
2.1.7.3 Substrate vectors
pat153 was used as a substrate vector. It contains 19 unaddressed
MutH recognition sites and an ampicillin resistance-gene.
pat153_t-3-h/pat153_t-6-h were made by Gabsalilow et al. [78]
for the analysis of the in vitro activity and specificity of the AvrBs4_MutH
protein. The vectors harbours the 18 bp AvrBs4 recognition site with
different spacer length to the recognition site of MutH (Table 9).
pat153_t3-4-p-4-t3 were made by Yanik et al. Yanik et al. [239]
for the analysis of the in vitro activity and specificity of the AvrBs3-
PvuII variants. In table 9 the inserted target site is listed.
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Table 9: Addressed target sites
Specific sequences of the target site of AvrBs4 (T), AvrBs3(T3), MutH(H),
and PvuII(P) are underlined. The number between T and H represents the
spacer length in basepairs.
Target site Abbreviation
5‘-TGCAGTATAATTAATAATCCACTTGAGGATCCTCGCTACATG-3‘ T-3-H
‘5‘-TGCAGTATAATTAATAATCCACTTGAGCCGGATCCTCGCTACATG-3‘ T-6-H
‘5- TCTATAAACCTAACCCTCTATCCCAGCTGTCTAAGAGGGTTAGGTTTATAGA-3‘ T3-4-P-4-T3
pcp5 vector from Daniel Voytas (Addgene plasmid # 35397) [33],
a E. coli/yeast shuttle vector, was used as a reporter plasmid in yeast.
It harbours a URA3 selective maker, which is flanked by a divided
lacZ-gene which contains 125 bp duplication. Additionally, it encom-
passes a TRP1 selective marker, kanamycin resistance and chloramphen-
icol resistance. The pCP5 vector uses a GDP promoter. A ccdB
lethal gene, which is used as a selection marker, is also integrated
in between the divided lacZ gene.
2.1.8 E. coli and Saccharomyces cerevisiae strains
E. coli
XL10 – Gold strain was used for the expression of pQE_Strep-
AvrBs4-MutH-His and pQE_Strep-AvrBs3, as well as for several clon-
ing steps of pZHY500.
Genotype: endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183
Δ(mcrCB-hsdSMR-mrr)173 tetR F’[proAB lacIqZΔM15 Tn10(TetR Amy
CmR)]
DH5α strain was mainly used to sub clone the reporter plasmid
pCp5.
Genotype: F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ–
JM109 strain was used for cloning the TALE binding domain by
employing the Golden Gate strategy.
Genotype: endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB+ Δ(lac-
proAB) e14- [F’ traD36 proAB+ lacIq lacZΔM15] hsdR17(rK-mK+)
JM110 strain was used to multiply the substrates inserted in pAT153.
JM110 lacks methylase dam and dcm and therefore produces non
methylated DNA.
Genotype: rpsL thr leu thi lacY galK galT ara tonA tsx dam dcm
glnV44Δ(lac-proAB) e14- [F’ traD36 proAB+ lacIq lacZΔM15] hsdR17(rK-
mK+)
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Saccharomyces cerevisiae
YPH500 yeast strain was used for the yeast activity assay, which
is describe in 2.2.. Genotype: MATα ura3-52 lys2-801_amber ade2-
101_ochre trp1-Δ63 his3-Δ200 leu2-Δ1
2.1.9 Enzymes and markers
Enzymes used were provided by Thermo Scientific Fermentas or New
England Biolabs (NEB). Markers for gel electrophoresis are listed in
table 10.
Table 10: Maker for gel electrophorese
Marker Provider
PageRulerTM Unstained Protein Ladder
Thermo Scientific FermentasGeneRulerTM 1kb DNA ladder
pUC Mix Marker, 8, ready to use
2.1.10 Primer and oligonucleotide
Cassettes used as inserts are summarized in table 11.
Table 11: Cassettes used as inserts
Specific sequences of the target site of TALE(T) and MutH(H) are un-
derlined. The number between T and H represents the spacer length in
basepairs.
Sequences of cassettes Abbreviation
..........5‘-TCTCAGCGAGGATCCGGAAGTGGATTATTAATTATACTGCACATG-3‘
H-3-T
3‘-CATGAGAGTCGCTCCTAGGCCTTCACCTAATAATTAATATGACGT-5‘
...........5‘-TGCAGTATAATTAATAATCCACTTCCGGATCGATCCGGAAGTGGATTATTAATTATACTGCACATG-3‘ T-3-HH-3-T
3´-CATGACGTCATATTAATTATTAGGTGAAGGCCTAGGCCTTCACCTAATAATTAATATGACGT-5‘
............5‘-TGCAGTATAATTAATAATCCACTTCCGGATCCGGAAGTGGATTATTAATTATACTGCACATG-3‘
T-3-H-3-T
3´-CATGACGTCATATTAATTATTAGGTGAAGGCCTAGGCCTTCACCTAATAATTAATATGACGT-5‘
5‘- CTAGGCGGTACCTAATAGTAGCT - 3‘
stop codon
...........3‘- CGCCATGGATTATCA - 5
5‘- GCTGCGATTGGCAGAAGCTTGGATAACAGGGTAATATAGCGTTTTAGAGCTAGAAATAGC-3‘ insert for
gRNA5‘- CGACGCTAACCGTCTTCGAACCTATTGTCCCATTATATCGCAAAATCTCGATCTTTATCG-3‘
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Cassettes used as target DNA for anisotropy and FRET experiments
are given in table 12.
Table 12: Cassettes used as target DNA
The specific DNA contains the AvrBs3 binding site (underlined) and is
either labelled with Hex at the 5´ -end of the bottom strand or does not
posses a fluorophore label. For fluorecence based experiments, specific
DNA was labelled with Cy3 at the 5´ -end of the top or bottom strand.
The scramble DNA consists of the same nucleotide composition, but in a
random order.
DNA Name Length [bp] Fluorophores
5‘-TTTATCTATAAACCTAACCCTCTCT-‘3
specific DNA 25 HEX or Cy3
3‘-AAATAGATATTTGGATTGGGAGAGA-‘5
5‘-ACACCTCTACCTATCTTATATCTTA-‘3
scramble DNA 25 -
3‘-TGTGGAGATGGATAGAATATAGAAT-‘5
Primer used to create magaprimer for Mutagenesis-PCR are listed in
table 13.
Table 13: Primers used to create Megaprimers
The first four oligos were used to create megaprimer, which induces a
AvrII cutting site to the plasmid, respectively. All the rest were used to
create megaprimers to substitute C (cysteine) to M (methonine) in the
given plasmids.
Sequence Number
5‘-GAGCTCCCTAGGCAGGCCAAGGCGACGAGG-3‘ 558 558/455 (AvrII site
in stuffer-MutH)5‘-catcgcgcaatgcactgac-3‘ 455
5‘-CTGCAGGTCGACGGATCCTCCCAGACCCGGTTTAC -3‘ 423 423/455 (AvrII site
in pTal1)
5‘-CAGGACGTCCGCCTAGGCAGGCCAAGGCGAC-3‘ 523 455/523 (AvrII site
in pZHY500)
C to M substitution
5‘-GCGGCTGTTGCCAGTACTGATGCAGGACCATGG-3‘ 499 499/498 (pHD1,8,9;
pNI1,6,7; NG10)5‘-CGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAG-3‘ 498
5‘-GCTGTTGCCAGTACTGATGCAGGGAGACCCTCGAGC-3‘ 501 501/498 (pNI3,
pHD3)
5‘-TCCTCTAGAGGTCTCGGCAGGATCATGGCCTGACC-3‘ 502 502/498 (pNG4)
5‘-CTCCTGTTGCCAGTACTGATGCAGGACCATGGCCTG-3‘ 503 503/498 (pNI5,
pHD5)
5‘-CCTCTAGAGGTCTCGGCAGGATCATGGCCTGACTC-3‘ 695 695/498 (pHD4)
5‘-TAATACGACTCACTATAGGG-3‘ 41
41/686 pTal1(AvrII)
5‘-CAGGACGTCCGCCTAGGCTGGCCAAGGCGACGA-3‘ 696
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Primer used for screening and sequencing are shown in table 14.
Table 14: Primers
Oligos used for screening
Sequence Number
5‘-GTATCACGAGGCCCTTTCGTCT-3‘ 126 (for)
5‘-CATTACTGGATCTATCAACAGGAG -3‘ 68 (rev)
5‘-catcgcgcaatgcactgac-3‘ 455(for)
5‘-ggcgacgaggtggtcgttgg-3‘ 454(rev)
5‘-ttggcgtcggcaaacagtgg -3‘ 453(for)
5‘-GGAGAAAATACCGCATCAG -3‘ 477(rev)
5‘-CGGTTGCGCCACCCTGTCTCCCTTGC-3‘ MutHseq4 (rev)
5‘-TCATCGCAAGACCGGCAACAGGAT -3‘ 577 (rev)
5‘-CAACTTTCCACCATTGCCTTGAAAAATATCATTTA -3‘ 457 (rev)
5‘-TCCCCAGAAGCTACTCATGAAGCTATTGTTG -3‘ 564 (rev)
5‘-ATCCTGCACCATCGTCTGCT -3‘ 476 (rev)
5‘-ATGCACTAGATCTGGCGACCACACCCGTCAG -3‘ 473 (for)
5‘-CCCAGTACTAGTGAGGCCGTTGAGCACCGC -3‘ 474 (rev)
5‘-TTTATCTATAAACCTAACCCTCTGGATCCCAGCTGTCTAGACATG -3‘ 339 (for)
5‘-GGATCCCAGCTGTCTAGAAGAGGGTTAGGTTTATAGATAAACATG -3‘ 337 (rev)
5‘-TGACCTCCCATTGATATTTAAGTTAATAAACG -3‘ 487 (for)
5‘-CGTTCTCGGAGCACTGTCCGACCGCTTTGG-3‘ lab S/H (for)
5‘-GCACCGCCGCCGCAAGGAATGGTGC-3‘ t4-x-H (rev)
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2.2 methods
Microbiological standard methods (producing competent cells, trans-
formation of plasmids in E. coli cells or Saccharomyces cerevisiae cells
etc.) and microbiological standard methods (agorse- and polyacrylamide-
electrophoresis, DNA isolation, restriction digest etc.) were performed
as described in Current Protocols in Molecular Biology and Protein Sci-
ence [10, 46].
2.2.1 Molecular cloning
Molecular cloning is a technique to assemble recombinant DNA, which
is then replicated in a host organism. Recombinant DNA was intro-
duced to the host bacterium E. coli. In figure 8 the basic principles of
molecular cloning are shown. First, an insert has to be created, which
is then ligated into a plasmid. Inserts can be constructed by cassettes,
PCR amplification or digestion. Cassettes used as inserts for cloning
strategies are listed in table 11. These oligos were mixed in a 1:1 ratio,
heated at 95°C for 3 minutes and then slowly cooled down to RT. The
remaining inserts were processed either by PCR amplification of the
gene of interest or by digestion of a plasmid containing the gene of
interest. The amplified PCR fragments were digested by the required
restriction enzymes. Receiving the insert through digestion, the DNA-
fragments were separated by gel electrophoresis and the fragment
were purified by the Wizard R SV Gel and PCR Clean–up System
(Promega). The needed backbones were prepared by digesting the
plasmid with restriction enzymes and dephosphorylation of the DNA
ends by Fast AP (37°C, 15 min.). Digestion of DNA fragments or
plasmids were preformed at 37° C for 1 hour. For ligation 5 nM in-
sert, 3 nM backbone DNA, 1 x T4-ligase buffer and 1 μl T4–ligase, as
suggested by the manufacture, were mixed in 20 µl. Ligation were
performed at 22°C for 1 h or 16°C overnight. Z–competent cells were
prepared for transformation by the Z-competent E. coli Transforma-
tion Kit & Buffer Set (Zymo Research) and stored at -70°C. For trans-
formation cells were allowed to defrosted for 10 minutes on ice and
3-5 µl ligation–mixture was added to the cell aliquot. Further, the cell
aliquots stayed on ice over 5–10 minutes and 400 µl SOC media was
added. Cells were permitted to recover for about an hour at 37°C be-
fore distributing the cell aliquot on the essential LB–plate (37°C, o/n).
Figure 8 depicts the key steps of the cloning strategies.
Mutagenesis-PCR [118] was used to substitute precise amino acids.
First, a mega primer was amplified by PCR using primers including
the desired mutation. Next, the mega primer was then used for a
rolling circle PCR (Table 16), which amplified the complete vector,
containing the new mutation.
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(A)
(B)
double digestion
Figure 8: Basic steps of the cloning strategies
(A) Insert made by PCR amplification, followed by double digestion or
by immediate double digestion of the plasmid. (B) The backbone was
obtained by double digestion of the starting plasmid. The desired recom-
binant plasmid was gained by ligation.
Table 15: Components used for PCR are listed.
Components
100 ng DNA-matrix
400 nM 5‘-primer
400 nM 3‘-primer
200 μM dNTPs
1x Pfu-buffer
1 μl Pfu-polymerase
For exact amplification the pfu–polymerase of Pyrococcus furiosus
(3‘- 5‘ Exonucleaseactivity, Topt. = 68°C, ~ 500 nucleotide per minutes)
was used. To digest the template vector the mixture was digested by
DpnI, an enzyme which only cuts at methylated sites.
blue - white screening Blue -white screening was used to
simplify the cloning procedure, but the same principle was also ap-
plied in the single strand annealing assay, as described later. The
method is based on an enzyme, called ß-galactosidase. This enzyme
is able to convert 5- bromo-4-chloro-3-indolyl-β-D-galactopyranoside
(X–Gal) to a blue dye (figure 9). ß-galactosidase is encoded by the
lacZ gene of the lac operon and functions as a homotetramer. E. coli
strains carrying the lacZ deletion mutant (lacZΔM15) express a ß-
galactosidase (ω-peptide), which misses its N-terminal residues, res-
ulting in a non functional enzyme. If the E. coli strain carries a plas-
mid, which encodes the first 59 residues (α-peptide) of ß-galactosidase
the ω-peptide and the α-peptide reconstitute a functional ß-galactosidase
enzyme.
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Table 16: PCR-programs
PCR-programs applied for this thesis are described. The basic program
is used to amplify DNA fragments. Tannealing depend on length and com-
position of the primer and Toptdepends on the employed polymerase
(e.g. Taq-polymerase Topt.= 72°C). The rolling circle program is used for
mutagenesis-PCR. Prior to that, a megaprimer is processed, which con-
tains the relevant mutation.
basic program rolling circle program
temperature
[C°]
time
[min]
temperature
[C°]
time
[min]
94 2 94 2
92 0.75 94 0.75
Tannealing~
58-62
0.50 60 0.50
Topt. 500-1000
nt/min
go to step
one and
repeat 30 x
68 15 go to step
one and
repeat 20 x
Topt. 5 68 20
4 break 4 break
The LB-plates have to be spread with 40 μl 20 mg/ml X-Gal and
40 μl of a 0.1 M Isopropyl β-D-1-thiogalactopyranoside (IPTG). IPTG
is needed to inactivate the LacZ repressor in E. coli. The colonies
growing on the plate will either be white or blue, depending on the
existence of the α-peptide encoding plasmid.
NHOH
OOH
OH
OH
BrCl
O
OH
HO OH
OH
OH
+H2O
-
2x
2x
NH
Br
HO
Cl
2x
NH
Br
ClO
NH
Br
Cl O
X-Gal
+ ß-galactosidase
dimerisation
galactose
5,5'-dibromo-4,4'-dichloro-indigo
Figure 9: X-Gal converted to a blue dye
ß-galactosidase hydrolyse X-Gal to galactose and 5-bromo-4-chloro-3-
hydroxyindole. Due to spontaneous dimerisation followed by oxida-
tion, a 5,5’-dibromo-4,4’-dichloro-indigo is yielded and responsible for
the blue color.
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2.2.1.1 Golden Gate
The TALE binding domains were designed with the Golden Gate
TALEN and TAL Effector Kit 2.0 from Daniel Voytas and Adam Bog-
danove (Addgene Kit#1000000024) [33]. The kit consists of bacterial
glycerol stocks enclosing the required plasmids to construct a TALE
binding domain. The kit enables to design TALE binding domains
enclosing 12-31 repeats. The kit contains various plasmids. The back-
bone scaffold (pTAL1-4) contains the TAL-effector gene. Here the
repeat array is replaced with a lacZ gene, which functions as stuffer.
The lacZ gene enabled blue-white screening.
Plasmids containing the encoding sequence for one repeat (e.g. pNG1)
and a tetracycline resistence and plasmids carrying the encoding se-
quence for a last half repeat (e.g. pLR-HD) with a spectinomycin
resistence are included. Plasmids named, pFusA(1-10) or pFusB(1-10)
can assemble up to 10 repeats in one plasmid and enclose a spectino-
mycin resistence-gene.
The principle of Golden Gate cloning strategy is to use typeIIs
restriction enzymes, which induce DSBs outside of their recognition
sites. Due to that, sticky ends emerge which can exclusively be lig-
ated to a compatible other sticky end. The kit enables to assemble
ten repeats into one back bone in a one pot reaction. In figure 10, the
principle is illustrated. The protocol of the the Golden Gate TALEN
and TAL Effector Kit 2.0 take five days to construct one binding do-
main and we followed the protocol exactly as recommended by the
manufactures.
All constructed TALE binding arrays were assembled into a modi-
fied pTAL1 vector, which contained a AvrII cutting site. This enabled
us to insert the TALE binding arrays into the specific expression vec-
tor. We used modified versions of pZHY500[246] for yeast expression,
pVAX for expression in HEK297 cells and pQE-30 vectors for expres-
sion in E. coli. In table 17 the repeat composition of the designed
TALE binding domains are given.
2.2.2 vectors
expression vectors The expression vectors were modified for
the insertion of the TALE binding domains. An AvrII cutting site was
introduced by Mutagenesis-PCR to pTAL1 and pZHY500. This en-
abled us to remove the TALE binding domain from the pTAL1 vector
with the restriction enzymes AvrII and StuI and to insert the repeat
array into the modified pZHY500 expression vector.
yeast expression vector pzhy500_avrbs4-foki : The sequence
encoding AvrBs4 was inserted to create the coding sequence for the
homodimeric AvrBs4-FokI.
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RVD1CTAT GTAC
BsaIBsaI
RVD2CATG CCTG
BsaIBsaI
....
RVD10GCTC CCGT
BsaIBsaI
+ +
tet tet tet
+
LacZGATA GGCG
BsaIBsaI
spec
(I)
 (10)CCCT ACCG
Esp3IEsp3I
spec
 (7)TGGA
Esp3IEsp3I
spec
+
LacZGGGA AACG
amp
+
 (0.5)CTAT TTGC
Esp3IEsp3I
tet
GATA
pFUSA(10) pFUSB(7) e.g. pLR-HD
pFusA(10) or pFusB(7)
(II)
one pot reaction (I)
one pot reaction (II)
Esp3IEsp3I
pTAL(1-4)
Figure 10: Golden Gate cloning strategy
(I) The first one pot reaction can assemble up to ten repeats into the
pFusA(1-10) or pFusB(1-10) backbone. Each repeat is cut out by the
restriction enzyme BasI, which induces a DSB outside of the recognition
site. Due to the resulting sticky ends, the fragments are ligated to each
other in a specific order. (II) The second one pot reaction assembles
pFusA(10), pFusB(7), pLR-HD, and pTAL1 by the same principle, but
using the restriction enzyme Esp3I.
Table 17: Repeat composition assembled with the Golden Gate cloning
strategy
Two naturally occurring TALE binding domains were designed (AvrBs4
and AvrBs3). Additionally, five binding domains addressing a GATC site
(I) and (II) in the RPGR-gene were constructed.
Repeat composition Name
NI1 NG2 Ni3 Ni4 NG5 NG6 NI7 Ni8 NG9 NI10 NI1 NG2 HD3 HD4 NI5 HD6 NG7 NG AvrBs4
HD1 NG2 NS3 NG4 NI5 NI6 NI7 HD8 HD9 NG10 NS1 NS2 HD3 HD4 HD5 NG6 HD7 NG AvrBs3
TALE(RPGR)
HD1 NI2 NH3 NH4 NH5 NH6 NH7 NH8 NH9 NI10 NH1 NI2 NH3 NI4 Nh5 NI6 NH7 NI 1(I)
NG1 NG2 NH3 NI4 NG5 HD6 HD7 HD8 HD9 NH10 NG1 HD2 NI3 HD4 HD5 HD 2(I)
HD1 NI2 HD3 NI4 NH5 Ni6 NG7 NG8 NG9 NH10 NI1 NG2 HD3 HD4 HD5 NH6 NG7 HD8 NO 3(I)
HD1 NG2 NI3 NN4 NI5 HD6 NG7 HD8 NI9 HD10 HD1 NG2 NG3 HD4 NG5 HD6 NI7 HD8 NI9 NN10 NI 1(II)
NH1 NG2 NG3 NG4 HD5 NG6 NI7 NI8 NI9 HD10 NG1 NH2 NI3 HD4 HD5 NG6 NG7 HD8 NG9 HD10 NI1 HD 2(II)
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pzhy500_avrbs4 : A negative control vector (AvrBs4-stop) was
designed by replacing the homodimeric FokI cleavage domain by
the stop codon cassette (5‘- CTAGGCGGTACCTAATAGTAGCT – 3‘,
3‘-GATCCGCCATGGATTATCATCGA-5‘) inserted in the AvrII and
HindIII sites.
pzhy500_i-scei : The plasmid coding for I-SceI was created by
amplifying the I-SceI gene using pASK_His-MutH-I-SceI-Strep as a
template and inserting the PCR fragment into the vector pZHY500
following he cutting with XbaI and SacI.
pzhy500_avrbs4-muth : To construct an analogue yeast expres-
sion vector for AvrBs4-MutH the lacZ-gene was amplified by PCR
and inserted by StuI and SacI as a stuffer replacing TALE in the E. coli
expression vector pQE30_Strep-TALE-MutH-His6 [78]. Next, stuffer-
MutH was amplified and integrated into pZHY500 using StuI and
Ecl136, resulting in pZHY500_stuffer-MutH. An AvrII site was intro-
duced by mutagenesis PCR and the stuffer (lacZ-gene) was replaced
by the encoding sequence of AvrBs4.
pzhy500_avrbs3-pvuii (variants): To construct analogue yeast
expression vectors for AvrBs3-PvuII variants, the MutH-encoding gene
in pZHY500_lacZ-MutH was replaced by the respective PvuII (hfPvuII,
scPvuII, D30KPvuII, and K38DPvuII) encoding gene using AvrII and
Ecl136 sites. The stuffer (lacZ-gene) was replaced by the encoding
sequence of AvrBs3 using the AvrII and the StuI site.
hek297 expression vector pvax_tale(rpgr): All TALE ar-
rays addressing the RPGR-gene were inserted into pVAX_stuffer-MutH.
The encoding sequence stuffer-MutH was gained as described above
and inserted into the pVAX vector using StuI and Ecl136 sites. The
requiered pVAX-TALE(RPGR) vectors were constructed by using the
AvrII and StuI cutting sites.
Cysteine to methionine substitution in AvrBs3
Additionally, different variants of the TAL effector AvrBs3 were de-
signed using the plasmid kit for the generation of TALENs as de-
scribed by Daniel Voytas and Adam Bogdanove (Addgene kit # 1000000024)[33].
Cysteine residues at position 30 in all single 17 repeats were substi-
tuted by mutagenesis PCR to methionine. Furthermore, the cysteine
in the backbone pTAL1 was removed by mutagenesis PCR. An Av-
rII cutting site was introduced into the backbone pTAL1, to relocate
AvrBs3 variants into an E. coli expression vector pQE30_Strep-AvrBs3.
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Table 18: AvrBs3 variants
TALEs made with Golden Gate strategy. TALEs were cloned into pTAL1
+ AvrII backbone. RVDs which are underlined include cysteine to me-
thionine substitution. The last half repeat contains no cysteine. (I)
represent AvrBs3 without any cysteine; (A) represent AvrBs3 (A) carry
one cysteine residue in repeat domain one; (B) AvrBs3 (B) enclose one
cysteine residue in repeat domain sixteen; (AB) AvrBs3 (AB) contain one
cysteine residue in repeat domain one and one cysteine domain in repeat
number sixteen.
repeat composition name
HD1 NG2 NS3 NG4 NI5 NI6 NI7 HD8 HD9 NG10 NS1 NS2 HD3 HD4 HD5 NG6 HD7 NG (I)
HD1 NG2 NS3 NG4 NI5 NI6 NI7 HD8 HD9 NG10 NS1 NS2 HD3 HD4 HD5 NG6 HD7 NG (A)
HD1 NG2 NS3 NG4 NI5 NI6 NI7 HD8 HD9 NG10 NS1 NS2 HD3 HD4 HD5 NG6 HD7 NG (B)
HD1 NG2 NS3 NG4 NI5 NI6 NI7 HD8 HD9 NG10 NS1 NS2 HD3 HD4 HD5 NG6 HD7 NG (AB)
crispr-cas system : The guided RNA was constructed starting
with the plasmid pRPR1_gRNA_handle_RPR1t from Lu T. [69] (Ad-
dgene plasmid # 49014). Using a one-step Gibson assembly reaction a
20 bp reporter (5‘-GGATAACAGGGTAATATAGC-3‘) was introduced
into the gRNA- expression plasmid. The target site addressed overlap
with the I-SceI target site.
gibson assembly The Gibson Assembly® Cloning Kit from NEB
was used to design the gRNA. The HindIII site in pRPR1_gRNA_handle_RPR1t
was employed to insert the specific sequence via an one-step Gibson
assembly. The cassette used for insertion carried the 20 bp homo-
logous sequence upstream and downstream of the HindIII site. In
between the 20 bp duplications sequence, the 20 bp sequence address-
ing the Cas9 target site is located. HindIII digestion was followed by
5‘-end resection, the homologous parts anneal with each other and
the DNA polymerase extends the 3‘-ends. Finally, the DNA ligase
seals the nicks. The procedure was performed as recommended by
the manufactures.
substrates The substrate plasmids pat153_T-3-H-3-T, pat153_T-
3-HH-3-T and pat153_H-3-T were constructed as has been previously
described by Gabsalilow et al. [78]. The appropriate DNA-cassette
enclosing the target site was inserted to pat153 by using the KpnI
and SphI cutting sites.
To design and construct the E. coli/Yeast shuttle vectors the target
sites of the different pat153 plasmids were amplified and inserted via
the BglII and SpeI site into pCP5, a kind gift from Daniel Voytas [33]
(Addgene plasmid # 35397).
The target site (pCP5_T3-4-P-4-T3) for the AvrBs3-PvuII variants
was constructed similarly by Dr. Mert Yanik.
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2.2.3 Protein expression and purification
AvrBs3-MutH
Strep-AvrBs4(28) –MutH-His (Figure 13), containing a Strep-tag and
a His-tag, was purified by the tandem purification, recently described
by Gabsalilow et al. [78]. E. coli strain XL-10 Gold was transformed
with the expression plasmid. 25 ml LB-media containing ampicillin
(75 µg/ml) was inoculated and incubated over night at 37°C. Next,
500 ml LB-media, containing ampicillin, was inoculated with the overnight
culture and shaken at 37°C until an optical density (OD600) of 0.7
-0.9 was reached. Expression was induced with 1 mM isopropyl-β-
d-thiogalactopyranoside (IPTG). The LB-media was incubated over
night at 20°C. The cell suspension was centrifuged (3600 x g, 4°C;
15 min). The supernatant was removed and cells were washed with
40 ml His-binding-/ washing buffer (20mM tris-HCl, 1 M NaCl, 20
mM imidazole, 1mM phenylmethanesulfonyl fluoride (PMSF), pH
7.9). Cell lysis was achieved by sonification (Duty Cycle 50 %, output
Control 5; 12 x 15 sec) and cell extracts were centrifuged (31000 x g, 30
min at 4°C). Meanwhile Ni-NTA agarose (Qiagen) was equilibrated
with 30 ml His - binding -/ washing buffer for 30 min at 4°C. The
equilibrated Ni–NTA was incubated with the clean cell extract for 1 h
at 4°C and washed twice afterwards with 40 ml His-binding-/ wash-
ing buffer. The Ni-NTA beads were transferred to a Poly–Prep chro-
matography column (Poly-Prep, BioRad)) and the protein was eluted
with 3 x 1 ml elution buffer (20mM tris-HCl, 1 M NaCl, 200 mM im-
idazole, pH 7.9). The eluates of the His–purification were loaded on
a column with Strep–Tactin sepharose (IBA). The Strep-Tactin sphar-
ose was washed with 4 ml Strep-binding-/ washing buffer (100 mM
tris-HCl, 1 M NaCl, pH 7.9) and the protein was eluted with 5 x 500
µl Strep–elution buffer (100 mM tris-HCl, 500 mM NaCl, 2.5 mM,
desthiobiotin, pH 7.9). The eluates were combined and concentrated
at 4°C by dialysis into 10 mM HEPES-KOH, pH 7.9, 500 mM KCl, 1
mM EDTA, 1 mM dithiothreitol (DTT) and 50% (v/v) glycerol. The
protein was stored at -20°C and concentrations were determined by
absorbance (280 nm) according to Pace et al. [162].
AvrBs3 variants
Strep-AvrBs3 variants (Figure 33), containing a Strep-tag were pur-
ified using a Strep-Tactin sepharose column as describe in chapter
2.2.3. Except that the supernatant after cell lysis was filtered with a
syringe filter (0.45 μm Celluloseacetat Membran, VWR) and loaded
on the Strep –Tactin sepharose column. AvrBs3 variants were labeled
in the next step or purified in a second step over heparin sepharose
columns. The protein eluate of the Strep-tag purification was diluted
to a salt concentration of 160 mM. The ion exchange chromatography
was performed with Äktapurifier 10 Chromatographie System (GE
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Figure 11: Single strand annealing
Specific nuclease induces a DSB and triggers SSA. The blue arrows indic-
ate the partially duplicated fragments of the lacZ gene. DSB is followed
by 5‘-end resection and the duplicated parts anneal to each other. This
results in overhangs, which are resected and the gabs are filled with nuc-
leotides. Finally, the junction is ligated and resulting in a functionally
lacZ gene.
Healthcare). The gradient was shaped by a high (1000 mM NaCl)
and low salt (150 mM NaCl) buffer and AvrBs3 variants eluated at a
NaCl concentration of 285 nM. The eluate were combined and con-
centrated at 4°C by dialysis into 10 mM HEPES-KOH, pH 7.9, 500
mM KCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dith-
iothreitol (DTT), 50% (v/v) glycerol.
2.2.4 Eukaryote cell systems
Single strand annealing assay
To determine the specific in vivo activity and efficiency of the ana-
lyzed nucleases, a yeast based recombinant assay was established ac-
cording to the method previously described by Cermak et al. [33].
Briefly, successful cleavage of the target positioned between two par-
tially duplicated fragments of the lacZ gene reconstitutes a functional
lacZ gene due to subsequent single strand annealing (figure 11 ), thus
enabling a quantitative analysis of the nuclease activity. Yeast cells
YPH500 were co-transformed with a 1:1 ratio of the reporter plasmid
(pCp5_addressed site) and the expression plasmid (pZHY500_specific
nuclease). Three different amounts of respective inserted DNA were
tested (1000 ng, 2000 ng, and 3000 ng). 200 µl of the transformation-
mixture were evenly dispersed on a drop out media plate, contain-
ing 0.08 mg/ml 5- bromo-4-chloro-3-indolyl-β-D-galactopyranoside
(X–GAL). After 5 days of incubation at 30°C, outgrowth of blue and
white colonies was counted. All designed nucleases were compared
to I-SceI on target T-3-HH-3-T. Levels of significance were determined
by unpaired T-tests (P < 0.05 *, P < 0.01 **, P < 0.001 ***).
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2.2.4.1 HEK293T cytotoxicity assay
The TALE-MutH constructs were analyzed in terms of their cytoxicity
and activity in HEK293T cells together with Dr. Yanik in the retinal
gene therapy lab of Prof. Dr. Dr. Knut Stieger.
cytotoxicity assay [49]: To determine the nuclease-assocciated
toxicity, HEK293T cells were seeded in a 24-well plate at a density
of 150,000 cells per well in Dulbecco’s modified Eagle media sup-
plemented with 10% fetal bovine serum and penicillin/streptomycin
(Invitrogen). The cells were transfected using polyethylenimin (PEI)-
mediated transfection [203] containing the TALE-MutH pair TALE-
RPGR-1(I)-MutH (600 ng)/ TALE-RPGR-2 (I))-MutH (600ng) expres-
sion vectors and the eGFP expression vector (100ng, eGFP-N1, Clontech).
For comparison, the toxic ZFNs GZF1N/GZF3N [6] (kindly provided
by T. Cathomen, University Medical Center Freiburg, Germany), the
golden standard nuclease I-SceI (I-SceI was cloned into the pvax
plasmid, Invitrogen) and an empty vector pcDNA3.1 (Invitrogen) were
analyzed similar. The number of eGFP-postitve cells were determ-
ined by flow cytometry (FACSCalibur; BD Biosciences) at day 2 and
4 after the transfection. The survival rate is analyzed by counting the
decrease of eGFP-positive cells in this interval and is normalized to
I-SceI.
traffic light reporter (tlr) system : The traffic light re-
porter system has been described by Certo et al. [34] and was em-
ployed to determine the activity of the TALE-MutH pair (TALE-RPGR-
1(I)-MutH/ TALE_RPGR-2 (I))-MutH). The TLR system enclosing a
I-SceI recognition site was modified by replacing the incorrect mCh-
erry encoding sequence to the incorrect blue (BFP) encoding sequence
using the InFusion cloning (Clontech) system. NHEJ, triggered by I-
SceI, causes a frame shift which result in the correct BFP reading
frame. BFP positive cells were counted by flow cytometry (FAC-
SCalibur; BD Biosciences, kindly provided by H. Hackstein, JLU Gießen).
The recognition site for the TALE-MutH pair was introduced adjacent
to the I-SceI target site using a AvrII and BsiWI restriction site.
HEK293T cells were seeded similarly as for the cytoxicity assay.
After 24 h, cells were transfected with the PEI transfection mix (PEI
(0.1 g/l, pH: 5.5, 150 mM NaCl) containing 600 ng of the TLR plasmid
enclosing the specific target site and 600 ng of the specific nuclease
expression vector. Cells were harvested at day 3 after the transfec-
tion and the number of BFP positive cells was determined by flow
cytometry (FACSCalibur; BD Biosciences).
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2.2.5 Cleavage assays
To determine the cleavage specificity and activity in vitro two cleavage
assays, recently described by Gabsalilow et al. [78] were used.
Cleavage assay on plasmid
The in vitro activity of Strep-AvrBs4(28)-MutH-His6 on H-3-T and T-
3-H were analyzed on a plasmid containing the addressed site and
18 unaddressed GATC sites. 8 nM substrate were incubated with
32 nM Strep-AvrBs4(28)–MutH-His6 at 37°C (20 mM Tris-acetat, 120
mM K-acetat, 1mM MgCl2, 50 µg/ml bovine serum albumin (BSA),
pH 7,5). Aliquots of the reaction were stopped with 50 mM EDTA
at defined time intervals (1‘, 3‘, 10‘, 30‘, 60‘, 120‘, 180‘) and analyzed
by an 1.2% agarose gel electrophoresis. The gels were stained by
ethidium bromide and analyzed using LabImage 1D.
Cleavage assay on fluorescently labelled PCR fragments
To determine the strand-specificity of the substrates fluorescently la-
belled PCR products were used. To amplify the PCR products (T-3-H,
H-3-T, T-6-H, T-3-HH-3-T and T-3-H-3-T), 5’-end labeled (Atto 488 or
Atto 647N) forward and reverse primers were used. 20 nM labeled
PCR-substrate were incubated with six-fold excess of enzyme at 37°C
(20 mM Tris-acetat, 120 mM K-acetat, 1 mM MgCl2, 50 µg/ml (BSA),
pH 7.5). Reaction were stopped by 50 mM EDTA at defined time
points (3‘, 10‘, 30‘, 60‘, 120‘, 180‘) and analyzed by denaturingpoly-
acrylamide gel electrophoresis (10% polyacrylamide 19:1 (PAA), 7M
urea, formamide 30%, 1 x TBE).
Similarly, we incubated the targets with AvrBs4-MutH for 180 min,
followed by digestion with 1 µl Proteinase K (10 min at 37°C), fol-
lowed by protein heat deactivation for 10 min at 95°C. New 120 nM
AvrBs4-MutH was added and allowed to digest the substrate for an-
other 60 min at 37°C. The defined reaction steps were stopped with
50 mM EDTA and analyzed by denaturing PAGE (heat: 400 V, 40 mA,
30 min; run: 300 V, 30 mA, 45 min) and native 10% (PAA) gels (run:
300 V, 30 mA, 45 min). The fluorescent images were visualized with
TyphoonTM FLA 9500. Alexa 488 was excited at 473 nm using the
BPG1 (560-580 nm) filter and Atto647N was excited at 635 nm using
the LPR ( > 665 nm) filter.
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2.2.6 Fluorescence based methods
Labeling of AvrBs3 variants
The proteins were all labeled by a thiol Michael-type 1,4-addition
reaction, creating a covalent connection between the thiol group of
the cysteine residue and the maleimide fluorophores. The reaction
mechanism is shown in figure 12. The thiol group is deprotonated in
presence of a base. Next, the the thiol group is added to the double
bond of the maleimide creating an intermediate (I). Hydrolysis of the
intermediate result in the succinimide-thiolether (II).
(B) reaction mechanism:
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Figure 12: Thiol Michael-type addition reaction
(A) Equilibrium reaction of the thiol group of the cysteine with the
maleimide fluorophore. (B) Reaction mechanism of the thiol Michael-
type 1,4-addition. The thiol group is deprotonated in presence of a base
and is added to the maleimide by creating an intermediate (I). Hydro-
lysis results in the succinimide-thiolether (II).
labeling conditions : 5 mM redox reagent Dithiothreitol (DTT)
was added to 80 µM of the protein and incubated at 0°C for 1 h. Dia-
lyse puffer was exchanged to an adjusted puffer for labeling (10 mM
2-(4-(2-hydroxyethyl)-1-piperazinyl)-ethansulfonsäure (HEPES) /KOH
pH 8,0, 1 mM EDTA, 200 mM KCl, 10% glycerol) by a zeba spin de-
salting column 40 K. The fourfold excess of the maleimide dye was
supplemented to the single cysteine AvrBs3 variants and the twofold
excess of maleimide dye was added to the AvrBs3 (AB) variant. The
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protein was incubated at 0°C under exclusion of light for 1-2 hours.
AvrBs3 variants were purified by the zeba spin desalting column 40
K and eluted twice with the high salt labeling puffer (10 mM 2-(4-
(2-hydroxyethyl)-1-piperazinyl)-ethansulfonsäure (HEPES)/KOH pH
8,0, 1 mM ethylenediaminetetraacetic acid (EDTA), 500 mM KCl, 10%
glycerol). The aliquots were frozen with liquid nitrogen and stored
at -80°C.
2.2.6.1 Degree of labeling (DOL)
The degree of labeling was determined after each labeling reaction of
a protein with a fluorophore. DOL describes the ratio between the
dye and the protein concentration (Formula (1)).
DOL =
c(dye)
c(protein)
(1)
The concentrations of the dye and the protein were measured with
the spectrophotometer NanoDrop® 1000 (Thermo Scientific).
c(dye) =
Amax
εmax ∗ d (2)
c(protein) =
Aprot.
εprot ∗ d (3)
Aprot. = A280nm − Amax ∗ c f280 (4)
c f280 =
εmax
ε280nm
(5)
Similar to the determination of the protein concentration the DNA
concentration was analyzed and could be used to define the DOLs of
the labeled DNAs. The absorption maximum of protein exist at 280
nm, whereas the absorption maximum of DNA is at 260 nm. Thus,
the absorption at 260 nm (A260 nm) was measured and the extinction
coefficient ε260nm was required to calculate the DNA concentration.
2.2.6.2 Electrophoretic Mobility Shift Assay (EMSA)
EMSA can be used to analzye DNA-protein or RNA-protein interac-
tion. We applied an EMSA based on a fluorescently labeled DNA. A
25 bp long DNA containing the AvrBs3 recognition site labeled with
Cy3 at the 5‘-end of the lower strand was used. The unbound DNA
contains a high mobility due to its small size. Binding of protein to
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the DNA results in a reduction in the mobility and can be analyzed
on a gel. 5‘-end Cy3 labeled DNA (20 nM) was princubated under
high salt conditions (150 mM) in 1x NEB 3.1 buffer with protein (0-
600 nM) for 5 minutes on ice. The reaction was stopped with 50 mM
EDTA and the whole reaction was loaded to a 4% polyacrylamid gel
(35 mA, 100 V, 20 min, 4°C). The fluorophore Cy3 (filter: BPG1(560-
580 nm)) and Alexa 594 (filter: LPG (>575 nm)) was excited the the
green SHG 532 nm, the fluorophore Alexa488 (filter: BPB1 (520-540
nm)) was excited with the blue LD laser (473 nm), Alexa 647 (filter:
LPR (>665 nm)) was excited with the red LD laser (635 nm) and the
gel was visualized with the TyphoonTM FLA 9500.
Fluorescence anisotropy
Fluorescence anisotropy is a tool to analyze binding constants and
kinetics. It depends on the rotation time of the fluorophore part or
the whole molecule. An advantage of fluorescence anisotropy is that
only one molecule has to be labeled. For instance, using fluorescence
anisotropy to investigate DNA::protein binding, the DNA can carry
the fluorophore or the protein. Therefore, the protein does not has to
be modified, thus excluding the risk of changing the binding charac-
ter of the analyzed protein.
The fluorophore is excited with linear polarized light. It absorbs a
photon, which results in a higher energy level of the valence electrons.
The fluorescence lifetime τ describe the timephase the higher energy
level exist. The energy is mostly released in parts by oscillation and
the remaining energy is emitted by a photon. The fluorophore mo-
lecule has to be oriented in the angle of the polarized light to absorb
the photon. If the molecule tumbling is “slow” the emitted photon
will be polarized similar to the applied polarized light. whereas, a
small fluorophore molecule will change the orientation before emit-
ting the photon, thus resulting in a different orientation. Taken to-
gether, fluorescence anisotropy is dependent on the rotation lifetime
ф and the fluorescence lifetime τ of the fluorophore. To detect this
effect, the fluorescence intensity is measured parallel and perpendic-
ular to the polarized light by aligning the polariser and the analyzer
to each other [123].
Binding characteristics of the AvrBs3 variants to the DNA were ana-
lyzed by fluorescence anisotropy. The assays were performed under
low salt conditions (60 mM) in assay puffer (20 mM tris-acetat, 50
mM kkalium-acetat, 10 mM magnesium-acetat, 1 mM DTT, pH 7.9)
and fluorescence anisotropy was measured by using the Fluoromax-4
Spectroflurometer to determine the KD value. The 25 bp long DNA
contained the AvrBs3 binding site and was labeled with Hex at the 5´
prime end of the bottom strand. To determine the KD-value 0.5 nM of
the DNA was set constant and the protein was titrated to the solution.
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To define the active rate of protein, the titration was repeated with 10
nM DNA. The kinetic experiments were performed under the same
buffer conditions, but using the Tecan infinitie F200 pro plate reader.
10 nM labelled DNA with 50 nM AvrBs3 was used to achieve com-
plete binding. For competition experiments unlabeled specific DNA
(180 nM) and scramble DNA (180 nM) were used.
Förster-Resonanzenenergietarnsfer (FRET)
FRET is a physical process, which enable to measure the acceptor
emission resulted by donor excitation. Thus, FRET requires a donor
fluorophore and an acceptor fluorophore, which can be labeled to on
protein (intramolecular) or to diverse biomolecules (intermolecular).
The radiation-free energy transfer occur, when defined requirements
are given. The donor emission spectra have to overlap with the ac-
ceptor excitation spectra (I); the orientation of the transient dipole mo-
ments have to bee favourable (II); and the proximity between donor
and acceptor fluorophore has to bee given (1-10 nm) [74, 75, 73, 244].
2.2.6.3 FRET experiment between Cy3 and Cy5
The FRET experiments were performed under low salt conditions (80
mM) with assay puffer (20 mM tris-acetat, 50 mM kalium-acetate,
10 mM magnesium-acetat, 1 mM DTT, pH 7.9). The specific DNA
(Tabel 12) was labeled with Cy3 at the 5‘-end of the bottom (specific
DNA (I)) or the top (specific DNA (II)) strand. AvrBs3 (A)/AvrBs3 (B)
labeled with Cy5 was titrated to 1 nM of the labelled specific DNA,
respectively.
To calculate the FRET index (nF/FDexDemD[%]) the three cube method
described by Youvan et al. [242] was used (Formula 6). This method
describes no FRET efficiency, but a values, which change with FRET
[244]. Three measurements were required, when donor and acceptor
fluorophores were presence. First, the donor was excited and emis-
sion in acceptor (FexDemA) and donor (FexDemD) channel was detected.
Next, the acceptor was excited and emission was measured in the
acceptor channel, resulting in the FexAemA signal.
The donor fluorophore Cy3 was excited at 520 ± 5 nm and the ac-
ceptor fluorophore Cy5 was excited at 650 ± 5 nm using the Fluoromax-
4 Spectrofluorometer. To consider crosstalk of Cy3 and Cy5 both Cy3
labelled DNA and Cy5 labelled AvrBs3 were excited individually, and
the resulting emissions in the donor channel and in the acceptor chan-
nel were measured (Formula 7 and 8) . FRET efficiency was calculated
with the following formulas.
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nF = FexDemA − FexAemA ∗ α)− (FexDemD ∗ β) (6)
α =
FeDemAA
FeAemAA
(7)
β =
FeDemAD
FeDemDD
(8)
nF: indicates the corrected fluorescence signal
F: indicates the fluorescence signal in presence of the donor
and the acceptor
FA: indicates the fluorescence signal in presence of the acceptor
FD: indicates the fluorescence signal in presence of the donor
exD: donor excitation
exA: acceptor excitation
emD: donor emission
emA: acceptor emission
FRET efficiency can be described by the Förster equation (9). För-
ster radius (R0 ) describes the distance between donor and acceptor
fluorophores, when 50% energy transfer takes place and it depends
on the fluorophhores used. The actual distance between donor and
acceptor is given with r0. Formula (9) can be converted to calculate
r0, if FRET efficiency is given (Formula 10).
E =
R60
R60 + r
6
0
(9)
r0 = 6
√
R60
E− R60
(10)
A stoichiometric method which results in a FRET efficiency was
described by Hoppe et al. [98]. They applied the correction factor γ,
which describes the relative excitability of the donor and acceptor at
the donor excitation wavelength [244].
E fA∗ = γ ∗ nF
α ∗ FexAemAA
(11)
γ =
εA
exD
εDexD
(12)
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εAexD: extinction coefficient of the acceptor fluorophore at the
donor excited wavelength
εBexD: extinction coefficient of the donor fluorophore at the
donor excited wavelength
In the experiment we excited Cy3 at 520 nm to minimize cross talk.
Thus, we needed the εA520nm and εB520 nm to calculate the correction
factor γ.
Additional the the donor quench (Eq) was expressed in percentage
[%].
Eq =
FexDemDD − FexDemD
FexDemDD
(13)
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3.1 characterization of highly specific nucleases in vitro
and in vivo
This chapter characterizes the monomeric strand and site specific
nickase AvrBs4-MutH under in vitro and in vivo conditions with a
focus on the optimization of the target design. Additionally, AvrBs4-
FokI and AvrBs3-PvuII variants were studied in Saccharomyces cere-
visiae and compared to the golden standard meganuclease I-SceI.
Furthermore, the RNA guided Cas9 protein was evaluated in yeast.
Finally, the most promising TALEN with the optimized target design
was applied to a therapeutic relevant gene causing X-linked retinitis
pigmentosa.
3.1.1 Characterization of TALENs
3.1.1.1 AvrBs4-MutH
AvrBs4-MutH designed by Gabsalilow et al. [78], is a truncated AvrBs4
protein fused to the nickase MutH. The coding sequence of the N-
terminus of AvrBs4 is shortened by 152 aa resulting in 138 aa and
the C-terminus contains 28 aa. The nickase MutH, which addresses
the 4 bp sequence (GATC), is fused to the C-terminus of AvrBs4 via
two serine residues. The TALEN protein holds a Strep-tag at the N-
terminus and a His-tag at the C-terminus, which enable a tandem
purification (Figure 13 ).
NI NG NI NI NGNG NI NI NG NINI NG HD HD NI HDNG
NG
N-terminus 138 aa repeat domain 595 aa  28 aa+ SS
AvrBs4   N152-C28
  1   2   3 4 5 6 7 8 9 1110 12 13 14 15 16 17 17.5 N-1  N0N-2
LTPEQVVAIASNIGGKQALETVQRLLPVLCQAHG
34aa
strep-tag His-tag
MutH (299aa)
Figure 13: Architecture of AvrBs4-MutH
AvrBs4 contains a N-terminus with 138 aa, a repeat domain with 595 aa,
and a C-terminus with 28 aa. The Strep-tag is fused to the N-terminus,
which consist of the non-canonical repeats N0, N-1 and N-2. The binding
domain encloses 17.5 repeats. Every repeat holds 34 highly conserved
aa. In position 12 and 13 the aa residues are crucial for DNA recognition
(bold). Two serines (S-S) connect the truncated AvrBs4 to the nickase
MutH. The nickase carries a His-tag at the C-terminus and addresses a
GATC site.
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Previous in vitro experiments revealed that AvrBs4-MutH is capa-
ble to induce strand and site specific SSBs. Dependent on the spacer
length between the AvrBs4 addressed site and the GATC sequence,
the target is nicked on the bottom strand (3 bp spacer) or on the top-
strand (6 bp spacer) (Figure 14). These characteristics of the nickase
AvrBs4-MutH have been described by Gabsalilow et al. [78] in detail.
For the present study, AvrBs4-MutH was analyzed on specifically de-
signed target sequences. The construction of the new recognition
sites were based on recent findings in the filed of genome targeting
[53, 40, 199, 191]. In respect of HDR efficiency, the importance of nick-
ing either the transcribed or the non-transcribed strand has been em-
phasized [53]. Accordingly, the target T-3-H, T-6-H and H-3-T were
used to characterize AvrBs3-MutH under in vitro and in vivo condi-
tions. Double nicking by specific nickases has been shown to reduce
off-target activity [40, 199, 191]. This encouraged us to analyze the
mechanism of double nicking by AvrBs4-MutH on the double targets
T-3-HH-3-T and T-3-H-3-T. Three single targets (T-3-H; H-3-T and T-
6-H) were designed to be nicked by AvrBs4-MutH and two double
targets were created to detect double nicking. All targets comprise
an I-SceI target site and are visualized in figure 14.
T-3-H-3-T            18 bp I-SceI        17 bp   TATAATTAATAATCCACTTCCGGATCCGGAAGTGGATTATTAATTATAT
T-3-H                  18 bp I-SceI        17 bp   TATAATTAATAATCCACTTCCGGATC
H-3-T                  18 bp I-SceI        21 bp   GATCCGGAAGTGGATTATTAATTATAT
T-6-H                  18 bp I-SceI        17 bp   TATAATTAATAATCCACTTGAGCCGGATC
T-3-HH-3-T          18 bp I-SceI        17 bp   TATAATTAATAATCCACTTCCGGATCGATCCGGAAGTGGATTATTAATTATAT
N
DN
AvrBs4 MutH
Figure 14: Design of specific single and double targets
I-SceI target site encloses 18 bp and can be found in all targets 17-21 bp
in front of the binding site of AvrBs4-MutH. TALE binding site (T) is
marked in green, whereas the recognition site of MutH (H) is shown in
blue. The spacer length between the two binding sites is given in bp (x
= 3, 6). Arrows demonstrate the nicking positions of MutH. T-3-H, H-3-
T, and T-6-H are nicked (N) at a single position and are termed single
targets. T-3-HH-3-T and T-3-H-T carry two positions to induce SSB and
are termed double targets.
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3.1.1.2 in vitro Analysis
The cutting mechanism and activity of AvrBs4-MutH were analyzed
by employing a plasmid cleavage assay and a cleavage assay using dif-
ferent fluorescently 5‘-end labeled PCR products. First, the inverted
single target sites (T-3-H and H-3-T) were analyzed and compared
with a plasmid cleavage assay (Figure 15). AvrBs4-MutH induced al-
most two times faster (k = 3. 8 * 10-2 ± 9. 6 x 10 -4 min-1) SSBs to
target H-3-T, than to target T-3-H (k = 2. 2 x 10-2 ± 2. 9 x 10-3 min-1).
T-3-H H-3-T
_ 3` 10` 30` 60` 120`180` NDSB_ 3` 10` 30` 60` 120`180` N DSB
(A)
(B) .
.
.
.
.
.
.
Figure 15: Kinetic cleavage assay on T-3-H and H-3-T
Fraction of nicked DNA of T-3-H and H-3-T, analyzed by a plasmid
cleavage assay. 8 nM substrate was incubated with a four fold excess of
AvrBs4-MutH and time points were taken at 3‘, 10‘, 30‘, 60‘, 120‘, 180‘.
(A) Agarose gels (0.8%) stained with ethidium bromide. The gel demon-
strates the super-coiled DNA, linear DNA, and open circle DNA. Sub-
strates were digested by the nicking enzyme Nt.BspQ1 (N) and BamHI
(DSB), respectively. (B) Quantitative evaluation of the cleavage assay.
Each measuring point represents the mean ± standard error indicated
by error bars for each point. (n) number of independent experiments.
AvrBs4-MutH had a cleavage rate constant for H-3-T of k = 3. 8 x 10-2 ±
9. 6 x 10-4 min -1 and for T-3-H k = 2. 2 x 10-2 ± 2.9 x 10 -3 min-1.
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Next, we identified which DNA strand was nicked by AvrBs4-MutH
using the cleavage assay on 5‘-end labeled PCR fragments. The princi-
ple of the cleavage assay with fluorescently 5‘-end labeled PCR prod-
ucts is depicted in figure 16 by using the example of the double target
T-3-H-3-T. Relative to the strand which is cut on the fluorescently 5‘-
end labeled PCR product by AvrBs3-MutH, either a long fragment
(eg. 169 nt) with a red fluorescent signal or a short fragment (eg. 59
nt) with a green fluorescent signal result.
nt
nt
nt
Figure 16: Cleavage assay with labeled PCR fragments
Cleavage assay with fluorescently 5‘-end labeled PCR fragments exem-
plified by the double target T-3-H-3-T. The introduction of a SSB into the
top strand results in a long fragment (e.g. 169 nt) containing a green flu-
orescent signal (Atto 647N). While the SSB introduced into the bottom
strand will result in a short fragment (e.g. 59 nt) with a red fluorescent
signal (Atto 488). In case of the target T-3-H-3-H, the total size of the
fragment is 228 bp.
First, the results of the single targets were analyzed on denaturing
PAGE and native PAA gels. While the denaturing PAGE gel revealed
which DNA strand is nicked, the occurrence of DSBs was detected
by the analysis of native PAA gels. T-3-H was cleaved on the bottom
strand, whereas H-3-T and T-6-H were nicked on the top strand (Fig-
ure 17 (A)). No DSBs were induced (Figure 17 (B)). The analysis of
the fluorescently 5‘-end labeled PCR double targets on a denaturing
PAGE revealed that top and bottom strands were nicked in a 1:1 ratio
(Table 19 and Figure 18 (A) and 19). No double strand breaks were de-
tectable after 180 min of digestion. However, removing AvrBs4-MutH
by Proteinase K (PK) and adding new AvrBs4-MutH after deactiva-
tion of PK led to double nicks in particular on T-3-H-3-T (Figure 18
(B)). The analysis of enzyme kinetics on double targets revealed that
AvrBs3-MutH nicked T-3-H-3-T three to four times faster than T-3-
HH-3-T (Figure 19) and (Table 19).
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denaturing PAGE:
T-3-H T-6-H H-3-T
_ E
native PAA gel:
T-3-H T-6-H H-3-T
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Figure 17: In vitro characterization of AvrBs4-MutH on single targets (T-3-H,
T-6-H and H-3-T)
Cleavage assay with fluorescently 5‘-end labeled PCR products ana-
lyzed on a denaturing PAGE (A) and a native PAA gel (B). (-) uncut
labeled PCR target (20 nM). (E) Target preincubated for 180 min with
six fold excess of AvrBs4-MutH. (c) Target digested by BamHI. The un-
cut fragment is colored in orange. Fragments resulting from top strand
nicking were labeled with a green fluorophore (Atto 488), while frag-
ments resulting from bottom strand nicks were labeled with a red fluo-
rophore (Atto 647N). T-3-H was nicked on the bottom strand, whereas
T-6-H and H-3-T were nicked on the top strand. AvrBs4-MutH induced
no DSBs on the single targets.
T-3-H-3-T
_ E P+E c
T-3-HH-3-T
_ E P+E c _ E P+E c _ E P+E c
T-3-H-3-T T-3-HH-3-T
(A) (B)
denaturing PAGE: native PAA gel:
Figure 18: In vitro characterization of AvrBs4-MutH on double targets (T-3-
H-3-T and T-3-HH-3-T).
Cleavage assay with 5‘-end labelled PCR double targets (T-3-H-3-T and
T-3-HH-3-T) analyzed on a denaturing PAGE (A) and a native PAA gel
(B). (-) uncut labeled PCR target (20 nM); (E) target incubated with six
fold excess of AvrBs4-MutH for 180 min; (P+E) AvrBs4-MutH prein-
cubated on target site (E) was removed with PK (10 min, 37°C) and
additional protein (120 nM) was incubated for 60 min after deactivation
of PK; (c) control, target digested by BamHI (T-3-H-3-T) or ClaI (T-3-
HH-3-T). The uncut fragment is shown in orange. Fragments resulting
from top strand nicking were labeled with a green fluorophore (Atto
488), while fragments nicked at the bottom strand were labeled with a
red fluorophore (Atto 647N). After treatment with PK and adding new
AvrBs4-MutH after deactivation of PK DSBs were detectable in particu-
lar on T-3-H-3-T.
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Figure 19: Kinetics of DNA nicking of AvrBs4-MutH on the double targets
(T-3-H-3-T, T-3-HH-3-T)
Fluorescently 5‘-end labeled PCR target (20 nM) was incubated with a
six fold excess of AvrBs4-MutH and time points were taken at 3‘, 10‘, 30‘,
60‘, 120‘, 180‘. Each measuring point represents the mean ± standard
error indicated by error bars for each point. (n) number of independent
experiments. AvrBs4-MutH nicked T-3-H-3-T (A) three to four times
faster than T-3-HH-3-T (B). Cleavage rate constants of AvrBs4-MutH
(n= 3): T-3-H-3-T: 0.023 ± 2.5 x 10-2 min -1 (top strand), 0.029 ± 2.3 x 10-3
min -1 (bottom strand); T-3-HH-3-T : 6.8 x10-3 ± 9.4 x 10-4 min -1 (top
strand), 6.9 x10-3 ± 6.7 x 10-4 min -1 (bottom strand).
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Table 19: Enzyme activity of AvrBs4-MutH for two independent double tar-
gets
Top and bottom strand-specific cleavage rate constant K [min-1] of
AvrBs3-MutH is shown for the double targets T-3-HH-T and T-3-H-3-T.
The binding site of AvrBs4 is marked with T, the GATC binding site of
MutH is labeled with H, and the spacer length between the binding sites
is given in bp.
K [min -1]
T-3-HH-3-T top strand 6.8 x 10-3 ± 9.4 x 10-4
bottom strand 6.9 x 10-3 ± 6.7 x 10-4
T-3-H-3-T top strand 2.3 x 10-2 ± 2.5 x 10-3
bottom strand 2.9 x 10-2 ± 2.3 x 10-3
3.1.1.3 in vivo Analysis
To challenge the established specific nucleases (I-SceI or TALE-FokI),
TALE-MutH has to provide excellent in vivo efficiency. To investigate
the efficiency of TALE-MutH under in vivo conditions and to validate
the in vitro results, a single strand in vivo assay in yeast (Figure 20),
as has been previously reported by Cermak et al. [33], was employed.
S. cerevisiae is an eukaryotic microorganisms, providing a fast and
cost efficient model for in vivo conditions by using the single strand
annealing assay. The successful cleavage of the target positioned be-
tween two partially duplicated fragments of the lacZ gene reconsti-
tuted a functional lacZ gene is reconstituted by subsequent single
strand annealing (SSA) (Figure 11). This experimental approach en-
ables a quantitative analysis of the nuclease activity (Figure 20). The
functional lacZ gene encodes a lacZ fragment which dimerize with
the lacZ deletion mutant resulting in an active β-gal.
The ß-gal activity of TALE-MutH was compared to I-SceI and AvrBs4-
FokI. I-SceI induces DSBs within its non-palidromic 18 bp target se-
quence and is the established Golden Standard due to its high
specificity combined with high nuclease activity. The homodimeric
AvrBs4-FokI induces DSBs within a 36 bp (2 x 18 bp) substrate. The
repeat array of AvrBs4 was introduced to a truncated variant of the
TALE protein via the Golden Gate cloning strategy (Methods 2.2.1.1).
The AvrBs4-MutH design was similar to the in vitro design, but lack-
ing the His- and Strep-tag. Similar to AvrBs4-MutH, the N-terminus
of AvrBs4-FokI lacks the coding sequence of 152 aa residues, but con-
tains a 68 aa as linker to the unspecific cleavage domain FokI. A yeast
expression plasmid with AvrBs4 without catalytic domain served as
negative control.
Additionally, several variants of AvrBs3-PvuII were analyzed by the
SSA assay, as PvuII proofed to be a promising alternative to the un-
specific cleavage domain FokI. The specific nuclease PvuII increases
the number of bp in the target site (42 bp) [239].
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cleavage and 
recombination
I-SceI:
Figure 20: Single strand annealing assay
A yeast based recombinant assay was used to analyze the efficiency of
the specific nucleases. The specific nucleases bind to the recognition
sequence, which is flanked by two partially duplicated fragments of
the lacZ gene (blue), SSA is triggered and a functional lacZ gene is re-
constructed. Right corner: Yeast colonies (blue) with I-SceI expression
plasmid and target plasmid growing on a matrix containing X-Gal.
3.1.1.4 AvrBs4-MutH
Two versions of the viability assay were used. First, yeast cells were
transformed with expression plasmids, but no target plasmid was
present. The total amount of yeast colonies of AvrBs4 without nucle-
ase were compared to I-SceI, AvrBs4-FokI and AvrBs4-MutH and no
significant difference in the total amount of colonies could be detected
(Figure 21 (A)). Second, yeast cells were transformed with expression
plasmids in the presence of the plasmid with the defined target for
the specific nucleases. This resulted in a significant reduction of the
total amount of yeast colonies compared to the total amount of yeast
colonies transfected with AvrBs4 without nuclease activity, except in
the case of AvrBs4-MutH on the target T-3-H and H-3-T (Figure 21
(B)). AvrBs4-FokI revealed the lowest number of colonies, followed
by AvrBs4-MutH on the double target T-3-HH-3-T. However, when
compared to I-SceI, AvrBs4-MutH with the targets T-3-H-3-T, T-3-H,
and H-3-T led to higher colony counts, while colony counts with the
target T-6-H were comparable to I-SceI.
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Figure 21: Relative survival of yeast colonies
In vivo characterization of AvrBs4-MutH as nicking and double nick-
ing enzyme compared to established specific nucleases (I-SceI, AvrBs4-
FokI). The specific nucleases are compared to AvrBs4 without nuclease
activity and significant differences were determined by the unpaired
T-test (n ≥ 3, n.s. = not significant, P < 0.05 *, P < 0.01 **, P < 0.001
***). Targets underlined with DN (double nick) carry two positions to
induce a SSB, while N (nick) indicate a single position to induce SSB.
(A) Total amount of yeast colonies transfected with expression plasmid
for the specific nuclease without the target plasmid. (B) Quantification
of yeast colonies transfected with the specific nuclease and the specific
target plasmid.
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To analyze the specific activity of the nucleases on different targets,
the ratio between blue and unstained colonies was calculated and
compared to AvrBs4 without nuclease activity (Figure 22 (A and B)).
(A)
(B)
.
.
.
.
.
.
.
.
.
.
.
.
Figure 22: β-gal activity of specific nucleases (I-SceI, AvrBs4-FokI, and
AvrBs4-MutH) in S. cerevisiae
In vivo characterization of AvrBs4-MutH as nicking and double nick-
ing enzyme compared to established specific nucleases (I-SceI, AvrBs4-
FokI). The specific nucleases are compared to AvrBs4 without nuclease
activity and significant differences were determined by the unpaired
T-test (n ≥ 3, n.s. = not significant, P < 0.05 *, P < 0.01 **, P < 0.001
***). Targets underlined with DN (double nick) carry two positions to
induce a SSB, while N (nick) indicate a single position to induce SSB.
(A) Fraction of blue colonies expressed as percentage [%] of the differ-
ent specific nucleases. (B) Relative number of white and blue colonies
of the nucleases on their specific targets.
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When compared to AvrBs4 all constructs on all target combina-
tions showed a significantly higher β-gal activity. Even the single
targets showed a significantly higher β-gal activity. This finding in-
dicates that nicking can trigger SSA. The golden standard I-SceI
and AvrBs4-MutH addressing the double target T-3-H-3-T resulted
the highest activity, which approximated 100% of stained colonies
(I-SceI: 100 ± 1%; T-3-H-3-T: 99 ± 1%), followed by AvrBs4-MutH on
the double target T-3-HH-3-T (T-3-HH-3-T: 95 ± 2%) and AvrBs4-FokI
(AvrBs4-FokI: 83 ± 17%). The single target T-6-H (8 ± 3%); revealed
a three to four fold lower activity when compared to T-3-H (84 ± 9%)
and H-3-T (84 ± 2%) (Figure 22 (A)).
Next, the number of white and blue colonies relative to the re-
sults of AvrBs4 were analyzed (Figure 22 (B)). Here, AvrBs4-FokI and
AvrBs4-MutH targeting T-6-H showed relatively low activities, while
the highest enzyme activities were detected for the combinations of
AvrBs4-MutH with T-3-H-3-T, T-3-H, and H-3-T. This indicates that
AvrBs4-MutH has a greater in vivo efficiency compared to the golden
standard I-SceI. While incubation over two additional days led to a
further increase in the intensity of the blue-staining of the T-3-H and
H-3-T colonies, all other constructs did not change the intensity of
the blue color (Figure 23).
T-3-H H-3-T I-SceI
Figure 23: Yeast colonies growing on X-gal containing matrix
Clipping from the image of X-GAL containing plates. Yeast cells
(YPH500) were co-transformed with a 1:1 ratio of expression plasmid
and reporter plasmid. Cells were allowed to grow for 5 days (30°C) on
media plates, containing 0.08 mg/ml X-GAL. AvrBs4-MutH on T-3-H
(left) and AvrBs4-MutH on H-3-T (center) resulted in white, light blue,
and dark blue colonies. As example, a light blue colony and a dark
blue colony are marked in red (left). I-SceI on T-3-HH-3-T containing
the I-SecI recognition sequence (right) let to dark blue colonies.
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3.1.1.5 AvrBs3-PvuII variants
It has been recently shown that the catalytic unspecific domain of
FokI can also be replaced by the DNA specific cleavage domain PvuII
[239]. To investigate the efficiency of the “tool box” of TALENs,
AvrBs3-PvuII variants (Figure 24) were analyzed using the yeast based
recombinant single strand annealing assay.
(I) (II)
(III)
4
4
4
4
4
Figure 24: AvrBs3-PvuII variants
The binding domain AvrBs3 is fused to the specific cleavage domain
PvuII via a linker containing the remaining 28 aa of the C-terminus
from AvrBs3, a 14 aa linker from the FokI protein and two additional
serines. The three TALE-PvuII variants analyzed by the SSA assay in
Saccharomyces cerevisiae are shown. (I) AvrBs3-hf-PvuII, a homodimeric
TALEN, containing the high fidelity (hf) variant of PvuII(T46G) and
addressing a tripartial substrate of 42 bp. (II) AvrBs3-sc-PvuII holds ho-
modimeric PvuII domains, which are fused to each other by a 4 aa linker
(GSGG). The single chain variant target a bipartial sequence with 24 bp
and contains the T46G mutation. (III) AvrBs3-hd-PvuII, a heterodimeric
TALEN, includes the T46G mutation and either a PvuII domain with
the substitution D30K or a converse substitution K38D. Together, the
two PvuII variants yield an active PvuII nuclease.
AvrBs3-PvuII coding sequences were imported into the yeast ex-
pression plasmid. Similar to the previous TALEN constructs, the
AvrBs3 repeat array (Figure 33 (A)) was established by employing the
Golden Gate cloning strategy (Methods 2.2.1.1) and introduced into
a truncated TALE protein (NΔ152-C28). Additional to the C28 linker
from the TALE protein, a 14 aa linker based on the FokI-linker (VIP-
NRGVTKQLVKG) [225] and two additional serines link the binding
module to the cleavage domain. This design was previously used for
ZFNs [190] and adopted by Yanik et al. [239] for TALE-PvuII variants.
Three distinct AvrBs3-PvuII variants were characterized by the single
strand annealing assay and are described in Figure 24. (I) AvrBs3-hf-
PvuII [239] is a homodimeric TALEN containing the high fidelity (hf)
variant of PvuII(T46G) to prevent star site activity and it addresses a
tripartial substrate. Based on this architecture, the single chain vari-
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T-4-P-4-T
TCTATAAACCTAACCCTCTATCCCAGCTGTCTAAGAGGGTTAGGTTTATAGA
AGATATTTGGATTGGGAGATAGGGTCGACAGATTCTCCCAATCCAAATATCT
Figure 25: Recognition sequence of AvrB3-PvuII variants
All AvrBs3-PvuII variants were analyzed on the T-4-P-4-T target. Includ-
ing the 6 bp target site of PvuII (P) flanked by the the target sequence of
AvrBs3 (T). The spacer length between the two target sequences is given
in bp and the arrow refer to the cutting position of PvuII.
ant (II) AvrBs3-sc-PvuII [239] was designed and includes a T46G sub-
stitution. The homodimeric PvuII domains of AvrBs3-sc-PvuII (II) are
linked to each other by a 4 aa linker (GSGG) [202] and the monomeric
TALEN recognizes a bipartial sequence. (III) AvrBs3-hd-PvuII [238]
is a heterodimeric (hd) TALEN carrying a PvuII domain, including a
D30K substitution or a PvuII domain, which contains a K38D muta-
tion. Together, the two PvuII domains built an active PvuII cleavage
domain. All AvrBs3-variants induce DSBs and were analyzed on the
tripartial target T-4-P-4-T (Figure 25), which has been reported to be
the optimal substrate design [239].
Beginning with the analysis of viability, equal amounts of expres-
sion vector were introduced to the yeast cells (Figure 26 (A)). The
I-SceI results were set at 1.0 and all further results were correlated to
I-SceI. The total count of yeast colonies of the specific AvrBs3-PvuII
variants were compared to the count of yeast colonies of AvrBs4 with-
out nuclease activity. AvrBs3-hf-PvuII (I) and AvrBs3-sc-PvuII (II)
resulted in a significant reduction (P < 0.001 ***) of the number of
yeast colonies, when compared to the colony numbers of AvrBs4. The
count of yeast colonies of AvrBs3-hd-PvuII (III) compared to AvrBs4
showed no significant differences. Furthermore, no significant differ-
ent number of yeast colonies were detected, when single substitutions
of the heterodimeric TALEN (e.g. AvrBs3-K38D-PvuII) were analyzed
individually and compared to AvrBs4.
Next, the expression vector, as well as the target plasmid were in-
troduced into the yeast cells and the amount of yeast colonies were
analyzed (Figure 26 (B)). Again AvrBs3-hf-PvuII (I) and AvrBs3-sc-
PvuII (II) yielded a significant reduction (P < 0.05 *) of the number
of yeast colonies compared to AvrBs4 without nuclease activity. The
total amount of yeast colonies of AvrBs3-hd-PvuII and AvrBs3-K38D-
PvuII showed a significant decrease (P < 0.05 *) when compared to
the values of AvrBs4. AvrBs3-D30K-PvuII had no significant different
number of yeast colonies, when compared to AvrBs4.
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Figure 26: Relative survival of yeast colonies
The number of yeast colonies relative to the results of I-SceI is given.
The specific nucleases are compared to AvrBs4 without nuclease activity
and significant differences were determined by the unpaired T-test (n ≥
3, n.s. = not significant, P < 0.05 *, P < 0.01 **, P < 0.001 ***). (A) Relative
amount of yeast colonies transformed with expression plasmid for the
specific nuclease without any target. (B) Quantification of yeast colonies
transfected with the specific nuclease and the specific target plasmid.
Next, the β-gal activity of the specific nucleases was determined.
First, the ratio between white (no functional ß-gal ) and blue (func-
tional ß-gal ) colonies was calculated and compared to AvrBs4 with-
out nuclease activity (Figure 27). AvrBs3-hf-PvuII (I) and AvrBs3-sc-
PvuII (II) revealed no significant different β-gal activity, when com-
pared to AvrBs4 (percentage of blue colonies: 4 ± 2%) , while AvrBs3-
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hd-PvuII (III) had a significantly higher β-gal activity ( P < 0.001***;
percentage of blue colonies: 63 ± 10%). Still, AvrBs3-K38D-PvuII
reached a higher ß-gal activity (95 ± 3%) when compared to the het-
erodimeric construct. AvrBs3-D30K-PvuII uncovered no significantly
higher β-gal activity (2 ± 1%) compared to the AvrBs4 results. The
relative number of white and blue colonies is shown in figure 28.
AvrBs3-hf-PvuII (I) and AvrBs3-sc-PvuII (II) revealed no significant
differences in enzyme activity when compared to AvrBs4 without
nuclease (relative number of blue colonies: 0.03 ± 0.01). AvrBs3-
hd-PvuII (III) (relative number of blue colonies: 0.2 ± 0.1 ) and the
individual analysis of AvrBs3-K38D-PvuII (relative number of blue
colonies: 0.3 ± 0.2) disclosed a significantly higher number of blue
colonies (P < 0.01**) compared to the relative number of blue colonies
of AvrBs4. The individual analysis of AvrBs3-D30K-PvuII (relative
number of blue colonies: 0.01 ± 0.01) showed no significantly in-
creased activity compared to AvrBs4 without nuclease activity.
.
.
.
Figure 27: Relative β-gal activity of specific nucleases (I-SceI and AvrBs3-
PvuII variants) in S. cerevisiae as analyzed by the ratio of blue colonies
expressed in percentage [%]
Single Strand Annealing assay in yeast. All results were normalized to
I-SceI. Levels of significance were determined by unpaired T-tests (n ≥
3, n.s. = not significant, P < 0.05 *, P < 0.01 **, P < 0.001 ***). Percentage
of blue colonies [%] of the different specific nucleases. Relative number
of white and blue colonies of the nucleases on their specific targets.
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Figure 28: β-gal activity of specific nucleases (I-SceI and AvrBs3-PvuII vari-
ants) in S. cerevisiae
The specific nucleases are compared to AvrBs4 without nuclease activity
and significant differences were determined by the unpaired T-test (n ≥
3, n.s. = not significant, P < 0.05 *, P < 0.01 **, P < 0.001 ***). Relative
number of white and blue colonies of the nucleases on their specific
targets.
3.1.2 Characterization of RNA guided Cas9 protein in vivo
Due to simple handling and the ability of multiplexing RNA guided
Cas9 nuclease appears to be a promising new specific nuclease [127,
191, 249]. The β-gal activity of a type II bacterial Cas9 protein on a
target overlapping the I-SceI recognition sequence (Figure 29), was
analyzed by employing the SSA assay in S. cerevisiae (Figure 30).
The spCas9 kindly supplied by George Church [58] addresses a
20 bp sequence overlapping the I-SceI target in the T-3-H-3-T sub-
strate. At the end of the 20 bp target sequence, the required 5‘-NGG
protospacer-adjacent motif (PAM) is placed (Figure 30). The architec-
ture of the gRNA is based on the empty S. cerevisiae expression vector
from Timothy Lu [69]. The 20 nucleotides (nt) complementary to the
DNA target were introduced to the empty expression vector by using
the Gibson assembly cloning strategy. Analyzing the Cas9::gRNA sys-
tem in yeast revealed a significantly higher β-gal activity (P < 0.001***;
β-gal activity: 23 ± 0.1%) compared to AvrBs4 without nuclease activ-
ity (Figure 30).
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Figure 29: Architecture of Cas9::gRNA and its recognition sequence
(A) Cas9::gRNA addresses a 20 bp target which overlap with the I-SceI
target sequence in T-3-H-3-T. At the end of the 20 bp target the 5‘-NGG
protospacer-adjacent motif (PAM) is placed. gRNA, carrying 20 nt com-
plementary to the DNA target sequence recognizes its target via Watson-
crick base pairing. (B) Target of I-SceI is illustrated in bold letters. The
addressed sequence of Cas9::gRNA is underlined in black and the PAM
sequence is displayed in orange. The addressed site is positioned 9 bp
in front of the target site (T-3-H-3-T) of AvrBs4-MutH.
.
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Figure 30: ß-gal activity of Cas9::gRNA in S. cerevisiae
On the left site the ß-gal activity of Cas9::gRNA is compared to AvrBs4
without nuclease activity and significant differences were determined
by the unpaired T-test (n ≥ 3, n.s. = not significant, P < 0.05 *, P < 0.01
**, P < 0.001 ***). On the right site the absolute counts of white and blue
colonies are shown.
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3.1.3 Alignment search of the addressed sites in the genome of Saccha-
romyces cerevisiae
One key limitation of the specific nucleases is off-target activity. We
therefore searched the yeast genome for recognition sites analyzed in
the SSA assay. Alignments in the genome of S. cerevisiae to the ad-
dressed sequences were search by using the Basic Local Alignment
Search Tool (BLAST) [5]. The S288c strain is the most widely applied
yeast strain and its genome has been completely sequenced. YPH500
is driven from the YNN216 strain, which is congenic to the S288c
strain and differs only in one locus and a linked segment of chromo-
some [200].
First, no hits for any of the recognition sequences were found within
the genome of S. cerevisiae holding an identity of 100%. It has been de-
scribed that specific nucleases can address a target site including mis-
matches. How many mismatches are tolerated depends on the family
of the specific nuclease and the location of the mismatch within the
target sequence. Beginning with the I-SceI recognition site, which
consist of 18 bp, the best hit was found in the chromosome XII (Na-
tional Center for Biothechnology Information (NCBI) reference se-
quence: NC_001144.5) with an identity of 77% (14 nt /18 nt), but
missing the 3’-end. It is known, that I-SceI has a two step recogni-
tion mechanisms. First, a strong binding take place to the 3‘-end of
the target (seed region) followed by binding of I-SceI to the 5‘-end
region [168]. Consequently, mismatches at the 3’-end have a high
impact on the specificity of I-SceI. Thus, alignments were searched
which included at least the 9 bp seed region at the 3‘-end. The two
best alignments, including the 3‘-end, were identified in the chromo-
some XVI (NCBI reference sequence: NC_001148.4) (identity: 66% (12
nt / 18 nt); Table 20). Furthermore, single hits were found with an
identity to the I-SceI target sequence of 61% (11 nt / 18 nt) in chromo-
somes XII (NCBI reference sequence: NC_001144.5) and XIII (NCBI
reference sequence: NC_001145.3).
Next, the target sequence of AvrBs4-MutH (T-3-H) was analyzed.
In contrast to I-SceI, TALE proteins bind more efficiently to the 5‘-
end of the target [142]. There were several hits to the AvrBs4 target
with an identity of 68% (13 nt / 19 nt), including the 10 bp 5’-end of
the AvrBs4 recognition site (Table 20). But there was no AvrBs4 recog-
nition site next to a GATC site with a distance of 3 bp. Furthermore,
there was no sequence containing the GATC site and the 5‘-end of the
TALE recognition site.
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Table 20: Identity of the best hits enclosing the seed region of the specific
target site
The size of the specific target site of each investigated specific nuclease
are given in bp. The seed region can be located at the 5‘end or at the
3‘end of the recognition site. TALE binding site in combination with
the additional specific sequence of the nuclease do not exist (n.e.: non-
existence).
identity [%] of the best hits enclosing seed region
specific nuclease target size [bp] 5‘end seed region 3‘end seed region + nuclease target
I-SceI 18 bp - 66 -
AvrBs4-MutH 18 bp 68 - n.e.
AvrBs3-PvuII 18 bp 68 - n.e.
Cas9::gRNA
20 bp + 5’ NGG - 52 -
20 bp + 5‘NAG - 52 -
Furthermore, a fraction of the target site of AvrBs3-PvuII (T-4-P)
was analyzed. One alignment was detected in chromosome XII, in-
cluding the 10 bp 5‘-end containing an identity for the AvrBs3 se-
quence of 68% (13 nt / 19 nt), but not containing the PvuII-site (Table
20). The best hit to the AvrBs3 target site was found in chromosome
VII with an identity of 79% (15 nt / 19 nt), yet missing the 5‘-end
sequence and the PvuII recognition site.
Finally, the sequence addressed by Cas9::gRNA was analyzed. To
target a sequence with the Cas9::gRNA construct a 5‘-NGG a 5‘-NAG
PAM is required [107]. Additionally, Cas9::gRNA is more sensitive to
mismatches at the 3’-end (15 bp to the PAM) [108, 47, 107]. The yeast
genome was searched for hits including one of the PAMs and parts of
the 3‘-end target sequence. Three alignments containing the 5‘-NGG
PAM motif were detected, one in chromosome VIII (NCBI reference
sequence: NC_001140.6) with an identity of 52% (12 nt / 23 nt) (Ta-
ble 20) and two with an identity of 48% (11 nt / 23 nt) in distinct
chromosomes. Similar results were found with a 5‘-NAG PAM (Ta-
ble 20). One hit was detected in the chromosome IX (NCBI reference
sequence: NC_001141.2) with an identity of 52% (12 nt / 23 nt) and
two alignments with an identity of 48% (11 nt / 23 nt) were found
in chromosome II (NCBI reference sequence: NC_001143.8) and in
chromosome XI (NCBI reference sequence: NC_001143.9).
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3.1.4 Addressing X-linked Retinitis Pigmentosa with specific nucleases
3.1.4.1 Design of TALE-MutH proteins addressing the retinitis pigmen-
tosa GTPase regulator (RPGR) gene
Due to the promising results of the SSA assay, TALE-MutH was re-
designed to target the retinitis pigmentosa GTPase regulator (RPGR)
gene, which is involved in the inherited eye disease X-linked retinitis
pigmentosa (RP) (Table 17). In figure 31 the constructed TALENs are
illustrated.
GAGTCAGGGGGGGAGAGAGAGGACGGATCTGAGGGTGACGGGGATCAAATCTGTGAGAAGGTGAGTTCAGAAACA
CTCAGTCCCCCCCTCTCTCTCCTGCCTAGACTCCCACTGCCCCTAGTTTAGACACTCTTCCACTCAAGTCTTTGT
TALE(RPGR)-1(I) (I) (II)
TALE(RPGR)-2(I)
TALE(RPGR)-3(I)
TALE(RPGR)-2(II)
TALE(RPGR)-1(II)
Figure 31: Sequence within the RPGR gene targeted by the designed TALE-
MutH variants
The illustrated sequence is a part of ORF15 within the RPGR gene. The
GATC site (I) (blue) is addressed by three of the five constructed TALE-
MutH variants (TALE(RPGR)-1 to 3 (I)). Two of them (TALE(RPGR)-
1(I) and TALE(RPGR)-2(I) address a target site which contain a 3
bp spacer between the TALE recognition site and the GATC site (I).
TALE(RPGR)-3(I) recognizes a sequence including a 6 bp spacer be-
tween the two recognition sites. For the second GATC site (II) (light
blue) two additional TALE-MutH variants were created. Recognition
site of TALE(RPGR)-1(II) includes a 3 bp spacer and is therefore nicked
on the sense strand. Due to its 6 bp spacer TALE(RPGR)-2(II) nicks the
anti-sense strand on the target sequence.
Similar to the naturally occurring TALE binding domains (AvrBs4
and AvrBs3), the new binding domains were reconstructed with the
golden gate (methods 2.2.1.1) cloning strategy and introduced into
an eukaryotic expression vector containing the coding sequence of
MutH. Mutations causing X-linked retinitis pigmentosa are located
inside the ORF15 of the RPGR gene. The TALENs were designed
to address a sequence within the ORF15 nearby a GATC site. A
correct DNA matrix will be introduced to the gene for gene edit-
ing. This can occur by inducing DSBs, SSBs, or by double nick-
ing. Three TALE-MutH were designed to address the GATC site
(I). TALE(RPGR)-1(I)-MutH and TALE(RPGR)-2(I)-MutH contain a 3
bp spacer on their addressed sites in between the recognition site
of TALE and the GATC site. The design is based on the target
site construction T-3-H-3-T. TALE(RPGR)-3(I)-MutH also addresses
the GATC site (I), but recognizes the target site with a 6 bp spacer.
This result in two heterodimeric TALE(RPGR)-MutH (TALE(RPGR)-
1(I)-MutH / TALE(RPGR)-2(I)-MutH and TALE (RPGR)-2(I)-MutH /
TALE(RPGR)-3(I)-MutH), which are able to induce double nicking
within the ORF15. The second GATC site (II) can be addressed by
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TALE(RPGR)-1(II)-MutH and TALE(RPGR)-2(II)-MutH. TALE(RPGR)-
1(II)-MutH addresses the GATC site (II) with a 3 bp spacer in be-
tween the TALE target site and GATC site, whereas TALE(RPGR)-
2(II)-MutH contains a spacer distance of 6 bp in between the TALE
target site and GATC site. The heterodimerc TALE-MutH introduces
a nick into the bottom strand and into the upper strand. Additionally,
both GATC sites (I and II) can be addressed (e.g. TALE(RPGR)-1(I)-
MutH / TALE(RPGR)-1(II)-MutH) resulting in a double nick, 13 bp
apart from each other. Finally, all TALE-MutH constructs can also be
applied individually to induce one SSB into the ORF15. Two more
GATC sites are located in the ORF15, which represent further possi-
ble target for TALE-MutH constructs.
3.1.4.2 Characterization of TALE-MutH specific nucleases for the RP
3.1.4.3 GTPase regulator gene
TALE-MutH
constructs
addressing RP
GTPase regulator
gene were
analyzed together
with Dr. Mert
Yanik in the retinal
gene therapy lab of
Prof. Dr. Dr. Knut
Stieger.
The heterodimer TALE(RPGR)-1 (I) -MutH/ TALE(RPGR)-2 (I) -MutH
described in section 3.1.4.1 were analyzed under in vivo conditions in
cooperation with the group Retinal gene therapy of Prof. Dr. Dr.
Knut Stieger at the University of Giessen (FB 11). The specific nu-
cleases were analyzed together with Dr. Mert Yanik episomal in
HEK293T cells. Due to a DNA break NHEJ is triggered and a frame
shift occurs, which results in a functional gene expressing blue fluo-
rescent protein (BFP). The BFP was detected by flow cytometry and
the results were compared to the Golden Standard I-SceI (Figure 32
(A)). Analysis of TALE(RPGR)-1 (I) and TALE(RPGR)-2 (I) addressing
the GATC (I) site revealed a similar NHEJ activity, when compared
to I-SceI.
Additionally, cell toxicity studies were performed, by co-transfection
of mCherry and the specific nucleases expression plasmids (Figure 32
(B)). A pair of ZF-FokI [6] and the TALE-MutH pair (TALE(RPGR)-1
(I)/TALE(RPGR)-2 (I)) were analyzed using the cell toxicity assay.
The empty control vector (pcDNA3) served as negative control.
The ZF-FokI (survival rate: 42 ± 18%) pair led to a significantly re-
duced survival rate when compared to I-SceI (survival rate: 100 ±
8%). Whereas the heterodimeric TALE(RPGR)-MutH (survival rate:
89 ± 15%) resulted in a comparable survival rate to I-SceI. The empty
vector pcDNA3 (survival rate: 100 ± 8%) showed a similar survival
rate as I-SceI.
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I-SceI
I-SceI TALE(RPGR)-1(I)-MutH
TALE(RPGR)-2(I)-MutH
ZF-FokI pCDNA3
TALE(RPGR)-1(I)-MutH
TALE(RPGR)-2(I)-MutH
n.s. = not signiﬁcant
P < 0.05 *
P < 0.01 **
P < 0.001 ***
n  >   3
.
Figure 32: Analysis of TALE-MutH addressing GATC (I) site within the
ORF15 of the RPGR gene
Levels of significance were determined by unpaired T-tests (n ≥ 3, n.s.
= not significant, P < 0.05 *, P < 0.01 **, P < 0.001 ***). (A) NHEJ activ-
ity analysis of TALE(RPGR)-1 (I) and TALE(RPGR)- 2 (I) addressing the
GATC (I) site, compared to NHEJ activity of I-SceI. NHEJ activity result
in a functional gene, expressing BFP. (B) Cell toxicity was analyzed by
the co-transfection of mCherry and specific nucleases expression plas-
mids. Survival rate was defined as the decrease of mCherry-positive
cells from day 2 to day 5. Number of mCherry-positive cells were de-
tected by flow cytometry and data were normalized to the I-SceI results.
The empty vector (pcDNA3) served as negative control.
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3.2 characterization of binding characteristics of avrbs3
This chapter provides a detailed analysis of the TALE binding pro-
tein AvrBs3(1 N152-C28). The AvrBs3(1 N152-C28) protein was re-
designed to enable labeling at specific positions in the protein, thus
resulting in several AvrBs3 variants. These new designed TALEs pro-
vide promising possibilities to analyze the DNA binding properties
of TALEs and facilitate the analysis of the off-target problematic.
3.2.1 Variants of AvrBs3
The modified protein AvrBs3(1 N152-C28) is a truncated version of
the naturally occurring AvrBs3. The N-terminus lacks 152 aa and
the C-terminus holds 28 aa. All AvrBs3(1 N152-C28) variants carry
a strep-tag at the N-terminus and were generated by the Golden
GATE cloning strategy (methods 2.2.1.1). Based on the mechanism
of a thiol Michael-type addition reaction cysteine residues can react
with the double bond of maleimide to succinimide-thiolethers. This
mechanism can be used to label cysteine residues with maleimide-
fluorophores. Thus, various AvrBs3 mutants were created and la-
beled at distinct positions (Figure 33).
HD NG NS NG NI NG NI HD HD NSNG NS HD HD HD NG HD
NG
773 aaN-terminus 138 aa repeat domain 598 aa C-terminus 28 aa
AvrBs3   N152-C28
  1   2   3 4 5 6 7 8 9 1110 12 13 14 15 16 17 17.5 N-1  N0N-2
LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG
34aa
strep-tag 8 aa
Figure 33: Architecture of AvrBs3 variants
All AvrBs3 variants contain a N-terminus with 138 aa, a repeat domain
with 598 aa and a C-terminus with 28 aa. The Strep-tag is fused to the
N-terminus, which comprises N0, N-1 and N-2. The binding domain
encloses 17.5 repeats. Each repeat holds 34 highly conserved aa. In
position 12 and 13 the aa are crucial for DNA recognition (bold). Each
repeat contains one cysteine residue located at position 30. In the newly
constructed variants, cysteine residues are mutated to methionine in
each repeat except for repeat number 1 and/or 16 (blue) depending on
the specific AvrBs3 variants (AvrBs3 (A), AvrBs3 (B), and AvrBs3 (AB)).
The AvrBs3 binding domain contains 17.5 repeats and each repeat
consists of 34 highly conserved aa, which enclose a cysteine residue
in position 30 (Figure 34 (A)). To permit labeling at defined positions,
the cysteine residues in the specific repeats were substituted to me-
thionine residues via site-directed mutagenesis PCR.
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The web server PoPMuSiC [55] was used to estimate the stability
change of these single-site mutations of cysteine. It revealed that
methionine has the smallest shift in its thermodynamic stability (ΔΔ
G = 0.3 [kcal/mol]) when compared to cysteine (Figure 34 (B)). While
methionine belongs to the non-polar aa and cysteine to the polar aa,
they both include an alkyl chain and a sulfur atom.
(A) (B)
Figure 34: Single-site mutation of the cysteine residue
(A) Crystal structure of AvrBs3 bound to DNA with a focus to one
repeat is shown (pdb: 2YPF) [205]. The alpha-turn-alpha structure of
this repeats is exhibited and aa 12 (H) and 13 (D) (orange) recognize the
nucleotide cytosine. The cysteine residue at position 30 in each repeat is
marked in blue and its thiol group in orange. (B) Prediction of AvrBs3
mutant stability changes ΔΔ G [kcal/mol]. Methionine has the lowest
stability change with ΔΔ G = 0.3 [kcal/mol].
Having the choice between plasmids encoding each repeat either
with or without cysteine residues allowed to generate AvrBs3 vari-
ants with different numbers and positions of cysteine residues in its
binding domain. Beside the variant AvrBs3(1 N152-C28), which con-
tains a cysteine residue in each repeat, three additional AvrBs3(1
N152-C28) variants were created (Figure 33). Two of theses AvrBs3(1
N152-C28) variants ((A) and (B)) contain a single cysteine residue in
the entire protein and all remaining cysteine residues were mutated
to methionine. AvrBs3 (A) encloses a single cysteine residue in its
first repeat and AvrBs3 (B) has its single cysteine residue in repeat
sixteen. These two variants enable to label AvrBs3(1 N152-C28) with
a single fluorophore at the beginning of the binding domain (AvrBs3
(A)) or at the end of the binding domain (AvrBs3 (B)). Furthermore,
an AvrBs3(1N152-C28) variant was generated which allows labeling
simultaneously at two positions in the binding domain (AvrBs3 (AB)).
This variant carries two cysteine residues, one cysteine is located in
the first repeat and one cysteine in repeat sixteen.
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To enable labeling, the cysteine residue has to be accessible for the
used dye in a way that it does not influence the protein functional-
ity. Regarding the crystal structure of AvrBs3 the cysteine residue at
position 30 in each repeat is in an exposed position and should be
available for labeling. Figure 34 (A) shows the crystal structure of
one repeat unit and the location of the cysteine residue is marked.
Purification of the AvrBs3(1 N152-C28) variants was examined by
affinity purification using a strep-tag fused to their N-terminus. In
figure 35 (A), an example of a strep-tag purification of AvrBs3 (B) ana-
lyzed with a 12% SDS-polyacryamide gel electrophoresis (SDS-PAGE)
is given. AvrBs3 protein has a molecular weight of 80 kDa and was
analyzed on the 12% SDS-polyacrylamid gel above 85 kDa. TALEs
used for characterization of unlabeled AvrBs3 variants (e.g. determi-
nation of KD-values) were purified in an additional step, using hep-
arin sepharose affinity chromatography. The AvrBs3(1 N152-C28)
variants eluded at a NaCl concentration of 285 nM (Figure 35 (B)).
M FT W1 E1 E2 E3 E4 E5 DW2
100
85
50
kDa
UV [mAU]
conductibility  [%]
fractions
volume [ml]
(A) (B)
Figure 35: Purification of AvrBs3 (B)
(A) Strep-tag purification, taking the example of AvrBs3. This 12% SDS-
polyacrylamide gel shows the marker (PageRulerTMUnstained Protein
Ladder) and each working step of the strep-tag purification: Marker
(M), flow through (FT), washing step 1 and 2 (W1 and W2), elution
steps (E1-5), and dialysis (D). AvrBs3 band appears above the 85 kDa
band. (B) Heparin sepharose affinity chromatography: In a second step
AvrBs3 was purified over a heparin sepharose column. A conductibility
gradient with high salt buffer B (0-100%) was created and AvrBs3 eluted
at a NaCl concentration of 285 nM. Blue = absorption [mAU] at 280 nm;
magenta = conductivity [%], red = fractions.
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3.2.2 Binding character of the AvrBs3 variants
The KD-values of AvrBs3(1N152-C28) and AvrBs3 (B) were deter-
mined by fluorescence anisotropy (Figure 36 and Figure 37). Protein
was added in increasing concentrations to 5‘-end Hex labeled specific
DNA (0.5 nM). The KD-values of both AvrBs3 proteins were about
1 nM (AvrBs3(1N152-C28): 1.9 ± 0.8 nM , AvrBs3 (B): 0.9 ± 0.3 nM
(Table 21; Figure 36).
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Figure 36: KD-values of AvrBs3(1N152-C28) and AvrBs3 (B)
KD-values were analyzed by fluorescence anisotropy. A 25 bp long spe-
cific DNA (0.5 nM) labeled with HEX at the 5‘-end of the bottom strand
was used. Labeling position of HEX is marked in yellow in the crystal
structure of AvrBs3 bound to specific DNA (pdb: 2YPF) [205]. TALE
variants were titrated with increasing concentration to specific DNA.
Each measuring point represents the mean ± standard error indicated by
error bars for each point. n : number of independent experiments. Mea-
suring points were fitted with a non-linear regression. KD-values deter-
mined: 1.9 ± 0.8 nM (AvrBs3(1N152-C28)) and 0.9 ± 0.3 nM (AvrBs3
(B)).
The active fraction of protein was determined by titrating the pro-
tein with a total DNA concentration (10 nM) much higher than the
KD-values (Figure 37). Under these conditions the KD-value cannot
be determined, but the number of binding positions can be analyzed.
The experiment revealed, that 13% of AvrBs3(1N152-C28) and 15%
of AvrBs3 (B) of the purified stock solutions were active. The cal-
culated KD-values of 100% active protein were 0.23 ± 0.07 nM for
AvrBs3(1N152-C28) and 0.14 ± 0.05 nM for AvrBs3 (B) (Table 21).
Next, the rate constants for dissociation were analyzed for the AvrBs3
variants. Here, the 5‘-end HEX labeled specific DNA competed with
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Figure 37: Determination of active fractions of AvrBs3(1N152-C28) and
AvrBs3 (B)
To determine the active fraction of TALE variants a 5‘-end Hex labeled
specific DNA with a concentration (10 nM) much higher then the KD-
values was applied. Labeling position of HEX is marked in yellow in
the crystal structure of AvrBs3 bound to specific DNA (pdb: 2YPF) [205].
TALE variants were titrated with increasing concentration to the HEX
labeled specific DNA. Each measuring point represents the mean ± stan-
dard error indicated by error bars for each point. n : number of inde-
pendent experiments. Active fractions: 13% (AvrBs3(1N152-C28)) and
15% (AvrBs3(B)).
unlabeled DNA (Figure 38 (A)). HEX labeled specific DNA (10 nM)
was incubated for 5 minutes with an excess of TALE (50 nM). Next,
unlabeled-specific DNA or -scramble DNA was added to compete
with HEX labeled specific-DNA (Figure 38 (B)). As a negative control,
buffer was added instead of unlabeled specific/scramble DNA. Rate
constant of AvrBs3 (B) for scramble DNA was k-1= 9.6 x 10-3 ± 1.3 x10-3
s-1with t = 103 ± 11 s and rate constant for specific DNA was k-1= 1.3 x
10-3 ± 4.2 x 10 -5 s-1with t = 795 ± 27 s (Table 21). Competition with un-
labeled scramble DNA was fitted by a one-phase exponential decay
function, whereas unlabeled specific DNA was fitted by two-phase
exponential decay function.
Almost identical rate constants were determined by adding unla-
beled scramble DNA and specific DNA consecutive to labeled DNA
with an excess of AvrBs3 (B). Rate constant of AvrBs3 (B) for scramble
DNA was k-1= 9.7 x 10-3 ± 1.1 x10-3 s-1with t = 102 ± 11 s and rate
constant for specific DNA was k-1= 1.5 x 10-3 ± 1.1 x 10 -4 s-1with t =
650 ± 45 s.
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Consecutively to the competition experiment, AvrBs3 (B) was di-
gested by Proteinase K (PK) and baseline values of DNA with un-
bound protein were reached (Figure 39 (A); Table 21).
AvrBs3(1N152-C28) (k-1= 2.1 x 10-3 ± 3.8 x10-3 s-1, t = 465 ± 83 s)
competed with unlabeled unspecific DNA 4.5 time slower, compared
to AvrBs3 (B) (k-1= 9.7 x 10-3 ± 1.1 x10-3 s-1, t = 102 ± 27 s) (Figure 39
(B), Table 21 ). Competition to unlabeled specific DNA could not be
fitted.
(A)
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Figure 38: Individual competition of AvrBs3 (B).
(A) Crystal structure of AvrBs3 (pdb: 2YPF) [205] binding to 23 bp
specific labeled DNA and unlabeled DNA. Labeling position of HEX
is shown in yellow. (B) Individual competition: specific HEX labeled
DNA was incubated with AvrBs3 (B) (50 nM). Then unlabeled specific
DNA (180 nM; blue), unlabeled scramble DNA (180 nM; red), or buffer
(green) was added to compete with specific DNA. Competition with
unlabeled scramble DNA is fitted with a one-phase exponential decay
function and competition with unlabeled specific DNA is fitted with a
two-phase exponential decay function. n : number of independent ex-
periments. Rate constant of AvrBs3 (B) with scramble DNA: k-1= 9.6 x
10-3 ± 1.3 x10-3 s-1with t = 103 ± 11 s. Rate constant of AvrBs3 (B) with
specific DNA: k-1= 1.3 x 10-3 ± 4.2 x 10 -5 s-1with t = 795 ± 27 s.
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Figure 39: Consecutive competition of AvrBs3 (B)
(A) Specific HEX labeled DNA was incubated with AvrBs3 (B) (50 nM)
for 5 min (black), then unlabeled scramble DNA (180 nM) was added
and fluorescence anisotropy changes were measured for 20 min (red).
Thereafter, unlabeled specific DNA (180 nM) was added and fluores-
cence anisotropy was monitored over further 20 min (blue). At the end
Proteinase K was added to digest the AvrBs3 (B) and the starting value
was analyzed (magenta). Data points were fitted with a one-phase ex-
ponential decay function. Rate constant (B) Specific HEX labeled DNA
was preincubated with AvrBs3 (B) (50 nM) for 5 min (black), then unla-
beled scramble DNA (180 nM) was added and fluorescence anisotropy
changes were measured for 20 min (red). Thereafter, unlabeled specific
DNA (180 nM) was added and fluorescence anisotropy was detected
over further 20 min (blue). Data points were fitted with an one-phase
exponential decay function. Competition to unlabeled specific DNA
could not be fitted.
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Table 21: The KD-values of AvrBs3(1N152-C28) and AvrBs3 (B)
The KD-values of the TALE variants are listed for direct comparison. Con-
sidering the determined active fraction of 13% (AvrBs3(1N152-C28)) and
15% AvrBs3 (B) the KD-values improve to 0.24 ± 0.09 nM (AvrBs3(1N152-
C28)) and 0.14 ± 0.05 nM (AvrBs3 (B)) for 10% active TALE. Rate con-
stants of dissociation for AvrBs3(1N152-C28) and AvrBs3 (B) for indi-
vidual competition assay (1) and consecutive competition experiment (2)
are also given.
AvrBs3(1N152-C28) AvrBs3 (B)
KD [nM] 1.9 ± 0.8 0.9 ± 0.3
KD [nM] 100% active protein 0.24 ± 0.09 0.14 ± 0.05
t [s];k-1 [s-1] (1)
scramble DNA -
103 ± 11
9.6 x 10-3 ± 1.3 x 10-3
specific DNA -
795 ± 27
1.3 x 10-3 ± 4.2 x 10-5
t [s]; k-1 [s-1] (2)
scramble DNA
465 ± 83 102 ± 11
2.1 x 10-3 ± 3.8 x10-4 9.7 x 10-3 ± 1.1 x 10-3
specific DNA -
650 ± 45
1.5 x 10-3 ± 1.1 x 10-4
3.2.2.1 Electrophoretic mobility shift assay of AvrBs3 (AB)
Binding of AvrBs3 (AB) on a 5´-end Cy3 labeled 25 bp specific frag-
ment was analyzed with an electrophoretic mobility shift assay (EMSA)
on a 4% PAA gel. AvrBs3 was added with increasing concentration
ranging from 0-600 nM to 5‘-end Cy3 labeled specific DNA (20 nM)
and mixtures were incubated for 5 min (0°C) (Figure 40). DNA to-
tal concentration was much higher then the KD-value of the protein
([DNA]total >> KD). Thus, the KD-value cannot be determined by this
experimental set up. We expected to gain a curve, which increases lin-
early to its plateau. A plateau indicating the concentration, where all
binding positions on the DNA are occupied. As expected, increasing
protein concentration resulted in a linearly increasing curve (Figure
40 (B)).
Two DNA shifts have been detected by EMSA. The shift (I) in-
creases linearly to a plateau of 0.46 ± 0.06 rel. fluorescence intensity,
followed by a slight decrease due to the second shift. The shift (II)
begins at a protein concentration between 250 nM and 450 nM and
does not reach a plateau at 600 nM AvrBs3. In figure 40 (B), shift (I)
and (II) are plotted and the rel. fluorescence intensity of shift (I) and
(II) are added.
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Figure 40: EMSA of AvrBs3 (AB)
AvrBs3 (AB) in increasing concentrations (0-600 nM) were preincubated
for 5 min (0°C) with 20 nM 5´-end Cy3 labeled specific DNA. (A) EMSA
was analyzed on a 4% PAA gel and the fluorophore Cy3 was excited
and visualized with TyphoonTM FLA 9500 (532 nm). The 5´-end Cy3
labeled specific DNA is shown in green. Three distinct settings were
detected, unbound DNA, shift (I) (blue), and shift (II) (red). (B) Relative
fluorescence intensity [a.u.] of shift (I) (blue), shift (II) (red), and shift
(I+II) (magenta) are plotted.
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3.2.3 Labeled AvrBs3 variants
Since the mutated AvrBs3(1N152-C28) variants retained their bind-
ing characteristic, we analyzed if this is also the case for the labeled
AvrBs3(1N152-C28) variants. The single cysteine variants were la-
beled with the fluorophore Cy5 as well as Alexa 488. Binding effi-
ciencies were detected with anisotropy and FRET distance measure-
ments. The double cysteine variant AvrBs3 (AB) was labeled (Alexa
488, Alexa 594, and Alexa 647) and binding characteristics were ana-
lyzed with EMSA.
3.2.3.1 Labeling of single cysteine variants with Alexa 488 fluorophore
First, the applicability of the fluorophore Alexa 488 for labeling AvrBs3
(B) was analyzed. The labeling reaction was performed with an ex-
cess of dye (1:4) for 1.30 h and resulted in a degree of labeling (DOL)
of 158%. The binding characteristic was analyzed via anisotropy mea-
surements on the 5‘-end Hex labeled specific DNA (Figure 41). The
KD-value obtained for AvrBs3 (B)-Alexa 488 (KD = 1.3 ± 0.3 nM) was
similar to the KD-values of the unlabeled AvrBs3 variants.
 n = 3
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Figure 41: Determination of KD-value of AvrBs3 (B)-Alexa 488
Anisotropy measurement of AvrBs3 (B) labeled with the fluorophore
Alexa 488 at the 5‘-end Hex labeled DNA (0.5 nM). Protein was added
with increasing concentrations to the 5‘-end Hex labeled specific DNA.
Each measuring point represents the mean ± standard error indicated
by error bars for each point. n : number of independent experiments.
Data points were fitted with a non-linear regression. KD-value: 1.3 ± 0.3
nM.
3.2 characterization of binding characteristics of avrbs3 89
3.2.3.2 Labeling of single cysteine variants with Cy5 fluorophore
Next, the single cysteine variants were labeled with the maleimide
fluorophore Cy5. Labeling reactions were performed with an excess
of dye (1:4) for 90 min (Figure 42 (A)). Labeled protein was separated
from the free fluorophore using a Zeba Desalting column (40K) (Fig-
ure 42 (B)).
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Figure 42: SDS-PAGE of single labeled AvrBs3 variants with flourophore
Cy5
Single cysteine variants of AvrBs3 were labeled with an excess of Cy5
maleimide fluorophore (1:4) and analyzed by 12% SDS-polyacrylamide
gel electrophoresis. (A) Time resolved kinetics of the labeling reaction of
AvrBs3 (A) (left) and AvrBs3 (B) (right). 2 μg protein was loaded in each
lane. (-) represents the time point, when the fluorophore was added to
the protein. The respective time points were taken (20‘, 30‘, 60‘, 90‘) and
Cy5 fluorophore was excited at 635 nm with the TyphoonTM FLA 9500.
(B) Images of the single cysteine AvrBs3 variants (4 μg) after purifica-
tion with Zeba Desalting spin column (40K). Left: Coomassie Brilliant
Blue stained 12% SDS-gel with Marker (PageRulerTM Unstained Protein
Ladder; lane 1), AvrBs3 (A) (lane 2), and AvrBs3 (B) (lane 3). Right: Flu-
orescence image of the 12% SDS-gel visualized with TyphoonTM FLA
9500. The SDS-gel showed that AvrBs3 variants was analyzed above 85
kDa.
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The Coomassie Brilliant Blue stained SDS-gel revealed that AvrBs3
variants run above 85 kDa (Figure 42 (B, left)). The SDS-gel can be
visualized with fluorescence excitation (635 nm) (Figure 42 (B, right)).
The degree of labeling of the single cysteine variants was analyzed.
AvrBs3 (A)-Cy5 revealed a degree of labeling (DOL) of 115% and
AvrBs3 (B)-Cy5 a DOL of 82%.
3.2.3.3 Förster resonance energy transfer (FRET) between Cy5 labeled AvrBs3
single cysteine variants and Cy3 labeled DNA
FRET enables a detailed analysis of the binding character of AvrBs3.
The fluorophore Cy5 results in an effective FRET pair with fluorophore
Cy3. Here, Cy3 served as a donor fluorophore and Cy5 as the accep-
tor fluorophore. The Förster radius of Cy3 to Cy5 is given with 60
Å [96]. Binding characteristics of the two Cy5 labeled single cysteine
AvrBs3 variants were analyzed on two distinctively labeled 5‘-end
Cy3 specific DNAs (1 nM). The proteins were added to each DNA
with increasing concentrations. Binding of the AvrBs3 variants to the
DNA resulted in a donor quench and an increased indirectly acceptor
signal (Figures 43, 54 and 55).
AvrBs3 (A)-Cy5
Figure 43: Emission spectra of titrating Cy5 labeled AvrBs3 to 5‘-end Cy3
labeled specific DNA (I)
Representative example of emission spectra. AvrBs3 (A)-Cy5 analyzed
on DNA (I) (1nM). Protein was titrated with increasing concentrations
(0, 0.99, 2, 4, 6, 10, 14, 18 [nM]) to 1 nM DNA (I).
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This FRET indexes (nF) were retrieved by measuring the acceptor
emission resulted by the donor excitation (FexDemA) and calculated
by the three-cube method described by Youvan et al. [242]. This
does not represent the FRET efficiency, but provides an index which
change with FRET [17, 244]. The FRET signal had to be corrected
via the crosstalk between the donor and the acceptor fluorophores.
To receive the correction factors α and β the fluorophores had to be
excited both individual in the FRET channel (FexDemA), the acceptor
individual in the acceptor channel (FAexAemA), and the donor individ-
ual in the donor channel (FDexDemD). The donor was excited at 520
nm to reduce cross talk. The resulted spectra are given in figure
56 (appendix) for the donor fluorophore and figure 44 for the accep-
tor fluorophore. Furthermore, the cross talk considering the fluores-
cence signal FAexDemDand FDexAemA have to be analyzed. However, the
FRET pair Cy3 and Cy5 resulted in a fluorescence signal FAexDemDand
FDexAemAclose to zero, thus this correction can be neglected in this ex-
periment.
(A) (B)
AvrBs3-Cy5: FAex
AemAAvrBs3-Cy5: FAex
DemA
Figure 44: Spectra of AvrBs3-Cy5 to determined the correction factor α
The correction factor α had to be defined to correct the crosstalk be-
tween Cy3 and Cy5. Acceptor fluorophore was excited at 520 nm (exD)
and emission was detected in the acceptor channel as well as the ac-
ceptor was excited at 650 nm (exA) and emission was detected in the
acceptor channel. The factor α is characterized by the fluorescence sig-
nal FAexDemA (A) divided with the fluorescence signal FAexAemA (B). The
FAexDemA (A) indicates a partly direct excitation of the acceptor at 520
nm.
Both DNAs enclose 25 bp, but DNA (I) carries the Cy3 fluorophore
at the 5‘-end on the top strand (Figure 45 (A)) and DNA (II) is labeled
at the 5‘-end on the lower strand (Figure 46 (A)). The theoretical dis-
tances between Cy5 and Cy3 were measured on the crystal structure
of AvrBs3 (pdp. 2YPF) [205]. The crystal structure contains a 23 bp
long DNA, however in the experiment a 25 bp DNA was used. We
added per missing bp 3.4 Å to the distance between Cy3 and Cy5.
The measured distances r0* are given in table 22, in figure 45 (A), and
in figure 46 (A).
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FRET measurements of AvrBs3 (A)-Cy5 with DNA (I) revealed a
KD-value of 0.6 ± 0.3 [nM]. The FRET measurements of AvrBs3 (B)-
Cy5 on DNA (I) also resulted in a comparable KD-value of 0.6 ± 0.3
[nM] (Figure 45 (B) and Table 22).
(A)
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Figure 45: FRET distance measurement of AvrBs3 (A)-Cy5 and AvrBs3 (B)-
Cy5 on DNA (I)
Single cysteine AvrBs3-Cy5 variants were analyzed via FRET distance
measurements on 5‘-end Cy3 labeled specific DNA (I) (1nM). (A) Crys-
tal structure of AvrBs3 bound to 23 bp specific DNA [205]. 5‘-end Cy3
labeled DNA (I) carried the fluorophore Cy3 (yellow) at the top strand 4
bp ahead of the target sequence. Both AvrBs3-Cy5 variants ((A) and (B))
were analyzed on DNA (I) resulting in a close distance (AvrBs3 (A)-Cy5:
41 Å) or a far distance (AvrBs3 (B)-Cy5: 87 Å) between Cy3 (yellow)
and Cy5 (red). Theoretically calculated FRET efficiencies are given with
E. (B) FRET index was calculated by formula (6) and then the corrected
FRET signal (nF) was divided with the donor signal (FexDemD ). Each
measuring point represents the mean of FRET efficiency ± standard er-
ror indicated by error bars for each point. n : number of independent
experiments. The data points were fitted with a non-linear regression
curve. KD-values: 0.63 ± 0.3 [nM] (AvrBS3 (A)-Cy5); 0.62 ± 0.3 [nM]
(AvrBs3 (B)-Cy5).
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Performing the FRET measurements with DNA (II) resulted in a
KD-value for AvrBs3 (A)-Cy5 of 1 ± 0.6 [nM], while for AvrBs3 (B)-
Cy5 a KD-value of 6 ± 3 [nM] was determined (Figure 46 (B) and
Table 22).
AvrBs3 (A)-Cy5 AvrBs3 (B)-Cy5
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Figure 46: FRET distance measurement of AvrBs3 (A)-Cy5 and AvrBs3 (B)-
Cy5 on DNA (II)
Single cysteine AvrBs3-Cy5 variants were analyzed via FRET distance
measurements on 5‘-end Cy3 labeled specific DNA (II) (1nM). (A) Crys-
tal structure of AvrBs3 bound to 23 bp specific DNA (pdb: 2YPF) [205].
5‘-end Cy3 labeled DNA (II) carried the fluorophore Cy3 (yellow) at the
bottom strand 2 bp behind the target sequence. Both AvrBs3-Cy5 vari-
ants ((A) and (B)) were analyzed on DNA (II), resulting in a far distance
(AvrBs3 (A)-Cy5: ~58 Å ) or a close distance (AvrBs3 (B)-Cy5: ~40 Å)
between Cy3 (yellow) and Cy5 (red). Theoretically calculated FRET ef-
ficiencies are given with E. (B) FRET index was calculated by formula
(6) and then the corrected FRET signal (nF) was divided with the donor
signal (FexDemD ). Each measuring point represents the mean of FRET
efficiency ± standard error indicated by error bars for each point. n :
number of independent experiments. The data points were fitted with
a non-linear regression curve. KD-values: 1.1 ± 0.6 [nM] (AvrBS3 (A)-
Cy5); 6 ± 3 [nM] (AvrBs3 (B)-Cy5).
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The theoretical FRET efficiencies were calculated using the mea-
sured distance r0* with the mathematic formula (9) and are listed in
table 22. While it was expected to result a high FRET efficiency for the
“close-state”, such as AvrBs3 (A) on DNA(I) (ro*= 41 Å) and AvrBs3
(B) on DNA(II) (ro*= 40 Å), a low FRET efficiency was expected for
the “far-state”, such as AvrBs3 (B) on DNA(I) (ro*= 87 Å) and AvrBs3
(A) on DNA(II) (ro*= 58 Å).
Table 22: FRET distance measurements on DNA (I) and DNA (II)
Distance measurements between Cy3 and Cy5 were preformed in Py-
MOL [195] and result in ro [Å]*. The experimentally determined KD-
values, the theoretically calculated FRET efficiencies (E) as well as the
measured FRET efficiencies (EfA*) (mean values ± standard error for
three measuring points with the highest protein concentration) are listed.
The FRET efficiencies (EfA*) were calculated with formula (11). The FRET
efficiencies (EfA*) were used to define ro [Å]** with formula (10).
DNA (I)
ro* [Å] E KD-
value
[nM]
EfA* ro**
[Å]
Eq
AvrBs3
(A)
41 0.9 0.6 ±
0.3
0.42 ±
0.03
63 0.46 ±
0.02
AvrBs3
(B)
87 0.1 0.6 ±
0.3
0.52 ±
0.06
59 0.4 ±
0.1
DNA (II)
AvrBs3
(A)
58 0.55 1 ± 0.6 0.69±
0.12
52 0.44 ±
0.06
AvrBs3
(B)
40 0.9 6 ± 3 0.74±
0.06
50 0.64 ±
0.02
Hoppe et al. [98] described a stoichiometric method based on the
three cube-quantification that allows to measure FRET efficiency. We
calculated the FRET efficiency (EfA*) for the plateaus with this for-
mula (11). The resulted FRET efficiencies (EfA*) were used to re-
calculate the distance between Cy3 and Cy5 (r0**) via formula (10).
Formula (10) is the result of converting formula (9) towards r0. The
distances ro** are given in table 22. The calculations of FRET efficien-
cies (EfA*) on both DNAs revealed not the expected ratio of FRET
efficiencies between “close-state” and “far-state” when compared to
the theoretically calculated values (E).
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The distance ro** of AvrBs3 (A) on DNA(I) was ~34% greater as the
distance ro* measured within the crystal structure, while AvrBs3 (A)
on DNA(II) resulted in ~10% reduced ro** compared to the measured
ro*. Similarly AvrBs3 (B) resulted in ~32% reduced distance ro** on
DNA(I), while gaining ~20% increase distance ro** on DNA(II) when
compared to the measured ro* distance.
Furthermore, we calculated with formula (13) the donor quench for
the plateau. It resulted in a similar donor quench for all constructs, ex-
cept AvrBs3 (B)-Cy5 on DNA (II) which revealed an increased quench-
ing effect.
3.2.3.4 Can AvrBs3 (AB) be labeled without affecting binding characteris-
tics?
It has been discussed, that TALE binding proteins have a two-state
search mechanism. On the one hand, the crystal structure revealed
a looser conformation of unbound TALE protein, when compared to
the bound state [57, 230]. On the other hand, a two-state mechanism
was described recently in a single molecule study, distinguishing be-
tween a search state and a recognition state [51]. Additionally, the
conformation elasticity of TALE was predicted with computational
studies [226, 70]. Based on these observations, we aimed to reveal the
conformational changes of TALE proteins with FRET distance mea-
surements. To obtain a AvrBs3 variant which enable FRET distance
measurements within the TALE protein, an active AvrBs3 variant car-
rying two distinct fluorophores had to be designed.
3.2.3.5 Fluorophores for labeling AvrBs3 (AB)
An AvrBs3 (AB) variant enclosing two cysteine residues, was labeled
with single fluorophores to analyze the compatibility of the fluo-
rophores and the binding character of TALE. AvrBs3 (AB) was labeled
with the fluorophores Alexa 594, Alexa 488, or Alexa 647. Labeling
reactions were performed for 2 h for each variant (Figure 47).
Labeling efficiency of AvrBs3 (AB)-Alexa 594 (Figure 47 (A), 48 ±
2%) and AvrBs3 (AB)-Alexa 488 (Figure 47 (B), 82 ± 2%) reached their
plateau at approximately 60 min. AvrBs3 (AB) labeling reaction with
Alexa 647 Figure 47 (C)) did not reach its plateau phase during the 2
h time period and achieved a labeling efficiency of 69%.
96 results
AvrBs3 (AB)-Alexa 594 AvrBs3 (AB)-Alexa 488
AvrBs3 (AB)-Alexa 647
- 15` 30` 60` 90` 120` - 15` 30` 60` 90` 120`
- 15` 30` 60` 90` 120`
labeled AvrBs3 (AB) 
free ﬂuorophore 
labeled AvrBs3 (AB) 
free ﬂuorophore 
(A) (B)
(C)
Figure 47: SDS-PAGE of AvrBs3 (AB) labeled with Alexa 594, Alexa 488, or
Alexa 647
AvrBs3 (AB) was labeled with three distinct fluorophores: (A) Alexa
594, (B) Alexa 488, and (C) Alexa 647. The ratio of protein to dye cor-
responds to a 1:4 ratio. (-) represents starting point of the labeling re-
action. Respective time points were take during the labeling reaction (-,
15‘, 30‘, 60‘, 90‘, 120‘). Labeling reactions were analyzed with 12% SDS-
PAGE and fluorescent images were visualized with TyphoonTM FLA
9500. Each lane contained 2 μg protein.
Following the labeling reactions proteins were purified with a Zeba
Desalting column (40 K) and DOLs were analyzed (AvrBs3 (AB)-Alexa
594: 91%; AvrBs3 (AB)-Alexa 488: 77%; AvrBs3 (AB)-Alexa 647: 144%).
The binding characteristic of the single labeled AvrBs3 variants were
detected with EMSA on a 5’-end Cy3 labeled specific DNA and are
illustrated in figure 48 and figure 49. To ensure that the protein was
located on the DNA with increasing concentrations, the fluorophore
labeled to AvrBs3 (AB) was also exited on the corresponding 4% PAA
gel. The two resulting pictures were merged and are displayed in
figure 48. The 5‘-end Cy3 labeled specific DNA is colored in green
and the corresponding fluorophore is displayed in red. The analysis
of DNA and protein results in a yellow spot. The merged pictures
proofed that the labeled proteins did bind to the specific DNA (Figure
48 (B), (C) and Figure 49), except AvrBs3 (AB) labeled with Alexa 594
(Figure 48 (A) and Figure 49). The relative fluorescence intensities of
the shifted DNA was plotted in figure 49 (B).
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Figure 48: Merge fluorescent images of AvrBs3 (AB) labeled with single flu-
orophores (Alexa 594, Alexa 488, or Alexa 647)
Merged fluorescence images of the 4% PAA gels were visualized with
TyphoonTM FLA 9500. 5´-end Cy3 labeled DNA is excited at 532 nm
and colored in green. Each fluorophore was exited with a specific wave-
length and is shown in red. Region in which protein overlaps with DNA
is displayed in yellow. (A) Merged fluorescence images of AvrBs3 (AB)-
Alexa 594 using the green SHG laser (532 nm). Image was processed
afterwards. No DNA shift is detected. (B) Merged fluorescence images
of AvrBs3 (AB)-Alexa 488 were excited using the blue LD laser (473 nm).
DNA is shifted, due to the binding characteristic of AvrBs (AB)-Alexa
488. (C) AvrBs3 (AB)-Alexa 647 was excited with the red LD laser (635
nm). Protein binding resulted in a DNA shift.
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Figure 49: EMSA with AvrBs3 (AB) labeled with distinct fluorophores
(Alexa 594, Alexa 488, and Alexa 647)
The protein binding was analyzed on a 25 bp long 5‘-end Cy3 labeled
specific DNA (20 nM, green) via EMSA. TALE protein was added in in-
creasing concentrations to the 5’-end Cy3 labeled specific DNA (-, 100,
150, 250, 450, 550, 600 [nM]). (A) The 4% PAA gels of the EMSA from
AvrBs3 (AB)-Alexa 594 (I), AvrBs3 (AB)-Alexa 488 (II), and AvrBs3 (AB)-
Alexa 647 (II). Fluorescence images were visualized with TyphoonTM
FLA 9500 using the green SHG laser (532 nm). (B) Relative fluores-
cence intensity [a.u.] of the shifted DNA bands were plotted from each
labeled AvrBs3 (AB) variant. AvrBs3 (AB)-Alexa 488 (red) and AvrBs3
(AB)-Alexa 647 (blue) bound to the specific DNA, but AvrBs3 (AB)-Alexa
594 (black) lost its binding characteristic.
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3.2.3.6 Consecutive labeling of AvrBs3 (AB) with Alexa 488 and Alexa 647
Based on these results, AvrBs3 (AB) was labeled consecutively with
Alexa 488 and Alexa 647 (Figure 50).
free ﬂuorophore Alexa 647
free ﬂuorophore Alexa 488
labeled AvrBs3
- 30` 60` 90`
Alexa 488-
+ +
+
+
+
+
+
Alexa 647
Figure 50: Double labeling of AvrBs3 (AB) with Alexa 647 and Alexa 488
Labeling reaction of AvrBs3 (AB) with Alexa 647 and Alexa 488 ana-
lyzed with a 12% SDS-PAGE. In each lane 2 μg protein was loaded.
Merged fluorescence image was visualized with TyphoonTM FLA 9500,
using the red LD laser (635 nm) and the blue LD laser (473 nm). Flu-
orescence signals: Alexa 647 (red) and Alexa 488 (green). Overlap of
both fluorophores resulted in yellow color.
The labeling reaction was started with Alexa 647 for 30 min, then
Alexa 488 was added to the reaction. The fluorophores were given
to the reaction in a 1:2 ratio to the protein. After purification of the
protein with Zeba Desalting columns (40K), the protein had a degree
of labeling of 123% (Alexa 488) and 57% (Alexa 647). Next, the emis-
sion spectra of AvrBs3 (AB)-Alexa 488-Alexa 647 was detected, which
indicated a FRET signal (Figure 51), thus a location proximity was
proofed. The binding characteristic of AvrBs3 (AB)-Alexa 488-Alexa
647 was analyzed with EMSA, as described above (Figure 52). No
DNA shift was detected.
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Figure 51: Emission spectra of AvrBs3 (AB)-Alexa488-Alexa647
Alexa 488 was excited at 488 ± 5 nm using the Fluoromax-4 Spec-
troflurometer. Emission spectra was detected between 500-720 nm. The
donor fluorophore Alexa488 resulted in a maximum emission spectra
at ~ 518 nm and the acceptor fluorophore Alexa 647 showed a peak at ~
670 nm.
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Figure 52: Binding characteristics of AvrBs3 (AB) - Alexa 484-Alexa 647
Binding was analyzed on a 4% PAA gel via EMSA. Protein was added
with increasing concentrations ( -, 100, 150, 250, 450, 550, 600 [nM])
to the 20 bp long 5´-end Cy3 labeled specific DNA (20 nM). The fluo-
rescence images were visualized with TyphoonTM FLA 9500 using the
green SHG laser (532 nm, Cy3), blue LD laser (473 nm, Alexa 488), and
red LD laser (635 nm, Alexa 647). (A) 5‘-end labeled Cy3 specific DNA.
(B); (C): merged fluorescence images of excited DNA and each excited
fluorophore. No DNA shift was detectable.
4
D I S C U S S I O N
4.1 characterization of highly specific nucleases in vitro
and in vivo
Gene editing has been nominated to be the method of the year in
2011 by the journal Nature Methods [1]. It is a promising tool for
curing monogenetic human diseases [50]. This can be realized using
specific nucleases to disrupt a dysfunctional gene with NHEJ [131]
or through gene replacement using an exogenous DNA template by
the precise HDR [30, 95, 159, 60, 187]. In many monogenetic diseases
gene replacement is required for efficient treatment [50]. However,
HDR is less active than NHEJ and occurs only in the S/G2 phase of
the cell cycle [43, 50]. In contrast, NHEJ occurs during the whole cell
cycle [43, 50], but causes INDELs and chromosomal rearrangements
[112, 16]. Furthermore, off-target effects are a major limitation for
the successful application of gene editing. Off-target activity can in-
duce unwanted chromosomal rearrangements, resulting in deletions,
inversions, and translocations, thus causes cellular toxicity and long
term consequences [104, 112]. Furthermore, there are concerns that
off-target activity could activate oncogenes or inactivate tumor sup-
pressors. Several types of engineered nucleases have been developed
to optimize the efficiency and specificity of the cutting tools, such as
monomeric TALE-FokI [210], TALE-PvuII [238, 239] or Cas9-FokI [89].
While even the most specific nucleases which induce DSBs have been
reported to cause mutations at off-target sites [228, 93, 77], the newly
designed Cas9-FokI seems to induce solely specific DSBs [89].
Specific nucleases inducing SSBs have been continuously optimized
and represent promising tools for gene therapy [116, 157, 140, 78].
While the induction of SSBs increases HDR efficiency and reduces
off-target effects, the overall efficiency of gene editing is reduced
[145, 52, 222]. It has been recently reported that suppressing the key
players of NHEJ increased efficiency of HDR by 4-5 fold [42]. Further-
more, it has been demonstrated that a nick in the transcribed strand
triggers HDR eightfold more efficiently compared to a nick in the
non-transcribed strand [53]. These findings encouraged us to ana-
lyze the site- and strand-specific nickase TALE-MutH under in vitro
and in vivo conditions. Furthermore, studies with paired Cas9 nick-
ases reported low off-target effects and genome editing efficiencies
comparable to DSBs Schiml et al. [191], Shen et al. [199], Ran et al.
[180], Cho et al. [40]. Thus, we aimed to adapt this double nicking
approach to TALE-MutH and to optimize its specificity and efficacy.
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TALE-MutH is a specific nuclease, which has been designed and
analyzed under in vitro conditions by Gabsalilow et al. [78]. These
studies revealed that TALE-MutH cuts either the lower strand or
the upper strand depending on the target design. To optimize the
therapeutic application of TALE-MutH we tested various target de-
signs. Our data indicate towards the high therapeutic potential of
TALE-MutH to enhance gene editing even when compared to the es-
tablished specific nucleases I-SceI and TALE-FokI. To proof the ther-
apeutical applicability of TALE-MutH, we exchanged the naturally
occurring TALE binding protein AvrBs4 with engineered TALE bind-
ing domains, addressing the relevant gene target for X-linked retinitis
pigmentosa which resulted in a robust activity.
4.1.0.7 AvrBs4-MutH
single targets : The characteristics of TALE-MutH on the in-
verted single targets (T-3-H and H-3-T) were analyzed by employing
an in vitro plasmid cleavage assay. TALE-MutH induced almost two
times faster nicks to H-3-T, when compared to the single target T-3-H.
However, analyzing the two single targets with the in vivo SSA assay
led to no differences in the β-galactosidase (β-gal) activity. β-gal activ-
ity occurs due to the induced DNA breaks, which trigger SSA repair
mechanisms, restoring the gene encoding the missing β-gal domain.
Thus, the SSA assay did not confirm the finding by Davis et al. [53],
that a nick in the transcribed strand triggers HDR more effectively,
than a nick in the non-transcribed strand. However, the β-gal activity
of the two single targets (T-3-H: 84 ± 9% ;H-3-T : 84 ± 2%) were close
to the I-SceI β-gal activity (I-SceI : 100 ± 1%). Following the analysis
of the relative number of blue yeast colonies (Figure 22 (B)), the sin-
gle targets T-3-H and H-3-T revealed a better activity than the β-gal
activity of I-SceI. Additionally, we analyzed TALE-MutH on the sin-
gle target T-6-H, which had been described by Gabsalilow et al. [78]
to cut the top strand 3 times slower then the bottom strand on T-3-H
under in vitro conditions. We were able to confirm a reduced activity
of TALE-MutH on T-6-H by employing the in vivo SSA assay.
Interestingly, SSAs were triggered by inducing SSBs. While it is
well recognized that HDR can be induced by SSBs with a low effi-
ciency [145, 52, 222], the finding that SSAs can also be stimulated by
SSBs has just recently been reported by Katz et al. [113].
These results indicated that TALE-MutH on single targets seem to
be a promising tool for the in vivo application. Furthermore, when
comparing the survival rate of TALE-MutH to the negative control
(AvrBs4 without nuclease activity), no significant differences could
be detected.
Analyzing the survival rate with the specific single targets only
T-6-H revealed a significant reduction of the survival rate, when com-
pared to the negative control. The survival rate of T-6-H proofed to be
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comparable to that of the golden standard I-SceI and the inverted
single targets revealed even an increased survival rate when com-
pared to I-SceI. The latter finding is of high interest considering that
TALE-MutH revealed a surprising high β-gal activity on the inverted
single target.
double targets : TALE-MutH was analyzed on two double tar-
gets to investigate the double nicking approach of TALE-MutH. The
first double target enclosed two adjacent GATC sites (T-3-HH-3-T).
While adjacent GATC sites do not occur naturally, the experiment
demonstrated the enzyme activity on a target without a distance be-
tween the two GATC sites. The second double target contained one
GATC site flanked by the recognition sites of AvrBs4 (T-3-H-3-T). A
pair of TALE-MutH introduced a site-specific DSB, thus creating a
blunt end on T-3-HH-3-T and a 4 bp 5‘overhang on T-3-H-3-T.
By using paired Cas9 nickases, it has been shown that the created
5‘ overhang improves NHEJ and HDR efficiency to a comparable or
even higher level when compared to induced blunt ends, while gen-
erating a 3’ overhang resulted in no improvement of the NHEJ and
HDR efficiency [180, 140, 40]. Ran et al. [180] reported that no HDR
was detectable with paired Cas9 nickases creating a 3’ overhang. Ad-
ditionally, double nicking reduced the off-target effect by 50–1000 fold
[180, 140, 40]. This encouraged us to analyze the characteristics of
double nicking with TALE-MutH. The double targets were analyzed
in vitro under denaturing conditions on a 5‘ labeled PCR fragment.
Here, TALE-MutH nicked T-3-H-3-T three to four times faster than
T-3-HH-3-T. This finding indicated towards steric hindrance on the
double target with two adjusted sites. Additionally, the in vitro ki-
netics revealed that TALE-MutH induces SSBs in a 1:1 ratio to top-
and bottom-strand on both target sites. The question arise if TALE-
MutH induced a DSB or only nicked the PCR fragments. Analyzing
the 5‘ labeled PCR fragments on native gels revealed that under in
vitro conditions, no DSBs were induced unless TALE-MutH were di-
gested with PK and new TALE-MutH were added. In this case, DSBs
were detected particularly on the target T-3-H-3-T. When one TALE-
MutH binds to its specific site, the target site is blocked under in vitro
conditions.
The in vivo SSA assay revealed that β-gal activity on T-3-H-3-T (
T-3-H-3-T: 99 ± 1%) is similar to the β-gal activity of I-SceI and the
double target T-3-HH-3-T (T-3-HH-3-T: 95 ± 2%) is close to the β-
gal activity of I-SceI. Both double targets showed a slightly higher β-
gal activity, when compared to the inverted single targets. However,
the relative number of blue colonies revealed a low activity on T-3-
HH-3-T, whereas comparable levels to the inverted single target sites
were found for T-3-H-3-T. Furthermore, the survival rates indicated
that T-3-H-3-T is the preferred double target. Both targets showed a
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significant reduction in the relative number of yeast colonies, when
compared to AvrBs4 without nuclease activity, indicating a toxic ef-
fect on cell growth. Whereas T-3-HH-3-T had a lower survival rate
compared to I-SceI, the survival rate of T-3-H-3-T was between I-SceI
and the inverted single targets. Taken together, T-3-H-3-T proofed to
be an excellent target design combining high efficiency and low toxi-
city. However, it remains unclear if an optimized off-set between the
two GATC sites in T-3-HH-3-T could improve SSA efficiency, as it has
been reported for the paired Cas9 nickases [180]. The TALE-MutH
design is limited by the availability of GATC sites in the genome and
GATC sites close to each other are rare. Finally, the double target
T-3-H-3-T revealed to be a suitable target design to induce a strand-
and site-specific DSBs with a efficiency comparable to I-SceI.
4.1.1 Beyond AvrBs4-MutH
4.1.1.1 AvrBs4-FokI
AvrBs4-FokI was the first TALEN construct and is based on the design
of ZF-FokI [117]. The cleavage module consists of the non-specific
cleavage domain of FokI. The cleavage domains have to dimerize to
induce DSBs [167, 188, 23] and due to its non-specific nature high
off-target effects have been reported [93]. We characterized TALE-
FokI in our yeast assays, analyzing survival rates and β-gal activity.
Comparing the survival rate without inducing the target plasmid, re-
vealed no significant differences when compared to the negative con-
trol. However, analyzing the survival rates with target plasmids led
to the highest reduction of the survival rate of all analyzed constructs,
indicating towards toxic effects on cell growth.
The β-gal activity of AvrBs4-FokI (AvrBs4-FokI: 83 ± 17%) revealed
a robust β-gal activity. Yet, the relative number of blue colonies
showed the toxic effects of AvrBs4-FokI. Both, I-SceI and TALE-MutH
on all tested targets displayed a higher specificity and efficiency, when
compared to TALE-FokI. In table 23 the in vivo characteristics of I-SceI,
TALE-FokI and TALE-MutH are summarized.
4.1.1.2 AvrBs3-PvuII
An alternative architecture of the specific TALENs is the combina-
tion of the site-specific cleavage domain PvuII with the binding mod-
ule TALE [238, 239]. Our data showed that the TALE-MutH variant
has superior characteristics for gene editing, when compared to the
TALE-PvuII variants. PvuII was initially used as an alternative cleav-
age domain to FokI in combination with the binding module TOF
[65]. Similar to FokI, PvuII has to dimerize to induce DSBs. The main
advantage of PvuII is its site-specific character, which is based on
the recognition of a palindromic 6 bp sequence [37, 170, 169]. Due
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Table 23: Overview of the I-SceI, TALE-FokI and TALE-MutH results
Significant difference between analyzed AvrBs3-PvuII variants and
AvrBs4 without nuclease activity were determined by the unpaired T-
test: n ≥ 3, n.s. = not significant, P < 0.05 *, P < 0.01 **, P < 0.001 ***
in vivo
Survival rate β-gal activity
with target
site
without
target site
blue
colonies [%]
rel. number
of yeast
colonies
I-SceI * n.s. *** ***
AvrBs3-FokI *** n.s. *** *
TALE-MutH - n.s. - -
TALE-MutH
T-3-H n.s. - *** **
H-3-T n.s. - *** **
T-6-H ** - ** **
T-3-HH-3-T * - *** ***
T-3-H-3-T * - *** ***
to the limitation of TOF-sc-PvuII for in vivo applications the spe-
cific nuclease were optimized using binding modules such as ZFs
or TALEs [239, 190]. Previous, investigations reported that TALE-
PvuII had superior features, when compared to ZN-PvuII [190]. To-
day, three TALE-PvuII variants are available (TALE-hf-PvuII, TALE-
sc-PvuII and TALE-hd-PvuII). The variants were designed and opti-
mized by Yanik et al. [239, 238]. Using the two distinct yeast viability
assays, we were able to confirm the high toxicity of TALE-hf-PvuII
and TALE-sc-PvuII, which has been previously reported by Yanik et
al. [239, 238] in E.Coli strains. To optimize the TALE-PvuII design,
a heterodimeric variant was designed by introducing a mutation in
each subdomain of PvuII [238]. Under in vitro conditions, the vari-
ants AvrBs3-K38D-PvuII and AvrBs3-D30K-PvuII have been shown
to be inactive on their own, but when introduced together they in-
duce specific DSBs. Similar results were achieved when the variants
were analyzed in HEK293 cells, however with a reduced activity [238].
We could not reproduce this finding in yeast cells. Here, isolated
AvrBs3-D30K-PvuII showed no activity, while AvrBs3-K38D-PvuII (β-
gal activity: 95 ± 3%) revealed a similar β-gal activity as I-SceI. The
relative number of blue colonies of AvrBs3-K38D-PvuII was signifi-
cantly higher, when compared to the negative control. However, it
revealed a reduced activity, when compared to I-SceI. Analyzing the
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heterodimeric AvrBs3-hd-PvuII combination revealed a reduced ac-
tivity, when compared to AvrBs3-K38D-PvuII. Thus, it can be sug-
gested that AvrBs3-K38D-PvuII is active in yeast.
The viability assay without a specific target revealed no significant
difference in the relative amount of cell survival between the negative
control and the analyzed TALE-PvuII variants. However, the viabil-
ity assay with specific targets showed a reduced cellular growth for
AvrBs3-hd-PvuII and AvrBs3-K38D-PvuII.
Taken together, the different AvrBs3-PvuII variants proofed to pos-
sess major limitations in the SSA assay and the viability assays. We
were able to confirm the high toxicity of TALE-hf-PvuII and TALE-
sc-PvuII with our SSA assay, but the reported function of the het-
erodimeric AvrBs3-hd-PvuII could not be reproduced. Contrasting
to the reported characterization of AvrBs3-K38D-PvuII [238], isolated
AvrBs3-K38D-PvuII revealed to be able to induce DSBs in yeast. An
overview of the characteristics of AvrBs3-variants is given in table 24.
Table 24: Overview of the nuclease activity of AvrBs3-PvuII variants
Significant difference between analyzed AvrBs3-PvuII variants and
AvrBs4 without nuclease activity were determined by the unpaired T-
test: n ≥ 3, n.s. = not significant, P < 0.05 *, P < 0.01 **, P < 0.001 ***
in vivo
Survival rate β-gal activity
with target
site
without
target site
blue
colonies [%]
rel. number
of yeast
colonies
I-SceI n.s. n.s. *** **
AvrBs3-hf-
PvuII
* n.s. *** **
AvrBs3-
K38D-PvuII
* n.s. *** **
AvrBs3-
D30K-PvuII
n.s. n.s. n.s. n.s.
AvrBs3-sc-
PvuII
* *** n.s. n.s.
AvrBs3-hd-
PvuII
* *** n.s. n.s.
4.1.1.3 Cas9 endonuclease
The expression plasmid for Cas9 endonucleases in yeast has been es-
tablished in 2013 [58] and we aimed to investigate the β-gal activity
of Cas9 endonucleases with the SSA system. We were able to confirm
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a significant induction of β-gal activity in S. cerevisiae by the Cas9 en-
donuclease, when compared to the negative control. Still, compared
to I-SceI the Cas9 system showed low β-gal activity. Three plasmids
had to be introduced; the expression plasmid of Cas9, the gRNA plas-
mid, and the target plasmid. The expression plasmid for Cas9 nucle-
ase and the target plasmid carry the same selective marker (TRP1).
Thus, our results could be significantly influenced by transformation
efficiency.
4.1.1.4 Alignment search of the addressed sites in the genome of Saccha-
romyces cerevisiae
We screened the yeast genome of the S288c strain for similar off-
target sites of the employed specific nucleases. No 100% similar off-
target site for the analyzed on-target sites were found. Next, the
seed regions of the target site for each specific nuclease was analyzed.
AvrBs4 and AvrBs3 revealed the highest off-target similarity with 68%
containing the 5‘ seed region. This finding is in agreement with the
low cell growth of AvrBs4-FokI. Yet, no similar off-target was found
including the 10 bp of the 5’ seed region and the addressed site of
MutH (5‘-3GATC-3‘) or PvuII (5‘-CAG3CTG-3‘). For the on-target of
I-SceI, the best two hits had a similarity of 66%, enclosing the 3’ seed
region of I-SceI. The on-target for Cas9::gRNA revealed off-target site
hits with a similarity of 52% containing the PAM site and the 3’ seed
region. Cas9::gRNA has been shown to possess a lower specificity,
compared to the TALE binding domains. Furthermore, the Cas9 sys-
tem has been reported to tolerate up to 5 mismatches [101, 163, 76].
It is therefore, that the difference of the off-target sites and on-target
sites are adequate to limit off-target effect.
therapeutic target : The next step was to analyze if the nat-
urally occurring binding module AvrBs4 could be exchanged by an
engineered TALE binding domain without losing the specificity and
efficiency of the designed nuclease TALE-MutH. We targeted the rel-
evant gene in X-linked retinitis pigmentosa, which is caused by mu-
tations in the RPGR-gene. 80% of the mutations leading to RPGR
dysfunction are located in the ORF15, which consists primarily of
an imperfect repeat motif [100, 223, 198, 165]. Treatment of X-linked
retinitis pigmentosa could be realized by insertion of a AAV vector
enclosing the encoding sequence for the RPGR as has been demon-
strated in dogs [15] and mice [234].
Distinct GATC sites are located in the ORF15 and TALE binding
modules were created by employing the Golden Gate cloning strat-
egy. The newly designed TALE-MutH constructs (TALE(RPGR)-1 (I)
-MutH/ TALE(RPGR)-2 (I) -MutH) were analyzed in terms of their ac-
tivity and toxicity in HEK293T cells. They addressed a heterodimeric
double target site containing one GATC site flanked with the two
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TALE binding sites. The design is based on the double target T-3-
H-3-T and the heterodimeric TALE-MutH induces a strand- and site-
specific DSB resulting in a 4 bp 5‘overhang. The activity was detected
with a frame shift assay, which is triggered by NHEJ. The high fre-
quencies of NHEJ and the independence of a DNA template simplify
the analysis of nuclease activity, when compared with the detection
of HDR efficiency. Thus, we analyzed NHEJ activity to characterize
nuclease activity on the therapeutic target.
It revealed similar NHEJ activity for the heterodimeric TALE-MutH
design (TALE(RPGR)-1 (I) -MutH/ TALE(RPGR)-2 (I) -MutH) , when
compared with the Golden Standard I-SceI. Additionally, no sig-
nificant difference between the survival rates of I-SceI and the het-
erodimeric TALE-MutH constructs were found. Furthermore, an empty
plasmid (pcDNA) was analyzed as a negative control. No significant
difference between the survival rates of I-SceI and empty vector were
detected, while the ZF-FokI [6] construct revealed a reduced survival
rate. The episomal in vivo analysis of TALE-MutH on the therapeutic
target underlined its high potential as a specific and efficient tool for
gene targeting.
Our results indicate that TALE-MutH can challenge the established
specific nucleases (I-SceI and TALE-FokI), when addressing the rele-
vant gene causing 80% of X-linked retinitis pigmentosa [100, 223, 198,
165]. The target site T-3-H-3-T, proofed to be a powerful target design
to induce double nicks. Further important steps are the analysis of
HDR efficiency of TALE-MutH on the T-3-H-3-T targets, charactering
the exogenous DNA template, such as its overall length, the length
of the homologous parts, or its double stranded or single stranded
DNA character. Additionally, the effect of TALE-MutH addressing
its target site on a genome have to be investigated. Here, the chosen
genome should be screened for similar off-target sites and the acces-
sibility of the target sequence in the chromatin structure remains to
be analyzed.
Nevertheless, TALE-MutH requires a GATC site to induce a SSBs
and TALE binding modules have to be designed for each new target
site respecting several conditions, such as the required thymine at the
beginning of the target sequence [193] and the higher sensitivity to
mismatches at the 5‘end of the addressed site [142].
The Golden Gate cloning strategy enables to design TALE binding
modules for any given target within a 5 days protocol [67]. TALE
binding modules can be very specific [215, 160, 59], but depending on
the addressed target site, the TALE domain can also looses its specific
features [88]. Computer programs have been developed to predict
the best composition of a TALE binding domain [184, 86, 62]. Yet, an
improved understanding of the TALE binding mechanism remains to
be investigated.
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The second part of this thesis concentrates on the characterization of
the naturally occurring TALE protein AvrBs3. Four distinct AvrBs3(1N152-
C28) variants (two single cysteine variants, a double cysteine variant,
and a variant containing all cysteine residues) were expressed and
characterized. The KD-values of the AvrBs3 variants were analyzed
and functional labeled AvrBs3 variants were designed.
TALE proteins have been used as binding module for specific nu-
cleases and were successfully employed in genome and epigenome
editing technologies [109, 48, 135]. Deciphering of the recognition
code of TALE [25] and the introduction of the one pot cloning strat-
egy Golden Gate represent important steps toward a therapeutic use
of the TALE proteins [33]. Theoretically, any given target can be ad-
dressed by an engineered TALE protein. Despite these developments,
off-target effects of TALENs were described and limit their applica-
tion [88]. Improving the knowledge on the binding mechanism of
TALE has been a central aim of many researchers [142, 205, 193, 194].
For instance, a polarity effect has been recognized, indicating that
the 5‘ -end is more sensitive to mismatches [142]. Furthermore, the
impact of adjacent repeat domains were investigated and computer
programs were developed to identify the best fitting TALE construct
for a specific target [184]. Still, a better understanding of the binding
mechanism of TALE proteins is required, which could result in an
improved prediction of potential off-target effects.
4.2.0.5 Determination of KD-values
The KD-values of AvrBs3 with different lengths of its N- and C-terminus
were analyzed under various conditions using several methods [205,
142, 194]. Schreiber et al. [194] described the KD-value of AvrBs3(1
N152-C16) with similar N- terminus length to AvrBs3(1 N152-C28)
using fluorescence anisotropy on a 36 bp long DNA under physiolog-
ical conditions (c(NaCl) = 150 mM, pH: 7.5 ). Their studies revealed
a higher KD-value of the AvrBs3(1 N152-C16) (KD= 282 ± 18 nM),
when compared to the KD-value of the AvrBs3(1 N152-C28) (KD=
1.9 ± 0.8 nM) as we have determined on a 25 bp long DNA under low
salt conditions (60 mM). These divergent results could be explained
by the extended DNA and the high salt concentration employed by
Schreiber et al. [194]. Additionally, they measured the KD-values of
wtAvrBs3 (KD-value = 23.2 ± 1.6 nM) and AvrBs3(1 N152-C278) car-
rying the entire C-terminus (KD= 99.2 ± 7.5 nM), suggesting that a
truncation of the C-terminus to 16 aa has a high impact on the bind-
ing characteristics of AvrBs3. Stella et al. [205] measured the KD-value
of wtAvrBs3 (KD= 33.6 ± 4,9 nM) with fluorescence anisotropy on a
20 bp long DNA under physiological conditions (c(NaCl) = 150 mM,
pH: 7.5). The KD-values of wtAvrBs3 in both studies were compa-
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rable. However, using the same conditions, but isothermal titration
calorimetry for detection resulted in a KD-value of 88 ± 32 nM [205].
A third group reported KD-values of 3.2 ± 1.6 nM (AvrBs3(1 N143-
C54)) and 3.9 ± 0.1 nM (AvrBs3(1 N0-C192)) using EMSA under low
salt conditions (c (KCl)= 60 mM) [142]. These findings were similar to
the KD-value of AvrBs3(1 N152-C28) (KD= 1.9 ± 0.8 nM) measured
in our study. Furthermore, the ratio of active and inactive AvrBs3
influences the KD-value. Here, protein expression, purification, and
storage have an impact on the ratio between active and inactive pro-
tein and could be important factors for comparing the analyzed KD-
values. We determined the ratio of active AvrBs3(1 N152-C28) to es-
timate the KD-value for 100% active protein. About 13% of AvrBs3(1
N152-C28) was active, resulting in a KD-value of 0.24 ± 0.09 nM. The
high inactive portion of AvrBs3(1 N152-C28) indicates towards a rel-
evant degeneration under in vitro conditions. An activity assay with
the fusion construct AvrBs3-PvuII revealed a 50% reduction of the
cutting activity under physiological conditions in 4 h [238].
4.2.0.6 Cysteine variants
The characterization of the crystal structure of the apoenzyme and the
bound TALE protein was a mayor step in identifying the binding char-
acter of the TALE::DNA interaction. Here, a superhelical conforma-
tion of TALE was shown to interact with the major groove of the DNA
[139, 205] and a positive charge along the inner surface contributes to
the non-specific binding energy of the TALE::DNA interaction [57, 81].
The positive charged amino acids G14, K16 and Q17 interact with the
negatively charged phosphate backbone of the DNA, thus supplying
the main binding energy. Interestingly, the so called di-residues at
position 12 and 13 do not significantly contribute to the binding en-
ergy, despite the fact that residue 13 is the only known AA perform-
ing direct interactions with the DNA. This suggests, that binding to
the specific DNA occurs by negative discrimination due to steric and
electrostatic clashes between DNA and the di-residues [230, 57, 139].
Furthermore, the crystal structure and computer based analysis of
TALE binding revealed a conformation elasticity of the binding mod-
ule, resulting in a loose conformation as apoenzyme and a more tight
conformation when bound to its target site [57, 230, 226, 70]. It has
been reported, that the superhelical turn of TALE is reduced from 60
A° to 35 A° in its bound state [57]. Recently, the AvrBs3 binding mech-
anism has been described on the single-molecule level [51]. To enable
this, AvrBs3 was labeled with Cy3 at the N-terminus via an unnatural
aldehyde. The TALE protein was tagged with a six AA motif and the
formylglycine generating enzyme (FGE) converted the cysteine en-
closed in the motif on protein level. The single-molecule experiment
revealed a conformation dynamic between search and recognitions
state, as well as the interactions between NTR and non-specific DNA
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that facilitate 1D diffusion [51]. The main advantage of the labeling
strategy used by Cuculis et al. [51], is the lack of mutations which
could impact the binding character of AvrBs3. However, AvrBs3 hold
a tag at the N-terminus, which could influences the binding charac-
teristics due to steric clashes. Moreover, the fluorophore is fused to
the flexible linker and therefore precise distance measurements via
FRET are not possible. Another strategy to label proteins is to cre-
ate single cysteine variants. While the fluorophore is located closer
to the protein, the cysteine residue has to be accessible for the la-
beling reaction and the removed cysteine residues are not allowed
to have a mayor impact to the binding characteristics of the protein.
AvrBs3 has a cysteine residue at position 30 in each repeat domain
[57, 139]. In AvrBs3(ΔN152-C278) Schreiber et al. [194] substituted
all cysteine residue to serine or alanine residues (AvrBs3(C30S)Rep /
AvrBs3(C30A)Rep). This study proofed that the cysteine residues are
required for gene activation in planta. Interestingly, the specific in-
teraction between AvrBs3(C30S)Rep::DNA is only minimally reduced
under in vitro conditions, when compared to AvrBs3(ΔN152-C278)
containing all cysteine residues. The cysteine residues are required
for dimerization via disulfide bridges to homodimers, which facilitate
the nuclear transport [91, 194]. AvrBs3(C30S)Rep revealed reduced
complex formation to AvrBs3(ΔN152-C278) due to the missing cys-
teine residues. Furthermore, Schreiber et al. [194] postulated that cys-
teine substitution resulted in a plasticity change of AvrBs3. The miss-
ing cysteine residues led to a small conformation variance in each
repeat. This effect might increase with increasing repeat numbers
and result in the incapability of AvrBs3(C30S)Rep to activate genes in
planta.
In the present thesis, the cysteine residue was substituted to me-
thionine, as methionine has the least shift to cysteine in its thermody-
namic stability (ΔΔ G = 0.3 [kcal/mol]) when compared to all other
aa. Serine and alanine revealed a shift in the thermodynamic stabil-
ity above 1 [kcal/mol]. We designed three distinct cysteine variants.
AvrBs3 (A) carrying one cysteine residue in repeat one, AvrBs3 (B)
encloses a cysteine residue in repeat 16, and AvrBs3 (AB) contains
two cysteine residues. First, we analyzed the KD-value of AvrBs3 (B)
and were able to show that the KD-value of AvrBs3 (B) was similar to
the KD-value of AvrBs3(1N152-C28) containing all cysteine residues.
Consequently, the cysteine residues did not affect the binding charac-
teristics of AvrBs3 under in vitro conditions regarding the determined
KD-values. While the substitution of cysteine to methionine revealed
similar binding characteristics compared to AvrBs3(1N152-C28), the
substitution described by Schreiber et al. [194] resulted in a slightly
decreased affinity of AvrBs3(C30S)Rep compared to AvrBs3(ΔN152).
Next, we performed competition assays in which AvrBs3 (B) bound
to its specific target site (AvrBs3 (B)::DNA) competed with an ex-
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cess of non-specific or specific free DNA. The experiment revealed
a non-specifc binding state and a specific binding state. This find-
ing was supported by an individual competition assay and a consec-
utive competition assay with AvrBs3 (B). Our results suggest, that
several AvrBs3 (B) are clustered to the specific AvrBs3 (B)::DNA com-
plex. Adding an excess of unspecific DNA to the specific AvrBs3
(B)::DNA complex resulted in a fast displacement of the non-specifc
bound proteins, followed by a slow displacement of the specific inter-
action (AvrBs3 (B)::DNA) when an excess of specific DNA was added.
Removing all specific interactions was achieved by digesting AvrBs3
(B) with Proteinase K.
On the contrary, AvrBs3(1N152-C28) carrying all cysteine residues
did result in an even slower decrease of the specific interaction (AvrBs3
(1N152-C28)::DNA) by adding an excess of specific DNA to the spe-
cific complex. These findings indicate towards a stronger AvrBs3(1N152-
C28)::DNA interaction, when compared to the cysteine substitution
variant (AvrBs3 (B)::DNA).
4.2.0.7 Labeling single cysteine AvrBs3 variants
Next, we labeled the AvrBs3 cysteine variants and analyzed their
binding characteristics under in vitro conditions. AvrBs3 (B) labeled
with Alexa 488 resulted in a DOL of 158% and a KD value of 1.3 ± 0.3
nM. This proofed that the fluorophore Alexa 488 is compatible with
the binding characteristics of AvrBs3. The KD-value is comparable
with AvrBs3(ΔN152-C28).
AvrBs3 (A) and AvrBs3 (B) were also labeled with the Cy5 fluo-
rophore and DOLs of 115% (AvrBs3 (A)-Cy5) and 82% (AvrBs3 (B)-
Cy5) were achieved. The binding characteristics of the variants were
analyzed on two distinct 25 bp long 5‘ -end Cy3 labeled specific
DNAs. DNA(I) carried the Cy3 fluorophore at the 5’ -end on the top
strand and DNA(II) held the Cy3 fluorophore at the 5’ -end on the
lower strand. Cy5 and Cy3 are a known FRET pair with a Förster
radius of 60 Å [96]. The FRET measurement depends on the overlap-
ping absorption spectra of donor and acceptor fluorophores, the dis-
tance between the chosen fluorophores and the orientation between
the donor and acceptor fluorophores to each other.
the kd -values of the different variants were analyzed on the
two DNA designs with FRET measurements. The measured FRET
signals were corrected by the cross-talk between donor and acceptor
fluorophores. The FRET indexes (nF) were calculated by the three-
cube method described by Youvan et al. [242]. This method does not
represent the FRET efficiency, but provides an value, which changes
with FRET [17, 244], thus it enables determination of KD -values.
On DNA(I) both Cy5 labeled AvrBs3 variants revealed comparable
KD -values to the unlabeled single cysteine variant. On DNA (II)
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AvrBs3 (A)-Cy5 also showed a similar KD -value when compared to
the unlabeled single cysteine variant, while AvrBs3 (B) revealed an
increased KD -value of 6 ± 3 nM, when compared to the anisotropy
results of the unlabeled cysteine variants.
the binding character of AvrBs3 was studied by using the
specifically labeled AvrBs3 variants on DNA(I) and DNA(II). AvrBs3
(A)-Cy5 on DNA(I) (r0*= 41 Å) and AvrBs3 (B) on DNA II) (r0*= 40
Å) was expected to have a “close-state” to the Cy3 label on the DNAs
leading to an increased FRET efficiency, when compared to AvrBs3
(B)-Cy5 on DNA(I) (r0*= 58 Å) and AvrBs3 (A)-Cy5 on DNA(II) (r0*=
87 Å), representing the “far-state”.
We measured the theoretical distance between donor and acceptor
fluorophores within the crystal structure of AvrBs3 on a 23 bp long
DNA (pdb: 2YPF) [205]. The DNAs used in this thesis were 25 bp
long and therefore 3.4 Å were added for each missing nucleotide.
The theoretical FRET efficiencies were calculated with the measured
distance between donor and acceptor fluorophores using formula (9).
These data revealed that the difference between “close-state” and “far-
state” is more pronounced on DNA(I) (E(AvrBs3 (A)= 0.9; E(AvrBs3
(B))= 0.1), compared to DNA(II) (E(AvrBs3 (A)= 0.55; E(AvrBs3 (B))=
0.9). Additionally, the difference between the theoretically calculated
FRET efficiencies of AvrBs3 (B)-Cy5 on the two DNAs is larger as the
observed FRET efficiencies of AvrBs3 (A)-Cy5 on the two different
DNAs.
Furthermore, we calculated the FRET efficiency (EfA*) for the three
measuring points with the highest protein concentration with a stoi-
chiometric method that is based on the three cube-quantification de-
scribed by Hoppe et al. [98]. The resulted FRET efficiencies (EfA*)
were used to recalculate the distance between Cy3 and Cy5 (r0**) as
decribed by formula (11).
The measured FRET efficiencies (EfA*) on both DNAs revealed not
the expected ratio of FRET efficiencies between “close-state” and “far-
state” when compared to the theoretically calculated values (E). The
distance ro** of AvrBs3 (A) on DNA(I) was ~34% greater as measured
within the crystal structure, while AvrBs3 (A) on DNA(II) resulted in
~10% reduced ro** compared to the measured ro*. Similarly AvrBs3
(B) resulted in ~32% reduced distance ro** on DNA(I), while gaining
~20% increase distance ro** on DNA(II) when compared to the mea-
sured ro* distance (Figure 53). These finding indicates towards di-
verged orientation of the Cy3 and Cy5 fluorophore as expected. The
fluorophores were covalent bound to the cysteine residue allowing
a certain elasticity of the fluorophores. Due to the plastic elasticity
of AvrBs3 and the fluorophore Cy5 the location of Cy5 fluorophore
was hardly described. A further step would be the calculation of an
expected flexibility of Cy5 according to its structural size.
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Figure 53: “close-state” and “far-state”
The distances on DNA(I) and DNA(II) of AvrBs3 (A)-Cy5 and AvrBs3
(B)-Cy5 are illustrated on the crystal structure AvrBs3 (pdb: 2YPF) [205].
The cysteine residues used for the labeling reaction with Cy5 is colored
in red, the position of Cy3 is displayed in yellow. The distances r0* were
measured within the crystal structure AvrBs3 (pdb: 2YPF) [205] and are
displayed in black, while r0** yield by the measured FRET efficiencies
(EfA*) are colored in orange. The arrows indicate the displacement of
Cy5.
The resulted distances ro** indicated that the fluorophore Cy5 la-
beled to the N-terminus of AvrBs3 (A) is shifted to the C-terminus, as
well as the Cy5 fluorophore labeled to the C-terminus (AvrBs3 (B)) is
shifted to the N-terminus. These would explain the greater distances
for the “close-state” and the reduced distances for the “far-states”
(Figure 53).
The EfA* were calculated by the formula (11) described by Hoppe
et al. [98]. However, Hoppe et al. [98] also described an extended for-
mula which corrects the FRET signal for the donor quench, thus the
FRET efficiencies could be defined more accurate. Additionally, FRET
signal could also be influenced by different factors which complicate
the comparison between the single experiments. For instance, the dif-
ferent DOLs of the labeled DNA and AvrBs3-Cy5, further quenching
effects, and preferred orientation of Cy3 and Cy5 within one of the
DNA::AvrBs3 complexes when compared with another DNA::AvrBs3
complex.
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Quenching in term of FRET has also become a tool to investigate
ligand binding, thus we calculated the donor quench for the plateau.
It resulted in a similar donor quench for all constructs, except AvrBs3
(B)-Cy5 on DNA (II) which revealed an increased quenching effect.
This finding indicates towards similar binding characteristics of the
AvrBs3::DNA complexes.
4.2.0.8 Labeling of the double cysteine variant AvrBs3 (AB):
It has been described, that TALE has a conformational elasticity. Bind-
ing to DNA results in a tighter superhelical conformation [57, 230,
226, 70], but conformational changes between non-specific and spe-
cific binding has also been described with single-molecule experi-
ments [51]. We aimed to show this effect with FRET distance mea-
surements. We designed a double cysteine AvrBs3 (AB) variant, car-
rying a cysteine residue in repeat 1 and in repeat 16. We expected,
that upon binding to the DNA the distance between donor and ac-
ceptor fluorophore would decrease, resulting in an increased FRET
signal.
The first challenge was to design a functional double labeled AvrBs3
variant. The binding characteristics of unlabeled AvrBs3 (AB) was
analyzed by EMSA, which revealed two shifts of the labeled DNA.
This suggested that the first shift contributes to the specific binding
and the second shift is a result of non-specific binding clustered to
the specific AvrBs3 (AB)::DNA complex. The next step was to find
donor and acceptor fluorophores compatible with the binding char-
acteristics of AvrBs3 (AB). AvrBs3 (AB) was labeled either with Alexa
488, Alexa 594, or Alexa 647; EMSA was performed to analyze the
binding capacity. AvrBs3 (AB) labeled with Alexa 488 and Alexa 647
kept its binding characteristics, but AvrBs3 (AB)-Alexa 647 showed
decreased binding to the specific DNA. AvrBs3 (AB)-Alexa 594 com-
pletely lost its binding characteristics. Alexa 488 and Alexa 647 have
overlapping absorption spectra and function as a FRET pair. There-
fore, AvrBs3 (AB) was labeled consecutively with Alexa 488 and Alex
647. Based on the isolated labeling kinetics with Alexa 488 and Alexa
647, we knew that Alexa 647 reacts slowly with the cysteine residue of
AvrBs3 (AB). Therefore, AvrBs3 (AB) was incubated for 30 min with
Alexa 647 and then Alexa 488 was added. Despite this, a DOL for
Alexa 488 of 123% and for Alexa 647 of 57% were measured. Thus,
Alexa 647 showed a reduced labeling capacity for AvrBs3 (AB). Alexa
488 (M = 721 [g/mol]) has a small molecular weight, when compared
to Alexa 647 (≈ 1250 [g/mol]). This could result in steric hindrance,
which causes the reduced labeling capacity of Alexa 647 to AvrBs3
(AB).
Next, we analyzed if AvrBs3 (AB)-Alexa 488- Alexa 647 kept its
binding characteristics by employing EMSA. However, it revealed a
complete loss of the protein::DNA interaction. Thus the FRET pair
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Alexa 488 and Alexa 647 could not be used for this experimental
approach. We could proof that AvrBs3 (AB)-Alexa 488- Alexa 647
displayed a FRET signal. Consequently, the donor and acceptor fluo-
rophores were close to each other, which indicates towards an aggre-
gation of the protein due to the covalently bound labels.
Further investigations identifying compatible FRET pairs with AvrBs3
(AB) binding capacity are required. For instance, the FRET pair Cy3
and Cy5 could be analyzed, but also Cy5 in combination with Alexa
488 could be a promising attempt, as Alexa 488 has shown an advan-
tageous labeling capacity.
In conclusion, we analyzed the in vitro binding characteristics of
AvrBs3(1 N152-C28) under low salt conditions and revealed a sim-
ilar KD-value to the reported value of Meckler et al. [142]. The
other groups determined the binding characteristics under physio-
logical conditions and measured higher KD-values [194, 205]. We
were able to design two single cysteine variants and one double cys-
teine variant, which kept their in vitro binding characteristics. The
competition assays revealed a stronger protein::DNA interaction of
AvrBs3(1 N152-C28), when compared to the single cysteine variant.
It remains unclear, if the substitution of cysteine to methionine im-
proves gene activation under in vivo condition, when compared to
the AvrBs3(C30S)Rep designed by Schreiber et al. [194].
Labeled single cysteine variants with Alexa 488 and Cy5 kept their
binding characteristics and could be used to further investigate the
binding mechanisms of the AvrBs3 in vitro.
The FRET efficiencies measurements (EfA*) with AvrBs3 (A)-Cy5
and AvrBs3 (B)-Cy5 on DNA()) and DNA(II) were not in concordance
withe the expected “close-state” and “far-state”. The results indicated
towards a displacement of the Cy5 fluorophore when compared to
the expected location within the crystal structure.
Finally, a double cysteine AvrBs3 labeled with a donor and an ac-
ceptor fluorophore was designed. Isolated labeled AvrBs3 (AB) with
Alexa 488 or Alexa 647 kept its binding capacity, while consecutively
labeling resulted in a loss of function.
Part IV
A P P E N D I X
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a.1 supplementary experiments
Experimental data additional to the results section.
AvrBs3 (B)-Cy5
Figure 54: Emission spectra of titrating Cy5 labeled AvrBs3 (B) to 5‘-end Cy3
labeled specific DNA (I)
Example of emission spectra. Proteins were titrated in increasing con-
centrations (0, 0.99, 2, 4, 6, 10, 14, 18 [nM]) to 1 nM DNA (I). AvrBs3
(B)-Cy5 analyzed on DNA (I) (1nM).
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Figure 55: Emission spectra of titrating Cy5 labeled AvrBs3 to 5‘-end Cy3
labeled specific DNA (II)
Example of emission spectra. Proteins were titrated in increasing con-
centrations (0, 0.99, 2, 4, 6, 10, 14, 18 [nM]) to 1 nM DNA (I). (A) AvrBs3
(A)-Cy5 analyzed on DNA (II) (1nM). (B) AvrBs3 (B)-Cy5 analyzed on
DNA (II) (1nM)
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Figure 56: Spectra of DNA-Cy3 to determined the correction factor β
The correction factor β had to be defined to correct the crosstalk between
Cy3 and Cy5. Donor fluorophore was excited at 520 nm (exD) and emis-
sion was detected in the donor channel and in the acceptor channel. The
factor β is characterized by the fluorescence signal FDexDemA (A) divided
with the fluorescence signal FDexDemD (B).
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